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Abstract – Part I 
Novel strategies and therapeutics for treating haematological malignancies and lowering 
disease recurrence are highly sought after. A promising approach towards reducing 
recurrence is to block the VLA-4/VCAM-1 protein-protein interaction using VLA-4 antagonists 
which mobilise malignant early haemopoietic stem and progenitor cells (HSPCs) from the 
bone marrow into peripheral blood. These cells show reduced susceptibility to 
chemotherapy drugs whilst in the bone marrow; an effect known as environment- mediated 
drug resistance. It has been proposed that mobilisation of these cells would make them more 
vulnerable to chemotherapy allowing them to be better cleared from the body during 
treatment. (±)-Thioridazine, a discontinued anti-psychotic drug, shows several useful 
activities against haematological malignancies, including the ability to act as a VLA-4 
allosteric antagonist and HSPC mobiliser, as well as being able to selectively induce apoptosis 
and differentiation in malignant HSPCs. A thioridazine-VLA-4 antagonist hybrid could provide 
multi-action synergy in treating haematological malignancies and lowering disease 
recurrence. Part I of the thesis describes the design and synthesis of two epimeric hybrids. 
 
An adaptation of the Ullmann reaction was used as the key step to produce a novel 
azido-VLA-4 antagonist obtained in 34% yield over 6 steps. The resolution and synthesis of 
northioridazine enantiomers from (±)-thioridazine was achieved, with the absolute 
stereochemistry confirmed by X-ray crystallographic analysis of a N-nosyl thioridazine 
derivative. N-Substitution of the (R)- and (S)-northioridazine enantiomers was optimised to 
produce the corresponding (R)- and (S)-N-propargyl northioridazine enantiomers in 22% and 
21% over 4 steps, respectively. A convergent synthesis of the (R)- and (S)-hybrid epimers was 
achieved via a ‘click’ reaction with an overall yield of 39% and 38% over 11 steps, 
respectively. These molecules may serve as pharmacological tools to probe the allosteric and 
competitive binding pockets of VLA-4. 
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Abstract – Part II 
(R)-Telomestatin, a macrocyclic polyoxazole-containing natural product isolated from 
Streptomyces anulatus 3533-SV4, is a potent inhibitor of telomerase, a reverse transcriptase 
that restores telomeric DNA repeats. This counteracts telomere shortening during DNA 
replication allowing for unlimited proliferation. Secondary DNA structures called 
G-quadruplexes are known to form in G-rich sites of telomeric DNA, where they act as 
regulatory switches to block telomerase-mediated extension of the telomere. 
(R)-Telomestatin inhibits telomerase activity through its impressive ability to stabilise 
G-quadruplexes. A major limitation to studying the biological effects of (R)-telomestatin has 
been the difficulty in obtaining useable quantities of the compound by isolation from the 
natural source. The total synthesis of (R)-telomestatin has been reported, however, it 
involved a complex multi-step pathway and afforded less than 1 mg of final compound. In 
part II of the thesis, a biomimetic mixed solid/solution-phase strategy was explored for the 
efficient production of (R)-telomestatin. 
A divergent synthesis was developed that allowed access to multi-gram quantities of two 
requisite pseudoproline dipeptides in 43% and 65% over 3 steps, respectively. The fragments 
were successfully employed in SPPS, which was optimised to afford near gram quantities of 
a linear peptidic backbone in 81% yield. Macrocyclisation of this peptide was optimised to 
give the protected macrocycle in an overall yield of 64% over 2 steps. A total of approximately 
700 mg of the macrocycle was produced over 10 reactions. Global deprotection of the 
protected macrocycle generated approximately 200 mg of a cyclic polyol in quantitative 
yield. Synthetic investigations of a one-pot conversion of the polyol to the heptaoxazoline 
were unsuccessful. Although the total synthesis was not completed, a promising alternative 
approach involving the simultaneous deprotection and cyclodehydration of a poly-TES 
protected macrocycle could lead to completion of the total synthesis in future. 
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Chapter 1 - Introduction 
1.1 Haematological Malignancies  
Haematopoiesis, the formation of cellular blood components, originates from pluripotent 
haemopoietic stem or progenitor cells  (HSPCs) located in the bone marrow.1 Various mature 
cell types develop from pluripotent stem cells through lineage-committed intermediates.2 
The haematological system, comprised of the myeloid and lymphoid systems, plays a major 
role in protecting the body against foreign infectious agents.1,2 The primary cell types of the 
myeloid and lymphoid lineages are leukocytes and lymphocytes, respectively. A simplified 
representation of the system is shown in Figure 1. 
 
 
Figure 1. Cell lineages of the haematopoietic system.  
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Malignant HSPCs can give rise to multiple haematopoietic malignancies that are defined by 
lineage and mature cell type. Blood cancers are collectively one of the most prevalent cancer 
types worldwide, accounting for approximately 10% of all cases.3 Although the main causes 
of haematological malignancies are unknown, chronic exposure to certain chemicals, such as 
benzene (smoking) and pesticides, increases risk.4 
The uncontrolled proliferation of dysfunctional leukocytes in the peripheral blood, bone 
marrow and lymphoid system defines leukaemia.2 The disease is classified according to cell 
lineage (lymphoblastic or myeloid) and whether the disease is acute or chronic. Patients with 
leukaemia often become anaemic and immunocompromised due to lowered red and white 
blood cell production in the bone marrow. Pneumonia and other opportunistic infections are 
frequent complications and are often fatal.5 With a 30% incidence rate, leukaemia is the most 
common cancer found in children, with Acute Lymphoblastic Leukaemia (ALL) accounting for 
78% of leukaemia diagnoses.6  
Lymphoma occurs when lymphocytes divide uncontrollably in the lymph nodes to form a 
solid tumour.7 There are more than 80 different forms of lymphoma, which are subdivided 
into four groups; B cell, T cell, natural killer cell and the less common Hodgkin’s lymphoma.8 
Hodgkin’s lymphoma is classified histologically by multi-nucleated abnormal lymphocytic 
cells known as Reed-Sternberg cells.9 Non-Hodgkin’s lymphoma encompasses all lymphomas 
other than Hodgkin’s lymphoma. Non-Hodgkin’s lymphoma is the most common 
haematological malignancy and is often successfully treated with chemotherapy.7  
Multiple myeloma is a disease of malignant B cells that reside within the bone marrow. The 
disease is characterised by plasmacytosis, bone lesions and the presence of an abnormal 
immunoglobulin fragment called a paraprotein.10 Myeloma forms infiltrating tumour cells 
Chapter 1 - Introduction 
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that interfere with haematopoiesis, leading to the pathogenic alteration of blood cell 
populations.  Like leukaemia, pneumonia and opportunistic infections are common and often 
fatal.11 Multiple myeloma is the second most prevalent haematological malignancy and is 
more difficult to treat.10,12  
Five-year survival rates for patients with haematological malignancies from 1975 to 2012 
(Figure 2) highlight the overall improvements in cancer detection and treatment over the last 
40 years. From 1975-1977 the survival rate for multiple myeloma was only 24.6% but this 
more than doubled by 2012 (50.2%). Current efforts to develop non-cytotoxic treatments 
and more efficacious dosage regimens will likely drive further improvements for patients 
suffering haematological malignancies. 
 
 
Figure 2. Five-year survival rates for the four haematological malignancies from 1975-2012.13 
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1.2 Treatment of Leukaemia, Lymphoma and Multiple Myeloma 
Treatment of haematological malignancies is largely determined by class and patient 
condition. Leukaemia is classified into four major subtypes; Acute Lymphoblastic Leukaemia 
(ALL), Acute Myeloid Leukaemia (AML), Chronic Lymphocytic Leukaemia (CLL) and Chronic 
Myeloid Leukaemia (CML). Lymphomas are separated into Hodgkin’s or Non-Hodgkin’s 
groups. Multiple myeloma is a specific malignancy where treatment is dependent upon 
patient condition. Cytotoxic chemotherapy is the mainstay, and combinations with radiation 
therapy, targeted therapy and bone marrow transplants significantly improve the likelihood 
of remission. A selection of multi-drug regimens arranged by cancer subtype and their 
respective survival rates are summarised in Table 1. 
 
Table 1. Multi-drug chemotherapy treatments used in haematological malignancies. 
Cancer Type Regimen Survival Rate* 
Acute Lymphoblastic Leukaemia (ALL) Dexamethasone, vincristine, 
asparaginase and daunorubicin.14  
90%15 
Acute Myeloid Leukaemia (AML) Cytarabine and daunorubicin.16  30%17 
Chronic Lymphocytic Leukaemia (CLL) Fludarabine, cyclophosphamide 
and rituximab.18  
82%19 
Chronic Myeloid Leukaemia (CML)  Imatinib.20  90%21 
Hodgkin’s Lymphoma Doxorubicin, bleomycin, 
vinblastine, dacarbazine (ABVD) 
and radiation.22  
90%23 
Non-Hodgkin’s Lymphoma Cyclophosphamide, doxorubicin, 
vincristine, prednisolone (CHOP) 
and radiation.24  
50%25 
Multiple Myeloma Bortezomib, thalidomide and 
dexamethasone.26  
35%12 
*Approximate survival rates five years after diagnosis 
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Extensive use of cytotoxic regimens may cause serious side effects, including bone marrow 
suppression, alopecia, nausea, nerve damage and sometimes major organ toxicity.27 These 
regimens are designed to interrupt rapid cell division by multiple mechanisms. For example, 
the ‘CHOP’ regimen used to treat Non-Hodgkin’s Lymphoma consists of four cytotoxins 
acting via four different mechanisms.24 Cyclophosphamide (C) is a DNA alkylating agent that 
triggers apoptosis, doxorubicin (H) is a DNA intercalating agent that interferes with 
replication, vincristine (O) actively binds to tubulin subunits to disrupt the metaphase of 
mitosis leading to apoptosis, and prednisolone (P) modulates inflammation in solid tumours. 
Figure 3 shows the structures of drugs used in the ‘CHOP’ regimen.  
 
 
Figure 3. Structures of cytotoxic chemotherapy drugs used in the ‘CHOP’ regimen for Non-
Hodgkin’s Lymphoma. 
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Radiotherapy focuses ionising radiation on a solid tumour to cause localised DNA damage 
and cell death. Because leukaemia is not localised, radiation is not effective. Side effects are 
relatively mild but radiation therapy can sometimes damage immune cells, resulting in 
immunosuppression and subsequent opportunistic infections.28 Other treatment options, 
such as bone marrow or stem cell transplantation and immunotherapy, can be effective but 
are expensive and require invasive surgery.29   
Stem cell transplantation is sometimes curative for patients with aggressive haematological 
malignancies.29 Allogenic transplantation uses donor-matched HPSCs that have been isolated 
from a donor’s bone marrow or peripheral blood. Alternatively, autologous transplantation 
uses the patient’s own cells. Bone marrow is the major site of haematopoiesis, with only 
small numbers of HSPCs found in the peripheral blood. Mobilisation of bone marrow HSPCs 
into the peripheral circulation is promoted through administration of granulocyte 
colony-stimulating factor (G-CSF).30 This enables large quantities of HSPCs to be harvested 
while lowering the invasiveness of the procedure. Transplantation is performed after high 
doses of chemotherapy or radiation, allowing haemopoietic regeneration and restoration of 
bone marrow function.31 
Experimental treatments currently being investigated include immunotherapy, gene 
therapy, vaccination and monoclonal antibody therapies. Depending on the time of diagnosis 
and severity of the malignancy, palliative care is often necessary, especially for patients with 
multiple myeloma.10 
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1.3 Drug Resistance and Minimal Residual Disease 
Malignant cells can sometimes deploy drug resistance mechanisms to avert apoptosis.  One 
contributor to resistance is known as minimal residual disease (MRD). This is where a small 
population of cells evade chemotherapy and continue to proliferate,32 and is common among 
haematopoietic malignancies and plasma dyscrasias. 33 
Although not completely understood, evidence suggests that the bone marrow 
microenvironment and de novo drug resistance mechanisms contribute significantly to MRD 
by providing a sanctuary for HPSCs through interactions with the physical environment and 
soluble factors. This is known as environment-mediated drug resistance (EM-DR).34  
Resistance promoted by soluble factors, such as interleukin-6 (IL-6), insulin-like growth 
factor-1 (IGF-1) and interferon type 1 alpha (INF-α), is called soluble factor mediated drug 
resistance (SFM-DR) and influences survival of malignant cells in the bone marrow 
microenvironment.34  
Cell adhesion mediated drug resistance (CAM-DR) arises from interactions between 
malignant cells and the stromal environment, including the extracellular matrix (ECM) and 
neighbouring cells. Adhesion of malignant HSPCs to the stromal environment is promoted by 
cell surface receptors from the cell adhesion molecule (CAM) family, namely 
immunoglobulins, cadherins and integrins. In vivo studies have shown that CAM-DR provides 
protection from cytotoxin and radiation-induced apoptosis.32,35 Prolonged survival of 
malignant cells results in ‘acquired’ resistance, where genetic alterations ultimately give rise 
to populations displaying therapy-resistant phenotypes.32 Acquired resistance has been 
shown to increase with exposure to cytotoxic agents.36 A simplified model illustrating the 
contribution of EM-DR to MRD and acquired resistance is shown in Figure 4.  
Chapter 1 - Introduction 
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Figure 4. The role of Environment Mediated Drug Resistant (EM-DR) in Minimal Residual 
Disease (MRD) and acquired drug resistance. Under normal conditions, malignant HSPCs are 
sensitive to chemotherapeutic treatments leading to cell death. In the bone marrow, 
malignant cells can develop EM-DR through upregulation of soluble factors (SFM-DR) and cell 
adhesion (CAM-DR). During treatment, many malignant cells undergo apoptosis but surviving 
populations can cause MRD. These cells can metastasise and undergo further genetic 
mutations to develop acquired drug resistance, giving rise to therapy resistant populations.  
 
Disruption of EM-DR pathways is an active area of investigation that aims to improve the 
clinical efficacy of current chemotherapeutic treatments. It is thought that EM-DR-targeting 
therapies may only be effective if used in the initial stages of haematological malignancies. 
Residual cells that have survived a barrage of chemotherapy generally develop ‘acquired’ 
drug resistance and no longer depend on EM-DR mechanisms for survival. This suggests that 
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research efforts should focus on the disruption of EM-DR mechanisms to lower the 
prevalence of MRD and acquired drug resistance.32  
 
1.4 Integrins and Very Late Antigen-4 (VLA-4) 
Integrins are a class of heterodimeric cell-surface proteins that participate in many cellular 
functions, including adhesion, proliferation, migration and activation.37 The integrin VLA-4 
(Very Late Antigen-4; α4β1, CD49d, CD29) functions to regulate the infiltration of immune 
cells into endothelia and sites of inflammation, and plays a key role in the 
retention/mobilisation of early HSPCs in bone marrow.38 VLA-4 is expressed on the surface 
of lymphocytes, leukocytes and HSPCs and its principal binding partners are Vascular Cell 
Adhesion Molecule (VCAM-1) and the CS-1 domain of fibronectin (FN).39 The affinity (KD) of 
the VLA-4/VCAM-1 interaction was estimated at 42 nM using a Förster resonance energy 
transfer (FRET) assay.40   
VCAM-1 is expressed on endothelial cells and interactions with VLA-4 facilitate rolling 
adhesion of leukocytes to the endothelium, promoting extravasation (i.e. migration out of 
blood vessels into tissues) during inflammatory responses.41,42 This process is summarised in 
Figure 5. Several inflammatory diseases are associated with aberrant immune cell 
extravasation, leading to investigations of VLA-4 as a potential anti-inflammatory drug 
target. Blockade of the VLA-4/VCAM-1 interaction appears promising in this regard, with 
VLA-4 antagonists actively being investigated as treatments for asthma, atherosclerosis, 
multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease.43,44  
Asthma is an inflammatory disease that causes restriction of respiratory airflow and smooth 
muscle bronchospasms. The disease is characterised by accumulation of VLA-4 expressing 
CD4+ T cells in the airways. Expression of VCAM-1 is also increased in asthma patients.45 
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Development of VLA-4 antagonists to evade accumulation of CD4+ T cells is ongoing. To date 
there are no small molecule VLA-4 antagonists approved for clinical use.  
 
Figure 5. Interactions between VLA-4 on leukocytes and VCAM-1 on endothelial cells 
facilitates leukocyte extravasation during inflammation. In the resting state, VLA-4 and 
selectin receptors are unoccupied on the surface of leukocytes. Upon receiving cytokine 
signals, the leukocytes are attracted towards the endothelium where their VLA-4 receptors 
interact with VCAM-1 and selectin causing rolling adhesion. Adhered leukocytes undergo 
transmigration (or extravasation) into the subendothelial matrix, where a chemokine 
gradient promotes migration towards sites of inflammation.42 
As previously mentioned, CAM-DR is a primary contributor to MRD in haematological 
malignancies. Malignant HSPCs develop resistance to chemotherapy treatments through 
interactions of VLA-4 and stromal components, such as the extracellular matrix, which 
mediate anti-apoptotic and proliferative signals.39 Evidence suggests that drug resistant 
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phenotypes of malignant HPSCs correlate with the overexpression of VLA-4.35 This suggests 
that VLA-4 may be a significant contributor towards CAM-DR through VLA-4 ligation, 
although the mechanisms are not yet clear.35  
One theory postulates that VLA-4 mediated adhesion through interactions with fibronectin 
upregulates the apoptosis regulator Bcl-2.39 Upregulation of anti-apoptotic Bcl-2 increases 
resistance to anoikis (cell death program triggered by loss of anchorage) and apoptosis. 
Matsunaga and co-workers identified that adhesion of VLA-4 positive cells to fibronectin 
induces PI-3K/AKT/mTOR signalling, leading to enhanced Bcl-2 expression.39 When the cells 
were treated with PI-3K inhibitors, Bcl-2 expression was suppressed and chemosensitivity 
restored. Survival rates of 100% were observed when mice with MRD were treated with 
cytarabine and VLA-4 specific antibodies, supporting the hypothesis that VLA-4 adhesion 
activates a signalling cascade leading to chemoresistance.39 
Integrin family members are attractive drug targets due to their diversity and apparent 
involvement in several disease states. While many VLA-4 antagonists show in vitro efficacy, 
a clinically effective drug remains elusive.46 Current efforts are focussing on adjuvant therapy 
with integrin antagonists.46 VLA-4/VCAM-1 interactions play a crucial role in determining the 
tissue distribution of early HSPCs, and blocking these interactions with antibodies or small 
molecule antagonists induces rapid mobilisation of these cells from the bone marrow 
(Figure 6).38,31 It is postulated that if VLA-4 antagonists induce rapid, large-scale mobilisation 
of MRD cells out of the bone marrow into the peripheral circulation, they will become more 
vulnerable to cytotoxic drugs.39,35,47 It has been proposed that VLA-4 antagonists in 
combination with cytotoxic chemotherapy could disrupt CAM-DR, allowing MRD populations 
to be eradicated leading to improved patient outcomes.   
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Figure 6. Blocking VLA-4/VCAM-1 interactions with antagonists or antibodies causes 
detachment of HSPCs from bone marrow and mobilisation into peripheral blood. 
 
1.5 Small Molecule VLA-4 Antagonists   
 
Since the 1990’s α-integrin antagonists have been extensively explored as potential drugs to 
treat multiple inflammatory diseases. Numerous integrin antagonists have failed to achieve 
pharmacokinetic goals, namely oral bioavailability and cardiovascular safety. Despite their 
shortcomings, several drug candidates show efficacy upon intravenous administration. For 
example, tirofiban (Merck) is an FDA-approved inhibitor of the αIIbβ3 integrin (platelet 
integrin), that is intravenously administered to prevent ischemia in patients with 
cardiovascular complications.46 Several promising orally active candidates (e.g. orbofiban) 
have been explored but ultimately failed phase III clinical trials due to drug-related 
cardiovascular side effects.46 More recent programs have focused on treating other 
inflammatory diseases, such as multiple sclerosis (firategrast) and asthma (IVL-745), through 
targeting VLA-4 (α4β1). The structures of these compounds are shown in Figure 7. 
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Figure 7. Structures of four α-integrin antagonists that have been investigated as treatments 
for inflammatory diseases.46 
The most successful VLA-4 mediated treatment is not a small molecule but a humanised 
monoclonal antibody marketed by Biogen Idec, called natalizumab. Inhibition of VLA-4 was 
validated as the therapeutic target and in 2004 natalizumab received FDA approval for 
treating multiple sclerosis and Crohn’s disease.35 In 2014 natalizumab generated sales of USD 
$2 billion for Biogen Idec. This antibody acts to reduce migration of leukocytes into the CNS 
by blocking the VLA-4/VCAM-1 interaction.48 Natalizumab use is associated with increased 
risk of developing the rare and fatal neurological condition called progressive multifocal 
leukoencephalopathy (PML).46 This disease is caused by the JC virus, a common pathogen 
that is normally controlled by the immune system but can be a threat to immunosuppressed 
individuals. It is common in patients with AIDS, multiple sclerosis and cancer. The success of 
natalizumab stimulated activity around VLA-4 antagonists, however, pharmaceutical 
companies were discouraged by the risk of inducing PML. Development of VLA-4 antagonists 
has since slowed, but not ceased. Research continues in the hope that small molecule VLA-4 
antagonists will be safer and more cost-effective than natalizumab.  
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Compound 1 (Figure 8) was a potent, orally active VLA-4 antagonist that was shown to 
alleviate immune responses in an asthmatic model.43 However, the compound showed an 
increased incidence of cardiac events and its development was abandoned.49 
 
Figure 8. Structure of small molecule VLA-4 antagonist 1.43 
 
Merck scientists studied VLA-4 antagonists as novel treatments for various inflammatory 
diseases.50 These studies identified that the ligands VCAM-1 and fibronectin (FN) bind to 
VLA-4 using short peptide sequences. The minimal binding epitope of VCAM-1 was identified 
as Ile-Asp-Ser (located in its C-D loop) and Leu-Asp-Val for FN (located in its CS-1 region).51 
Cyclic and acyclic peptide derivatives containing these sequences were explored in early 
medicinal chemistry programs.52 A common structural feature was a free terminal carboxyl 
group, which mimics the aspartic acid (Asp40) residue in the VCAM-1 and FN binding 
epitopes. Extensive SAR studies led to compound classes that include 2 and 3 (Figure 9).50  
 
Figure 9. Structures of non-peptide 2 and cyclic peptide 3 VLA-4 antagonists from early SAR 
studies.50 
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N-Acylphenylalanines constituted a major class of peptidomimetic VLA-4 antagonists. Over 
200 compounds with inhibition constants (IC50) ranging from 0.01 nM to 2,000 nM were 
published in a patent in 2003.50 Hagmann and co-workers used combinatorial chemistry to 
discover a range of sulfonylated dipeptides mimetics and identified 4 as a promising lead 
(Figure 10).53  
 
Figure 10. Structure of sulfonylated dipeptide mimetic 4.53 
 
Using solid phase peptide synthesis methods, over 300 compounds were synthesised to 
optimise the lead compound. Inhibition was measured in a competitive binding assay using 
radiolabelled 125I-VCAM-Ig and human Jurkat T-lymphocytes. The SAR studies yielded potent 
analogues 5-8.53 Replacing the isoquinoline with a proline residue as in 5 resulted in only a 
small change in potency. Changing the butyl sidechain to a 2-naphthyl group 6 produced an 
8-fold improvement. Substituting the 4,5-dimethoxybenzene sulfonamide with 
3,5-dicholorobenzene sulfonamide to produce 7 maintained potency. The individual 
contributions of these changes were found to be additive, with compound 8 showing 
100-fold higher potency than 4 (Figure 11).  
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Figure 11. Structures of the most potent VLA-4 antagonists 5-8.53  
 
Rat liver microsomes were found to oxidise 8 into several species, with the metabolic 
liabilities attributed to the naphthyl component. Further optimisation identified that 
biphenyl analogues circumvent this issue and further improved potency. An α-methyl group 
was subsequently introduced to limit hydrolysis of the adjacent amide bond and improve 
pharmacokinetic properties. These alterations, and inclusion of the 3,5-dimethoxy biphenyl 
appendage produced 9 (Figure 12). 
 
 
Figure 12. Structure of extraordinarily potent VLA-4 antagonist 9.53  
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In vivo studies in rats revealed that the sulfonylated dipeptide mimetics were rapidly 
eliminated from plasma.53 To address this, it was postulated that analogues with very slow 
VLA-4 “off-rates” would produce prolonged pharmacological responses despite their 
pharmacokinetic shortcomings.54 While compound 9 displayed picomolar (pM) affinity for 
VLA-4, its off-rate was rapid with only 1% remaining bound after 1 hour. Doherty and 
co-workers subsequently pursued analogues that maintained picomolar potency but showed 
slower off-rates. It was predicted that a small molecule VLA-4 antagonist with an 80% off-rate 
after 12 hours would match the efficacy of natalizumab.55 Insertion of an amide between the 
phenyl rings and addition of polar para substituents were found to maintain potency and 
significantly improve off-rates. Structures and data for a selection of compounds (10-15) are 
shown in Figure 13. 
Introduction of the 3,5-dichlorobenzamide group 10 improved the off-rate relative to 
compound 9. Para substitution with a methyl pyrrolidine 11 maintained potency and 
improved the off-rate. Incorporation of a 3,5-dichloroisonicotinamide group as in 12 further 
decreased the off-rate, with the effect attributed to the pyridine nitrogen. Removal of the 
α-methyl group resulted in 13, which showed a 62% off-rate. The program at Merck 
continued for some years and in 2009 three reports appeared describing new analogues with 
impressive activities.55,56,57  
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Figure 13. Compounds 10-15 showing improved VLA-4 off-rates whilst maintaining potency 
against VLA-4. Percentages refer to the amount of compound still bound to VLA-4 after 
1 hour. *Off-rate after 3 hours. Compound 13 is highlighted for its relevance to this PhD 
project (vide infra). 55,56,57 
 
Introduction of a (R)-cyclobutylamino group at the γ-position of the proline ring and replacing 
the 3,5-dichlorobenzene sulfonamide with a 3-cyanobenzene sulfonamide produced 
compound 14, an extremely potent VLA-4 antagonist with IC50= 50 pM and a slow off-rate. 
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The final compound developed was 15, which contained an (R)-3,3-difluoropiperidinyl 
substituent. The compound was the most potent VLA-4 antagonist (IC50= 20 pM) and was 
90% retained on the receptor after 3 hours. It also displayed prolonged effects in vivo (70% 
after 12 hours), which increased when administered as the ethyl ester prodrug (88% after 12 
hours). These off-rates were comparable to natalizumab. Despite its high receptor occupancy 
compound 15 suffered from low systemic exposure (poor oral bioavailability) and its 
development was stopped. 
 
1.6 Allosteric VLA-4 Antagonists 
While competitive VLA-4 antagonists have been extensively explored there are relatively few 
reports of allosteric VLA-4 antagonists. Competitive antagonism of αIIbβ3, αvβ3 and α4β1 
(VLA-4) integrins occurs at the α-subunit and β-subunit I-like domain. Several integrins 
contain an additional domain (I-domain) that can serve as a ligand binding site.42 Allosteric 
antagonists targeting I-domains have been explored for the treatment of inflammatory 
diseases. Two classes of allosteric antagonists have been identified and are labelled 
according their binding location; i.e. α-I allosteric antagonists and α/β I-like allosteric 
antagonists. Examples include BIRT0377 (Boehringer-Ingelheim), which targets the α-I 
domain, and XVA143 (Roche) which targets αβ-I (Figure 14).42    
 
Figure 14. Structures of representative allosteric antagonists from the α-I and αβ-I classes. 
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Several integrins (including VLA-4) do not contain the I-domain and no allosteric antagonists 
had been developed. In 2011 Chigaev et al. reported an assay capable of identifying both 
competitive and allosteric antagonists of VLA-4. Binding of competitive VLA-4 antagonists to 
the ligand orthosteric site induces a conformational change that exposes an antibody 
recognition epitope called the ligand-induced binding site (LIBS).58 Chigaev exploited this 
effect to identify novel VLA-4 antagonists and measure their binding affinities.59,60 Exposure 
of the epitope is exclusively triggered by occupancy of the orthosteric site, meaning that anti-
LIBS antibodies can discriminate between allosteric and competitive VLA-4 antagonists.61 
Chigaev showed that binding of a fluorescence peptide orthosteric site probe (LDV-FITC, 
Figure 15) induced exposure of the LIBS and its dissociation constant was equal to the EC50 
of anti-HUTS-21 allowing quantitative determination of competitive antagonist binding 
affinities.60   
 
Figure 15. Structure of FITC-tagged LDV-containing probe peptide used to bind the orthosteric 
site of VLA-4.  
In Chigaev’s modified assay, human U937 cells were loaded into 384-well plates with 
compounds from the Prestwick Chemical Library and incubated at room temperature for 10 
minutes. Non-fluorescent LDV peptide and R-phycoerythrin (PE) tagged anti-HUTS-21 mAb 
were then added to the wells. Addition of the LDV peptide resulted in exposure of the LIBS, 
triggering PE-antibody binding. After incubation for 1 hour at 37 °C, the cells were sampled 
using flow cytometry to measure fluorescence emitted from the PE-anti-HUTS-21 antibody. 
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Allosteric antagonists would reduce LIBS exposure upon binding by reducing LDV-peptide 
binding to the orthosteric site. Competitive antagonists also trigger opening of the LIBS and 
are thus not detected, making the assay selective for VLA-4 allosteric antagonists. A 
schematic of the assay is provided in Figure 16. Inhibition (%) was calculated from the 
equation shown and compounds were considered hits if inhibition was >50%.61
Figure 16. Assay of Chigaev et al. used to screen for novel VLA-4 allosteric antagonists.61 
The screen initially identified 36 structurally-related phenothiazines as allosteric antagonists. 
In follow-up assays cells were incubated with the LDV-FITC peptide and increasing 
concentrations of the hit phenothiazines. Addition of the hits caused dissociation of the 
LDV-FITC peptide, allowing determination of EC50 values. The structures and EC50 values of 
the three most potent phenothiazine-type antagonists identified are shown in Figure 17.   
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Figure 17. Structures and EC50 values of phenothiazine-type VLA-4 allosteric antagonists 
identified by Chigaev et al.61  
 
As previously discussed (Section 1.4), VLA-4 plays a primary role in cell adhesion through its 
interactions with VCAM-1 and fibronectin and blocking this interaction is a strategy for 
treating inflammatory diseases and a potential method of addressing MRD in haematological 
cancers. As it had been shown that antibodies and small molecule VLA-4 antagonists can 
induce mobilisation of HSPCs, it was hypothesised that allosteric antagonists would behave 
similarly. To test this, mice were injected with the most potent phenothiazine 
(±)-thioridazine 16, and the number of circulating HSPCs was measured against a positive 
control, AMD3100 (Plerixafor). Administration of thioridazine resulted in comparable 
mobilisation of HPSCs to AMD3100, thus supporting allosteric VLA-4 antagonism as a 
possible approach to addressing MRD.61  
In 2015 Chigaev and co-workers evaluated thioridazine as a HSPC mobilising agent in human 
subjects.62 The study indicated that long-term exposure to thioridazine leads to effective 
HSPC mobilisation but in the short-term does not. This finding correlated with a previous 
study of long-term thioridazine use. In 1966, Fieve et al. reported on the relationship 
between atypical lymphocytes found in the blood, phenothiazine use and schizophrenia. One 
key observation was that ‘atypical lymphocytes’ appeared in the peripheral blood of 
patients, both with and without schizophrenia, who had been treated with phenothiazines.63 
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The ‘atypical lymphocytes’ morphologically resembled early HSPCs, thus supporting 
Chigaev’s theory that phenothiazines cause mobilisation of HSPCs into peripheral blood 
through allosteric VLA-4 antagonism. 
In comparison to the optimised and extremely potent VLA-4 competitive antagonists, 
thioridazine 16 is only a lead compound. It is thought that allosteric antagonists might 
achieve similar therapeutic responses to competitive antagonists without the 
pharmacokinetic limitations. Extensive SAR work is still required to identify the structural 
features in the phenothiazine class required for potent VLA-4 allosteric antagonism. 
Nonetheless, thioridazine 16 represents a valuable new tool for exploring the 
pharmacological effects of non-competitive VLA-4 allosteric antagonists.  
 
1.7 Phenothiazines and Thioridazine 
Phenothiazines have been used historically as antidepressants and neuroleptics 
(antipsychotics) due to their well-characterised effects on dopamine, serotonin, and 
cholinergic receptors.64 Use of phenothiazines was hampered by serious side effects, 
including tardive dyskinesia (i.e. involuntary body movements) and neuroleptic malignant 
syndrome, a life-threatening condition that causes muscle rigidification, autonomic 
instability and delirium.65 Phenothiazines have largely been superseded by new generations 
of neuroleptics, such as Olanzapine, which offer more tolerable side effect profiles.66 
Phenothiazines are divided into three classes according to the substituent attached at the 
thiazine nitrogen; i.e. piperazines, aliphatics and piperidines. Each class shows different 
effects on the autonomic nervous system, varying between low, medium and high. These 
classifications also dictate sedative strength and severity of extrapyramidal symptoms like 
tardive dyskinesia. Thioridazine saw major use clinically as an antipsychotic but was 
ultimately removed from the market due to the frequency of cardiovascular side effects.67 
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Thioridazine is administered as a racemate and acts as a competitive antagonist at dopamine 
D1 and D2 receptors. Schizophrenia is caused by overstimulation of dopamine receptors or 
by abnormally high numbers of dopamine receptors and attenuation of dopamine signalling 
relieves psychotic behaviour. Being a dual D1/D2 antagonist, thioridazine received great 
interest. Studies showed that (R)-thioridazine has 2.7 times greater affinity for D2 receptors, 
while (S)-thioridazine has 10 times greater affinity for D1 receptors. It is believed that 
anti-psychotic effects are mediated through the (R)-thioridazine enantiomer, although no 
research has studied the enantiomer-selective effects in detail.68 
Since its market withdrawal, repurposing of thioridazine for other indications has received 
considerable interest, although dopaminergic side effects will always be a concern.69 
Thioridazine has shown promise as a new agent against methicillin-resistant Staphylococcus 
aureus (MSRA),70 breast cancer71 and multi-drug resistant tuberculosis (MDR-TB).64 
Thioridazine showed ‘curative’ effects in patients treated for MDR-TB in Argentina.72 There 
are many theories around its mechanism against MDR-TB, including its effects on efflux 
pumps.64 Thioridazine was more recently shown to increase the cell-envelope permeability 
of Mycobacterium tuberculosis, allowing standard treatments to be more effective.73 A 
structure activity study (2017) reported that compound 12e (Figure 18) shows stronger 
antimycobacterial activity than thioridazine and displays 15-fold lower eukaryotic cell 
cytotoxicity.74  
 
Figure 18. Structure and MIC data of 12e against MDR-TB strain CF81.74 
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Thioridazine has also shown promise as an anti-cancer agent. Sachlos and co-workers 
showed that neoplastic HSPCs treated with thioridazine 16 undergo differentiation that 
reduces neoplastic self-renewal.75 This suggested a new treatment approach towards AML 
as the disease is sustained by self-renewing leukemic HPSCs. It is noteworthy that malignant 
HSPCs express all five dopamine receptor subtypes. Selective binding of thioridazine to D2 
receptors implies that D2 signalling plays a role in AML cell survival. The effects of 
thioridazine were observed at concentration below 10 µM, which was a clinically relevant 
plasma level during antipsychotic treatment with the drug. The combination of cytarabine 
and thioridazine almost completely eradicated AML cells without effecting HSPCs.75 This 
corroborates the findings Chigaev and co-workers, who recommended thioridazine be 
assessed as a chemosensitising agent.62  
Thioridazine also induces apoptosis in multi-drug resistant lymphoma cells in a dose 
dependent manner at concentrations above 5 µg/mL.76 Complete eradications of cells was 
seen at 20 µg/mL, which is significantly higher than the plasma concentrations targeted 
during antipsychotic therapy.76 
Acquired drug resistance often develops through genetic alterations caused by cytotoxic 
exposure. A major mechanism of multi-drug resistance in cancer is expression of the 
ATP-dependant transporter known as the ATP-binding cassette (ABC). These efflux pumps 
recognise and extrude large molecules (ABC1) and drug conjugates (ABCC1/ABCG2). 
Thioridazine was shown to inhibit this transporter more effectively than two positive controls 
(verapamil and reserpine), triggering apoptosis.76 This result suggests a possible 
dual-therapeutic synergy for thioridazine where it inhibits CAM-DR through allosteric 
antagonism of VLA-4, and the ABC transporter. Thioridazine also induces apoptosis in cervical 
and endometrial cancer lines where it shows efficacy comparable to cisplatin.77 The 
mechanism involves inhibition of phosphorylation of Akt, one the major targets of the 
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PI-3K/AKT/mTOR signalling cascade and is thought to involve inhibition of VLA-4 mediated 
up-regulation of apoptosis protein Bcl-2.39 Matsunaga and co-workers identified that 
adhesion of VLA-4 positive cells to fibronectin induced PI-3K/AKT signalling that enhanced 
Bcl-2 expression.39 A summary of the multiple effects of thioridazine on malignant HSPCs is 
shown in Figure 19. 
 
 
Figure 19. Multiple effects of thioridazine against malignant HSPCs: (1) allosteric antagonist 
of VLA-4 (blocks VLA-4 interactions with stromal cells to disable CAM-DR mechanisms), 
(2) induction of apoptosis (disruption of PI-3K/AKt/mTOR signalling through inhibition of the 
ABC1 transporter), (3) binding to extracellular dopamine receptors (induce differentiation in 
malignant HSPCs). Thioridazine in combination with chemotherapy is predicted to enhance 
efficacy against MRD and reduce disease recurrence. 
 
 
(1) 
(3) 
(2) 
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To summarise, thioridazine elicits multiple effects on malignant HSPCs and when used in 
combination with chemotherapeutic regimens could impact MRD leading to reduced disease 
recurrence. Thioridazine can inhibit two key chemoresistance mechanisms; the ABC1 
transporter and the PI-3K/AKT/mTOR signalling cascade. When co-administered with 
cytotoxic agents, the response will likely be more effective, especially when malignant cells 
are mobilised into the peripheral blood and triggered to undergo selective differentiation.  
 
1.8 Multi-Action Thioridazine-VLA-4 Antagonist Hybrids 
Research into the repurposing of thioridazine 16 spurred our interest in creating a hybrid 
molecule that could probe both the orthosteric and allosteric sites of VLA-4. Ideally, a hybrid 
molecule could serve to improve the therapeutic effects of the two drugs (in one molecule) 
and reduce undesired effects. We designed a hybrid molecule that incorporates the key 
structural components of the competitive VLA-4 antagonist 13 (Figure 13)54 and thioridazine 
16, the most potent of the allosteric VLA-4 antagonists identified by Chigaev et al.61 The linker 
was arbitrary, serving only to connect the two compounds without interfering with the 
target-binding of the parent compounds. A 1,2,3-triazole linker was chosen as it allowed an 
efficient convergent synthesis that brought together late-stage synthetic intermediates via 
the reliable ‘click’ reaction. The structure of a prototype hybrid 17 is shown in Figure 20. 
The hybrid 17 was conceptualised to investigate an innovative approach for treating 
haematological malignancies. The combined effects of the VLA-4 competitive antagonist and 
thioridazine allosteric antagonist in one molecule might enhance malignant HSPC 
mobilisation from the bone marrow into the peripheral blood, thereby facilitating 
eradication during chemotherapy. Reducing malignant HSPC survival and minimising MRD 
could reduce disease recurrence. In addition, the thioridazine moiety may induce 
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differentiation and apoptosis by disabling multiple chemoresistance mechanisms, making 
co-administered cytotoxic agents more effective.  
 
  
Figure 20. Structure of thioridazine-VLA-4 antagonist hybrid 17 incorporating the structural 
components of competitive VLA-4 antagonist 13 (red) and allosteric VLA-4 antagonist 
thioridazine 16 (blue) tethered by a 1,2,3-triazole linker (black). 
In principal, binding of hybrid 17 to VLA-4 could occur at both the orthosteric site (via the 
region that mimics compound 13) or the allosteric site (via thioridazine moiety). Binding of 
the hybrid to the competitive site would reveal the ligand-induced binding site (LIBS) in 
Chigaev’s assay.61 Occupation of the allosteric site would induce a conformational change at 
the orthosteric site, preventing competitive ligands from binding. Consequently, the two 
VLA-4 components of hybrid 17 could not simultaneously occupy both sites on one VLA-4 
molecule. These concepts are summarised in Figure 21. 
Given the high molecular weight of 17, it is foreshadowed that the molecule would be 
unlikely to possess suitable drug properties for clinical use without further medicinal 
chemistry optimisation. Nevertheless, the model in Figure 22 suggests that 17 would at the 
very least be an interesting biological probe. The ability of a compound to target two sites 
Competitive VLA-4 antagonist based on 
compound 13 
Thioridazine: allosteric VLA-4 
antagonist and apoptosis 
triggering agent 
Linker 
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on a single protein is interesting and warrants investigation. Since thioridazine binds to 
dopamine receptors, unknown interactions between VLA-4 and dopaminergic systems might 
also be identified with the compound. 
 
Figure 21. Proposed modes of binding of 17 to VLA-4. Binding could occur at either the 
allosteric site (a) or at the competitive binding site (b). Binding at the competitive site would 
cause a conformational change, exposing the Ligand-Induced Binding Site (LIBS). Binding at 
the allosteric site would alter the conformation of the orthosteric site, thus preventing both 
sites from being simultaneously occupied by two molecules of 17. 
The synergistic effects and activity of the hybrid would be of moderate interest. Chigaev and 
co-workers synthesised a fluorescein analogue of 13 to investigate the binding modes of 
VLA-4 (Figure 22). The molecule maintained good potency (IC50= 50 nM) and was able to 
induce rapid mobilisation of HSPCs (personal communication). Addition of the large 
fluorescein moiety to the proline nitrogen without significant loss of affinity for the VLA-4 
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orthosteric site suggests that other large bulky groups could similarly be appended here, as 
in 17.  
 
Figure 22. Structure of 18, a fluorescein-labelled analogue of 13 that retained potent 
inhibition of VLA-4 and induced rapid mobilisation of HSPCs.78  
 
Combining the two VLA-4 antagonists into one molecule should increase VLA-4 receptor 
occupancy to promote better mobilisation of HSPCs into the peripheral blood. Secondly, the 
high affinity of compound 13 (IC50 = 100 pM) would localise thioridazine to the target cells in 
the bone marrow and peripheral blood, which may improve other thioridazine-mediated 
effects, such as its influence on cell differentiation and apoptosis. Finally, the hybrid 17 
should not show CNS side effects arising from the thioridazine moiety since its high molecular 
weight would preclude penetration of the blood brain barrier.  
The aim of this project was to develop a viable synthesis of the hybrid 17. As thioridazine was 
administered clinically as a racemate and because little is known about the effects of 
individual enantiomers, it was deemed necessary to synthesise both epimers of the hybrid 
i.e. (R)-17 and (S)-17, which are epimeric at the position indicated in Figure 20. It was 
anticipated that proceeding with only one thioridazine enantiomer would circumvent 
difficulties associated with formation of diastereomeric products. The following chapter 
details the successful synthesis of the two epimers. 
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Chapter 2 – Results and Discussion 
2.1 Synthetic Strategy Towards Hybrid Epimers  
The synthesis of the epimers of 17 was pursued via a convergent strategy that allowed the 
thioridazine and VLA-4 antagonist fragments to be synthesised in parallel and then ‘clicked’ 
together with only one additional step required thereafter (methyl ester hydrolysis). This 
strategy involved (±)-thioridazine 16 resolution as the key process for setting thioridazine 
stereochemistry in the epimers. The ‘click’ partners were designed such that the terminal 
alkyne was part of the (R)- and (S)-N-propargyl northioridazine enantiomers 19 and the azide 
was a para substituent on the benzene sulfonamide group of VLA-4 antagonist derivative 20 
(Figure 23).   
 
 
Figure 23. Structures of the ‘click’ partners required for the convergent synthesis of hybrid 17. 
(left) (R)- and (S)-N-propargyl northioridazine 19 and (right) p-azido functionalised VLA-4 
antagonist derivative 20. 
 
Separately reacting (R)- and (S)-19 with azide 20 under ‘click’ conditions aimed to connect 
the two fragments and generate two epimers of the penultimate methyl ester hybrid 
precursors, which upon hydrolysis would yield (R)- and (S)-17 (Figure 24). 
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Figure 24. Structure of target thioridazine-VLA-4 antagonist hybrid epimers (R)-17 and (S)-17. 
 
2.2 Convergent Synthesis of VLA-4 Antagonist Fragment 20 
Synthesis of this class of VLA-4 antagonist has been extensively developed and reported in 
the literature.79 Compound 20 was a novel analogue and incorporation of the p-azido 
function proved to be challenging. Convergent syntheses of key fragments 21 and 22 was 
undertaken, with subsequent amide coupling affording 20 (Scheme 1).  
 
 
Scheme 1. The convergent strategy involved synthesising fragments 21 and 22 and linking 
them via an amide coupling to produce ‘click’ partner 20.  
 
Fragment 21 is present in several reported VLA-4 antagonists and its synthesis is described.79 
Fragment 22 was a novel compound that required the development of new chemistry. The 
final peptide coupling was anticipated to be a reliable method for bringing the two fragments 
together in generating 20.  
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2.2.1 Synthesis of Boc-Tyr(p-3,5-dichloroisonicotinamide)-OMe 21 
Using a reported procedure, Boc-Phe(p-3,5-dichloroisonicotinamide)-OMe 21 was prepared 
by coupling commercial Boc-Phe(p-NH2)-OMe to the freshly prepared acid chloride of 3,5-
dichloroisonicotinic acid (Scheme 2).79 To generate the acid chloride, 3,5-dichloroisonicotinic 
acid was dissolved in CH2Cl2 and thionyl chloride (1.2 eq) was added along with catalytic DMF. 
The heterogeneous reaction mixture was heated at reflux until TLC analysis indicated 
consumption of the acid. If required, another portion of thionyl chloride (1.2 eq) was added 
to complete the reaction. Upon completion, the reaction was concentrated in vacuo and the 
excess thionyl chloride removed by azeotropic distillation with benzene. 
 
 
Scheme 2. Synthesis of Boc-Phe(p-3,5-dichloroisonicotinamide)-OMe 21. Reagents and 
conditions: (a) SOCl2, DMF (cat.), CH2Cl2, reflux; (b) Boc-Phe(p-NH2)-OMe, N-methyl 
morpholine, CH2Cl2, 0 °C-rt, (94% over two steps, Lit. 74%).79 
 
The acid chloride was immediately coupled to commercially available Boc-Phe(p-NH2)-OMe 
in dry CH2Cl2 with N-methyl morpholine (2 eq) as base. The reaction proceeded readily and 
was completed overnight. After an aqueous work-up and purification by silica gel column 
chromatography, compound 21 was isolated in excellent yield (94%, Lit. 74%)79 and the 
compound matched the reported spectral data. The compound was prepared several times 
on scales from 100 mg to 2.45 g in consistent yield.   
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2.2.2 Synthesis of 22 
Several VLA-4 antagonists have been synthesised previously that incorporate an N-sulfonyl 
L-proline.54 It was envisaged that fragment 22 could be accessed by N-sulfonylation of 
L-proline methyl ester hydrochloride with 4-azidobenzene sulfonyl chloride (Scheme 3).  
 
 
Scheme 3. Proposed synthesis of fragment 22 via N-sulfonylation of L-Pro-OMe.HCl with 
4-azidobenzene sulfonyl chloride followed by methyl ester hydrolysis.  
 
4-Azidobenzene sulfonyl chloride was not commercially available. Additionally, It is known 
that an explosive side product (4-azidobenzenesulfonyl azide) forms during the azidation 
step in the published synthesis of 4-azidobenzene sulfonic acid (Scheme 4).80 The 
unavailability of 4-azidobenzene sulfonyl chloride made the route proposed in Scheme 3 
intractable. It was next considered that 22 could be produced by installing the azide after 
N-sulfonylation of L-Pro-OMe.HCl if a suitably functionalised derivative was used. Several 
commercial p-substituted benzene sulfonyl chlorides were identified that could be 
transformed into the desired azide using reported methods. 
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Scheme 4. Literature synthesis of 4-azidobenzene sulfonyl chloride that reportedly produces 
explosive side product 4-azidobenzene sulfonyl azide.80 
 
Anderson et al. reported a facile rapid synthesis of aryl azides from aryl halides using a 
copper(I) iodide catalyst that is a milder alternative to the Ullmann reaction.81 Using this 
chemistry, access to 22 would be obtained by N-sulfonylation of L-Pro-OMe with 
4-bromobenzene sulfonyl chloride to generate 4-bromobenzene sulfonamide 23. Copper 
catalysed azidation by Andersen’s method would then transform 23 to azide 24, with 
subsequent methyl ester hydrolysis producing compound 22 (Scheme 5).  
 
 
Scheme 5. Revised synthesis of 22 using Andersen’s Ullmann-type reaction.81 Reagents and 
conditions: (a) Et3N, CH2Cl2, rt; (b) NaN3, sodium ascorbate (5 mol%), CuI (10 mol%), DMEDA 
(15 mol%), EtOH:H2O (7:3), reflux; (c) methyl ester hydrolysis. 
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2.2.3 N-Sulfonylation of L-Proline-OMe.HCl 
A summary of the reactions performed for the N-sulfonylation of L-proline-OMe.HCl with 
4-bromobenzene sulfonyl chloride is provided in Table 2. Initial reactions were carried out 
by adding 4-bromo benzenesulfonyl chloride (1.5 eq) to a solution of L-proline-OMe.HCl in 
anhydrous CH2Cl2, followed by addition of triethylamine (2 eq). The reaction was allowed to 
stir at room temperature and monitored by TLC analysis. These conditions produced the 
sulfonamide 23 in only 30% yield (Entry 1). 
 
Table 2. Summary of reactions for the N-sulfonylation reactions of L-proline-OMe.HCl with 
4-bromobenzene sulfonyl chloride to generate 23. 
 
Entry Scale (mg) Solvent Base Temperature Isolated Yield (%) 
1 300 CH2Cl2 Et3N rt 30 
2 500 CH2Cl2 DIPEA rt 35 
3 200 CH2Cl2 DIPEA reflux 29 
4 200 Pyridine Pyridine rt 61 
5* 500 Pyridine Pyridine rt 77 
6* 1000 Pyridine Pyridine rt 83 
* Pyridine was pre-mixed with the sulfonyl chloride 
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Changing the base to N,N-diisopropylethylamine (DIPEA) and heating the reaction at reflux 
had litte effect on the isolated yield (Entries 2 and 3). Use of pyridine as the reaction solvent 
and base gave higher yields of 23 (Entry 4, 61%). Pre-mixing the sulfonyl chloride with 
pyridine prior to addition of L-proline-OMe.HCl accelerated the reaction and led to higher 
yields (Entries 5 and 6). Pre-mixing resulted in a deep orange solution and a white precipitate, 
suspected to be the highly reactive N-sulfonyl pyridinium salt (Figure 25). The major product 
by TLC analysis was purified by silica gel column chromatography and its structure was 
confirmed by spectroscopy as 23. 
 
 
Figure 25. Proposed mechanism for the higher yield of 23 obtained after pre-mixing 
4-bromobenzene sulfonyl chloride with pyridine, which led to formation of a reactive 
N-sulfonyl pyridinium salt. 
2.2.4 Copper(I) Catalysed Azidation 
The next step explored was azidation of aryl bromide 23 to give aryl azide 24 using catalytic 
copper(I) iodide. A summary of the reactions attempted is provided in Table 3. Initial 
experiments were carried out using the conditions reported by Anderson et al. where 
conversion of aryl bromides to azides were achieved in 82-99% yield.81 Bromo-sulfonamide 
23 was dissolved in a mixture of ethanol and water (7:3) and copper(I) iodide (10 mol%), 
sodium ascorbate (5 mol%), sodium azide (2 eq) and N,N’-dimethylethylenediamine 
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(DMEDA, 15 mol%) were added.81 The reaction mixture was heated at reflux and monitored 
by TLC analysis. These conditions led to in situ transesterification to the ethyl ester and very 
little of the desired methyl ester product was isolated (Entry 1). Substituting ethanol for 
methanol avoided this issue and afforded the aryl azide 24 in 32% yield after silica gel column 
chromatography (Entry 2). As these conditions had previously been optimised by Andersen 
et al. no further optimisation was explored. Repeating the reaction on larger scale had little 
effect on the isolated yield (Entries 3 and 4).  
 
Table 3. Summary of reactions for transforming aryl bromide 23 to aryl azide 24 using sodium 
azide and a copper(I) catalyst. 
 
Entry Scale (mg) Solvent Isolated Yield (%) 
1 100 EtOH:H2O (7:3) <10 
2 150 MeOH:H2O (7:3) 32 
3 350 MeOH:H2O (7:3) 28 
4 500 MeOH:H2O (7:3) 25 
 
 
The modest yield was due to the reaction not reaching completion and because of formation 
of amine 25 (45% yield). Additionally, aryl bromide 23 and aryl azide 24 showed identical Rf 
values (Rf = 0.76 40:60, EtOAc: Pet. Spirit) under various combinations of solvent conditions, 
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making reaction monitoring and purification by chromatography difficult and inefficient. 
Scaling up the reaction afforded some material, but the low yields and purification difficulties 
led to abandonment of this route.  
An alternative was envisaged that exploited the amine 25 encountered during the failed 
route. Helquist et al. reported that the results of Andersen and co-workers could not be 
replicated, instead giving substantial yields of undesired amines with several substrates.82 
Helquist’s modifications to the reaction focussed on generating higher yields of the aryl 
amine from the aryl halides. Helquist’s method was explored for the preparation of aryl 
amine 25 from aryl bromide 23. Diazotisation of the amine 25 with sodium nitrite was 
expected to form the intermediate aryldiazonium salt, which after displacement with sodium 
azide would produce methyl ester protected aryl azide 24, which upon hydrolysis would yield 
the target 22 (Scheme 6). 
 
 
Scheme 6. Revised strategy towards aryl azide 22 using the amination method reported by 
Helquist and co-workers.82   
 
Amines were previously believed to form via thermal decomposition of the azide but this 
was later disproven.82 The revised mechanism begins with oxidative addition of the copper(I) 
catalyst, followed by nucleophilic displacement of the bromine to the azide. A two-electron 
reduction of the azide followed by reductive elimination produces the amine (Scheme 7). 
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Scheme 7. Putative mechanism for the copper-catalysed formation of aryl amines (e.g. 25) 
from an aryl bromide (e.g. 23). 
 
2.2.5 Copper-Mediated Conversion of Aryl Bromide 23 to Amine 25 
Helquist and co-workers had previously optimised the conditions of Andersen et al. for 
production of amines so only these conditions were explored.82 Aryl bromide 23, sodium 
azide (2 eq), copper(I) iodide (1 eq) and DMEDA (1.5 eq) in anhydrous DMSO were heated to 
100 °C and the reaction monitored by TLC analysis (Scheme 8).  
 
 
Scheme 8. Copper mediated conversion of aryl bromide 23 to amine 25 using the conditions 
reported by Helquist and co-workers.82 Reagents and conditions: (a) NaN3, CuI, (100 mol%), 
DMEDA (150 mol%), DMSO, 100 °C, 3 h (82%).  
 
Although the copper(I) in the reaction is theoretically catalytic, it was found that the reaction 
required 1 mol equivalent relative to the aryl bromide to drive amine formation. Under these 
conditions, amine 25 was cleanly produced in excellent yield (82%). Compound 25 was 
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prepared on up to 1 gram scale in similar yields. The sizeable difference in polarity between 
23 and 25 allowed for simple purification by column chromatography. The amine could also 
be purified by precipitating the hydrochloride salt using 1 M HCl in diethyl ether. The 
compound was fully characterised and its structure confirmed by spectroscopic analysis.  
 
2.2.6 Synthesis of Aryl Azide 24 
Formation of aryl azides from aryldiazonium salts is well documented in the literature but 
conditions vary depending on the substrate. Reported experimental procedures are typically 
similar, differing only in the solvent and HCl concentration. Two sets of conditions were 
explored for the synthesis of 24 and the results are summarised in Table 4.   
 
Table 4. Summary of reactions for converting aryl amine 25 to azide 24 via formation and 
displacement of an aryl diazonium salt.  
 
Entry Scale (mg) Solvent Isolated Yield (%) 
1 100 6 M HCl:THF:H2O (1:1:1) <10 
2* 163 6 M HCl:THF:H2O (1:1:1) <10 
3 135 Conc. HCl, EtOAc 75 
4 315 Conc. HCl, EtOAc 64 
* Reaction was allowed to stir for 3 hours. 
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Formation of the aryl diazonium salt was initiated by addition of sodium nitrite and 
hydrochloric acid (excess) to the dissolved aryl amine 25. Once formed, sodium azide was 
added to the diazonium salt intermediate, releasing N2 gas. Evolution of N2 gas indicated 
reaction progress and when it ceased TLC analysis was used to confirm completion of the 
reaction.  
Using the procedure of Chambers et al., sodium nitrite (1.2 eq)  was dissolved in a solution 
of 6 M HCl, THF and water (1:1:1) and added to a solution of 25 at 0 °C.83 After 1 hour sodium 
azide (1.3 eq) was added and the reaction monitored by TLC analysis. The analysis indicated 
that the diazonium species had failed to form, resulting in a low yield of 24 (Entry 1). Use of 
the same reaction conditions with warming to room temperature and stirring for 3 hours 
failed to improve the yield (Entry 2).  
A related literature approach made use of a biphasic solvent system of ethyl acetate and 
concentrated HCl.84 After dissolving amine 25 in the solvent mix, aqueous sodium nitrite 
(1.2 eq) was slowly added causing an immediate colour change to orange. After 1 hour, TLC 
analysis indicated near-complete consumption of 25. Aqueous sodium azide (1.3 eq) was 
then added and the reaction was stirred at room temperature and monitored by TLC analysis. 
After 2 hours nitrogen evolution had ceased, and TLC analysis indicated that the reaction had 
gone to completion. After aqueous work-up, the crude product was purified by silica gel 
column chromatography and its structure confirmed as 24 by spectroscopic analysis 
(Entry 3). The reaction produced 25 in 75% isolated yield over the two steps which reduced 
slightly (64%) when repeated at approximately twice the scale (315 mg, Entry 4). 
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2.2.7 Ester Hydrolysis of 24 
The final step in obtaining fragment 22 was hydrolysis of the methyl ester (Scheme 9). 
Hydrolysis reactions are often carried out using 1 M LiOH in an aqueous solvent system 
containing a miscible organic solvent, such as tetrahydrofuran, acetonitrile or methanol. 
Compound 24 was dissolved in THF:H2O (3:1) and 1 M LiOH (3 eq) was added. The reaction 
was allowed to stir at room temperature and monitored by TLC analysis. These conditions 
resulted in quantitative conversion to the carboxylic acid 22 at room temperature after a 
simple acid/base work-up. Compound 22 was characterised and its structure confirmed by 
spectroscopic analysis.  
 
 
Scheme 9. Hydrolysis of 24 to the carboxylic acid 22. Reagents and conditions: (a) 1 M LiOH, 
THF:H2O (3:1), rt, 1 h, quant. 
 
2.2.8 Preparation of VLA-4 Antagonist Fragment 20 
VLA-4 antagonist fragment 20 was approached via amide coupling of the free amine of 
fragments 21 and acid 22 (Scheme 1). Fragment 21 containing an N-Boc protecting group 
was treated with TFA:TIPS:H2O (95:2.5:2.5) for 30 minutes at room temperature. Upon 
completion, the reaction mixture was concentrated in vacuo and the resulting amine TFA salt 
was used immediately in coupling reactions. Competing amide coupling of TFA was avoided 
by separately pre-activating the carboxylic acid 22 with coupling reagent prior to addition of 
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the amine TFA salt 21. As a further precaution, 21 was placed under high vacuum to remove 
traces of TFA prior to reaction. Under high vacuum a brown amorphous foam formed from 
what was previously a non-viscous oil. The conditions and yields obtained for the coupling 
reactions attempted are shown in Table 5.  
 
Table 5. Summary of coupling reactions between amine TA salt 21 and carboxylic acid 22 to 
produce the advanced VLA-4 antagonist fragment 20.  
 
Entry Scale of 21 (mg) Coupling Reagent Solvent Time (h) Yield (%) 
1 50 HBTU CH2Cl2 18 20 
2 50 HATU CH2Cl2 8 62 
3 90 PyBOP CH2Cl2 18 67 
4 90 PyBOP DMF 18 78 
5 190 HATU DMF 18 69 
6 91 PyBOP* DMF 18 44 
* 1.2 eq used 
 
Under anhydrous conditions, the carboxylic acid 22 (1.2 eq) and coupling reagent (1.5 eq) 
were dissolved in CH2Cl2 or DMF and DIPEA (4 eq) was slowly added. The pre-activation 
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process took approximately 5-10 minutes and was characterised by formation of an intense 
yellow colour indicating formation of the HOBt ester. Using a cannula, the solution of 
pre-activated carboxylic acid 22 was slowly transferred into a solution of the amine 21 under 
argon. The reaction was allowed to proceed at room temperature and was monitored by TLC 
analysis and LR-MS. Upon completion, an acid-base work-up was performed prior to 
purification. The coupled product 20 proved difficult to isolate, with significant yield lost in 
the aqueous layer. The presence of the weakly basic pyridine nitrogen likely explains this. 
Avoiding use of acid during the work-up was found to overcome this issue.  
Initial investigations with HBTU in CH2Cl2 produced a complex product mixture and a modest 
yield of 20 (20%, Entry 1). Subsequent experiments exploring the use of HATU in CH2Cl2 
produced much cleaner reactions and improved yields (62%, Entry 2). It was noted that these 
reactions failed to go to completion, however, indicating that further optimisation was 
required. The next coupling reagent tested was PyBOP, which was expected to be effective 
given its reported use with 21.54 Use of PyBOP in CH2Cl2 was found to form the desired 
peptide 20 in comparable yields to HATU but the reaction was slower and not cleaner (67%, 
Entry 3). Changing the solvent to DMF improved reaction yields with PyBOP and HATU (78% 
and 69%, Entries 4 and 5, respectively).57 Overall, HATU produced cleaner reactions and the 
product was easier to purify by silica gel column chromatography (Entry 5). Reducing the 
amount of PyBOP (1.2 eq) resulted in lowered yields and unreacted starting material 
(Entry 6). Use of HATU in DMF was chosen as the best conditions and afforded sufficient 
material to proceed. The VLA-4 antagonist derivative 20 was comprehensively characterised 
and its structure confirmed by spectroscopic analysis.  
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2.3 Synthesis of N-Propargyl Northioridazine Enantiomers from (±)-Thioridazine 16 
The target hybrid molecules 17 should ideally be stereochemically pure at all three 
stereocentres. However, all the previous studies investigating the biological effects of 
thioridazine on VLA-4 and related targets were conducted using racemic mixtures. It was 
therefore unclear which thioridazine enantiomer (if not both) is responsible for the effects. 
It was therefore necessary to independently incorporate each of the thioridazine 
enantiomers into the hybrids to evaluate the effects of thioridazine stereochemistry. 
Stereochemistry of the thioridazine moiety was used to annotate the hybrid epimers as 
(R)-17 and (S)-17. Carrying racemic thioridazine through the hybrid synthesis would also have 
created complex diastereomeric product mixtures with unknown stereochemistry at the 
thioridazine portion. Use of stereochemically pure thioridazine ensured that the 
stereochemistry of the final hybrids was unambiguous at all three stereocentres and 
purification and NMR interpretation was greatly simplified. 
Enantiomerically pure thioridazine has previously been obtained by N-alkylation of the 
phenothiazine core with (R) or (S)-chloro-2-ethyl-N-methyl-piperidines (Scheme 10).85 These 
chiral piperidines are also not commercially available. Synthesis of the chiral piperidines was 
a possibility, but access to thioridazine enantiomers has also been reported from racemic 
thioridazine.86 
 
Scheme 10. Reported method for obtaining enantiomerically pure thioridazine via 
N-alkylation of the phenothiazine core with chiral chloro-2-ethyl-N-methyl-piperidine.85  
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Choi and co-workers reported that racemic thioridazine can be converted into two isolable 
diastereomers ((R)-26 and (S)-26, Scheme 11) using a menthol carbamate chiral auxiliary.86 
In this study, the menthyl carbamates were separated and reduced to enantiomerically pure 
thioridazine for later conversion to mesoridazine (i.e. thioridazine sulfoxide) enantiomers. 
This finding suggested that other chiral thioridazine analogues might be accessible using this 
route. It was envisaged that hydrolysis of the menthyl carbamates 26 would generate 
des-methyl thioridazine (northioridazine hereafter) enantiomers 27, which in turn could be 
used to produce the N-propargylated thioridazine derivatives required for the ‘click’ reaction 
to produce 17. The route explored for the synthesis of thioridazine and northioridazine 
enantiomers in the current work is summarised in Scheme 11.   
 
 
Scheme 11. Proposed route for resolution of (±)-thioridazine and synthesis of northioridazine 
enantiomers (R)-27 and (S)-27.  
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Using the method developed by Choi and co-workers, the two diastereomeric menthyl 
carbamates (R)-26 and (S)-26 are formed from commercially available racemic 
thioridazine.HCl. The absolute stereochemistry of the two thioridazine menthyl carbamates 
(R)-26 and (S)-26 obtained from the reaction would be unknown as this is not reported. Thus, 
hydrolysis of the diastereomers to the corresponding northioridazine enantiomers (R)-27 
and (S)-27 would produce products with unknown stereochemistry. The optical rotations of 
northioridazine enantiomers are surprisingly not reported. Optical rotation measurements 
of thioridazine enantiomers have been reported, however.85 After separation, each 
diastereomer could be reduced to enantiomerically pure thioridazines (R)-16 and (S)-16 and 
the optical rotations then used to establish absolute stereochemistry of the diastereomers 
by inference. The appropriate (R)-26 or (S)-26 diastereomer could then be used to generate 
northioridazine enantiomers (R)-27 and (S)-27 unambiguously via hydrolysis of the menthyl 
carbamate, which could then be used to produce optically pure N-substituted thioridazine 
derivatives, such as the N-propargyl northioridazine derivative (R)-19 and (S)-19. 
 
2.3.1 Resolution of Racemic Thioridazine 
Using the procedure developed by Choi and co-workers, racemic thioridazine.HCl was 
reacted with (-)-(1R)-menthol chloroformate (1.5 eq) in the presence of DIPEA (2 eq) at room 
temperature in CH2Cl2 (Scheme 12).86 Analysis of the reaction mixture by TLC analysis 
indicated formation of two new spots, consistent with formation of the two thioridazine 
diastereomers; one less polar and one more polar. For ease of reference, D1 refers to the 
diastereomer that was less polar by TLC analysis, and D2 refers to the more polar 
diastereomer (D1: Rf = 0.77, D2: Rf = 0.54; EtOAc:Pet. Spirit, 20:80).  
The reaction proceeded readily overnight and the diastereomers were purified using silica 
gel column chromatography. Choi and co-workers did not report any characterisation for 
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these compounds. The diastereomers were thus fully characterised here and their structures 
confirmed by spectroscopic analysis. The reaction was performed multiple times on 2-5 gram 
scales, producing the pure diastereomers in consistent yields (D1-26 38%, D2-26 43%). When 
the diastereomers were dried in vacuo they formed amorphous, hygroscopic foams that 
were difficult to work with. Storage under high vacuum hours before use in subsequent 
reactions helped with this minor issue.  
 
 
Scheme 12. Synthesis of thioridazine menthol carbamate diastereomers D1-26 and D2-26 
from racemic thioridazine. Reagents and conditions: (a) (-)-menthyl chloroformate, DIPEA, 
CH2Cl2, rt, 18 h; (b) chromatographic separation, D1-26 (38%) and D2-26 (43%). 
 
2.3.2 Synthesis of Thioridazine Enantiomers for Determination of Absolute 
Stereochemistry 
Reduction of thioridazine menthyl carbamates D1-26 and D2-26 aimed to produce optically 
pure thioridazine enantiomers, whose optical rotation measurements could be compared to 
literature values in order to assign stereochemistry. The two diastereomers D1-26 and D2-26 
were reduced separately using lithium aluminium hydride (LiAlH4) according to the method 
of Choi et al.86 Choi’s conditions involved stirring the diastereomers in diethyl ether at room 
temperature with LiAlH4 (quantities not reported) for 16 hours (lit. 54%). In our hands, these 
conditions resulted in low yields of thioridazine (Entry 1, Table 6). A series of optimisation 
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reactions were thus carried out. Experiments were mostly explored using the D1-26 
diastereomer and the best conditions were later applied to D2-26. A summary of the 
reactions explored is provided in Table 6.  
 
Table 6. Reaction conditions and isolated yields for reduction of D1-26 to an enantiomerically 
pure thioridazine 16.    
 
Entry Scale (mg) LiAlH4 Solvent Temperature Yield (%) 
1 100 3 eq Et2O rt 20 
2 100 6 eq Et2O rt 23 
3 100 6 eq THF rt 23 
4 200 6 eq THF reflux 59 
5* 742 8 eq THF reflux 73 
6* 2500 8 eq THF Reflux 62 
 * Reaction stopped after 8 hours 
 
Initial experiments used solvents that were scrupulously dry to avoid in situ decomposition 
of LiAlH4. Diethyl ether and THF were freshly distilled from sodium in the presence of 
benzophenone ketyl. The hygroscopic character of the carbamates was considered a risk to 
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the outcome of the reaction. The reaction vessel containing the carbamate was therefore 
placed under high-vacuum for 2 hours prior to starting the reaction. Doubling the amount of 
LiAlH4 (6 eq) and using THF at room temperature provided no improvement over the use of 
diethyl ether (Entries 2 and 3). Heating the reaction at reflux in THF significantly improved 
the reaction rate and afforded thioridazine 16 in 59% yield (Entry 4). It was noted that 
starting material was still present after 16 hours. Increasing the amount of LiAlH4 (8 eq) led 
to formation of thioridazine 16. Although some menthyl carbamate D1-26 was still present 
after 8 hours, the quality of the product obtained was best after this time and produced an 
isolated yield of 73% (Entry 5). On larger scale (2.5 g), these conditions produced thioridazine 
16 in a slightly lowered yield (62%, Entry 6). The optimised conditions were subsequently 
used with D2-26 to produce the opposite enantiomer in similar yield (67%). Following 
purification by silica gel column chromatography both the thioridazine enantiomers were 
comprehensively characterised. 
Chemical stability of the free base forms of thioridazine was questionable as the sulfoxide 
(mesoridazine) was observed by LR-MS and TLC analysis. The presence of sulfoxide impurities 
complicates the measurement of optical rotation due to the additional chiral centre at the 
phenothiazine sulfur. For optical rotation measurements, the enantiomers were further 
purified by preparative RP-HPLC and the measurements performed immediately after 
obtaining the freeze-dried products. 
Previous investigations had shown that (-) optical rotation corresponds to (S)-thioridazine 
and (+) optical rotation corresponds to (R)-thioridazine.85 However, this report failed to 
document a specific rotation measurement ([α]tD) for either enantiomer. Optical rotations of 
the thioridazine enantiomers synthesised here indicated that D1-26 provided 
(+)-(R)-thioridazine and D2-26 provided (-)-(S)-thioridazine. By inference, D1-26 contained 
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(R)-thioridazine and D2-26 (S)-thioridazine. The two carbamate diastereomers are hereafter 
labelled (R)-26 and (S)-26, respectively.  
 
2.3.3 Synthesis of Northioridazine Enantiomers via Carbamate Hydrolysis 
Northioridazine 27 is a major metabolite of thioridazine 16, along with thioridazine N-oxide 
and thioridazine-2-sulfoxide (mesoridazine).87 Recent interest in the repurposing of 
thioridazine have made  the enantiomers of northioridazine 27 attractive molecules for 
accessing N-substituted thioridazine derivatives. For our purposes, synthesis of 
northioridazine enantiomers would provide access to N-propargyl northioridazine 
enantiomers (R)-19 and (S)-19. The northioridazine enantiomers (R)-27 and (S)-27 were 
targeted via hydrolysis of carbamates (R)-26 and (S)-26. Table 7 is not exhaustive but shows 
representative reagents and conditions that were explored. Initial reactions were trialled 
with (R)-26 and the optimised conditions deployed with (S)-26.  
Base hydrolysis with lithium hydroxide resulted in no change by TLC analysis (Entry 1). 
Nucleophilic bases such as sodium methoxide (Entry 2) and lithium methoxide (not shown) 
also failed to hydrolyse the carbamate. Acidic hydrolysis using a biphasic 6 M HCl solution in 
chloroform heated at reflux showed no reaction by TLC analysis (Entry 3). Using neat TFA at 
room temperature also showed no reaction but upon heating at reflux (R)-27 was isolated in 
8% (Entry 4). Reaction at reflux for 2 days did not improve the yield (not shown). It was 
observed that addition of any acid immediately formed a deep-blue solution, presumably 
due to protonation of the phenothiazine nitrogen and generation of charge-delocalised 
species.  
Bender and co-workers explored conditions for menthyl carbamate hydrolysis on related 
substrates, and reported that cleavage was difficult.88  Their best method involved treating 
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menthyl carbamates with TFA and heating the mixture at 110 ˚C in a sealed tube for 6 hours. 
Under these conditions secondary amines were reportedly generated in modest to high 
yields. Subjecting (R)-26 to these conditions resulted in a complex mixture of side products 
and considerable starting material remaining. Following tedious purification, 
(R)-northioridazine 27 was isolated in 20% yield with its structure confirmed by spectroscopic 
analysis (Entry 5). Scaling up the reaction and leaving it for 2 days at 110°C produced similar 
yields (Entry 6).  
 
Table 7. Reaction conditions and isolated yields for hydrolysis of (R)-26 to 
(R)-northioridazine 27. 
 
Entry Scale (mg) Reagent Solvent Temperature Time Yield (%) 
1 100 LiOH THF:H2O rt 18 h  - 
2 100 NaOMe MeOH rt → reflux 18 h - 
3 100 6 M HCl CHCl3 rt → reflux 18 h - 
4 100 TFA TFA reflux 18 8 
5 200 TFA TFA 110 ˚C Sealed Tube 6 h 20 
6 500 TFA TFA 110 ˚C Sealed Tube 2 d 22 
7 200 TFA TFA 110 ˚C*  1 h 62 
8 500 TFA TFA:TIPS:H2O 110 ˚C Sealed Tube 3 d 36 
* Reaction performed in microwave reactor at 200 MHz  
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To explore microwave reaction conditions, the menthyl carbamate was dissolved in neat TFA 
and heated to 110 ˚C at 200 MHz for one hour. The reaction mixture appeared to be 
significantly cleaner by TLC analysis and afforded northioridazine (R)-27 in 62% yield (Entry 
7). It was observed that the rubber septum of the microwave vial was protruding outwards 
during the reaction due to internal pressure, suggesting this as a potentially dangerous 
procedure. TFA promoted cleavage was presumably releasing carbon dioxide in situ to 
generate the pressure. The TFA deprotection mechanism is shown in Figure 26.  
 
Figure 26. Mechanism for TFA-promoted removal of menthyl carbamate (R)-26 to provide 
(R)-27. 
 
Donation of the TFA acid proton to the carbamate oxygen generates an oxonium ion. An 
elimination reaction ensues leading to loss of 1-isopropyl-4-methyl-cyclohexene and 
formation of the N-carboxyamine (carbamic acid), which spontaneously decarboxylates to 
provide (R)-northioridazine 27 and CO2. 
Evolution of carbon dioxide in situ limited the scale in which the reaction could be performed 
safely in the microwave, where hot, pressurised TFA could be fatal if an unexpected release 
occurred. Alternative procedures were thus investigated. Use of a TFA cocktail that included 
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carbocation scavenger triisopropylsilane (TIPS) and water (95:2.5:2.5) in a sealed tube 
improved the yield slightly (36%) but produced a much cleaner reaction (Entry 8).   
Cleavage of the carbamate using atypical conditions was also explored. Various acids (HBr, 
H2SO4, BF3.Et2O) and bases (KOH, CaOH2, NaH, CaH2, MeLi) were investigated but did not 
yield northioridazine. Although yields with TFA were low, this route afforded usable 
quantities of optically pure northioridazine enantiomers from racemic thioridazine. 
However, our need to produce larger quantities of the northioridazine enantiomers for 
hybrid synthesis meant that a more efficient route was required.  
 
2.3.4 N-Demethylation of Thioridazine Enantiomers  
An alternative approach for obtaining optically pure northioridazine 27 was conceived that 
involved N-demethylation of (R)- and (S)-16 (Scheme 13). (±)-Northioridazine.HCl is 
commercially available and presumably synthesised via N-demethylation of (±)-thioridazine. 
The same process applied with thioridazine enantiomers was thus expected to generate the 
respective northioridazine enantiomers.  
 
Scheme 13. Synthesis of northioridazine enantiomers (R)-27 and (S)-27 by the 
N-demethylation of thioridazine enantiomers (R)-16 and (S)-16. Reagents and conditions: (a) 
1-chloroethyl chloroformate, DIPEA, CH2Cl2, rt, 18 h; (b) MeOH, reflux, 3 h, (R)-27 (65%), (S)-27 
(65%). 
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Reduction of carbamates (R)-26 and (S)-26 to the optically pure thioridazine enantiomers 
had previously been optimised (Section 2.3.2) and produced useful quantities of material for 
N-demethylation experiments. Despite introducing another synthetic step, this would avoid 
the challenges faced in the hydrolysis route. Furthermore, N-demethylation of secondary 
amines is well established in the literature and myriad reagents exist for this purpose. One 
reagent that is commonly used is 1-chloroethylchloroformate. N-Demethylation reactions 
with this reagent occur over 2 steps: (1) formation of the 1-chloroethyl carbamate and (2) 
methanolysis and decarboxylation. A summary of the N-demethylation experiments 
attempted is provided in Table 8 and the putative mechanism for the reaction is shown in 
Figure 27. 
 
 
Figure 27. Mechanism for N-demethylation of (R)-thioridazine to (R)-northioridazine 27 using 
1-chloroethyl chloroformate and methanol at reflux.  
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The first step involves nucleophilic attack on 1-chloroethyl chloroformate by the piperidine 
nitrogen. Loss of chloromethane then yields the stable 1-chloroethyl carbamate 
intermediate. Exposure to methanol at reflux triggers a decarboxylation that delivers 
(R)-northioridazine 27. 
Preliminary experiments made use of the more readily available racemic thioridazine.HCl to 
study reaction behaviour. Thioridazine.HCl and 1-chloroethyl chloroformate (2 eq) was 
dissolved in 1,2-dichloroethane (1,2-DCE) and heated at reflux. After 16 hours TLC and LR-MS 
analysis showed that no reaction had occurred (Entry 1). Subsequent reactions performed 
with the free-base form, which was prepared by neutralising the salt with 1 M sodium 
hydroxide and extracting into ethyl acetate, produced only 9% of 27 (Entry 2).  
In the next attempts, a solution of free-base thioridazine was prepared in dry CH2Cl2 and 
1-chloroethyl chloroformate (2 eq) and DIPEA (3 eq) were added. The reaction was allowed 
to proceed at room temperature and monitored by TLC analysis. Formation of the 
1-chloroethyl carbamate appeared to be rapid but the reaction stopped and failed to 
consume all of the starting material after 16 hours. Concentration of the reaction mixture 
gave a brown oil that was used immediately in the next step. The crude residue was dissolved 
in an excess of methanol and heated at reflux. Complete consumption of the carbamate 
intermediate was observed by TLC analysis after 3 hours. Isolation of northioridazine was 
challenging due to its similar polarity to unreacted thioridazine. Nevertheless, careful 
purification by silica gel column chromatography afforded racemic northioridazine 27 in 70% 
yield (Entry 3). 
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Table 8. Isolated yields and conditions for N-demethylation of thioridazine 16 to produce 
northioridazine 27  
 
Entry Scale (mg) thioridazine Solvent DIPEA (eq) Temperature Yield (%) 
1 500 (±).HCl 1,2-DCE - reflux -  
2 500 (±) 1,2-DCE - reflux 9 
3 500 (±) CH2Cl2 3 rt 70 
4 273 (R) CH2Cl2 3 rt 65 
5 220 (S) CH2Cl2 3 rt 71 
6 1000 (R) CH2Cl2 3 rt 61 
 
Significant losses were occurring due to purification difficulties and the presence of residual 
starting material. Purification was simplified by adsorbing the crude 1-chloroethyl carbamate 
onto silica and forming a ‘plug’. Washing the silica plug with excess chloroform resulted in 
isolation of the 1-chloroethyl carbamate without any trace of residual thioridazine. After 
heating at reflux with methanol, northioridazine was the major compound visible by TLC 
analysis and did not require further purification. These conditions were then applied to (R)- 
and (S)-thioridazine 16 enantiomers to successfully produce northioridazine enantiomers 
(R)-17 and (S)-27 in 65% and 71% yields, respectively (Entries 4 and 5). When performed on 
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a larger scale (1 g) the reaction produced comparable yields (61%, Entry 6). Compounds (R)-
27 and (S)-27 were structurally characterised and showed NMR signals that matched 
previous reports. This synthetic route was considered to be the most reliable and efficient 
for producing northioridazine enantiomers. 
Specific rotation data for northiordazine enantiomers has, to the best of our knowledge, not 
previously been reported. Each enantiomer was purified by preparative HPLC and their 
purities confirmed by analytical RP-HPLC. A representative chromatogram for (S)-27 is shown 
in Figure 28. Accordingly, the measured optical rotations indicated that (R)-northioridazine 
and (S)-northioridazine showed (-) and (+) rotations, respectively. 
 
Figure 28. Analytical RP-HPLC chromatogram for (S)-northioridazine 27. Solvent A: H2O, 0.1% 
TFA, Solvent B: CH3CN, 0.1% TFA. Gradient: 0% B to 100% B over 40 minutes, 254 nm, 
tR = 13.5 min. 
 
2.3.5 Confirmation of Stereochemistry: X-ray Crystal Structure of (R)-Nosyl-Northioridazine 
Absolute stereochemistry of the thioridazine enantiomers was inferred from data reported 
over two decades ago.85 The noted sensitivity of thioridazine to air oxidation created 
uncertainty in the stereochemical assignments.  Confirmation of the stereochemistry of the 
enantiomers created through our synthesis was pursued using X-ray crystallographic 
analysis. The menthyl carbamates 26 were amorphous solids and could not be used. Both 
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thioridazine 16 and northioridazine 27 are oils at room temperature and their hydrochloride 
salts were too hygroscopic to produce crystals suitable for analysis. Novel N-substituted 
northioridazine derivatives were thus pursued in attempts to generate crystals suitable for 
X-ray studies. One group often useful for producing crystalline products is the 
4-nitrobenzene sulfonamide (nosyl) group. N-Sulfonylation of the piperidine nitrogen of 
northioridazine (R)-27 was thus investigated (Scheme 14).  
 
 
Scheme 14. Synthesis of (R)-nosyl-northioridazine 28. Reagents and conditions: (a) 
4-nitrobenzene sulfonyl chloride, DIPEA, CH2Cl2, rt, 18 h, 55%. 
 
Northioridazine (R)-27 was dissolved in CH2Cl2 and 4-nitrobenzene sulfonyl chloride (2 eq) 
was added, followed by DIPEA (4 eq). The reaction was stirred at room temperature 
overnight and monitored by TLC analysis. The reaction proceeded slowly and considerable 
starting material remained after 18 hours. The reaction was stopped and the product was 
purified by silica gel column chromatography (EtOAc:Pet. Spirit, 0:100 to 40:60). Yellow 
crystals formed in several test tubes and 28 was isolated in 55% yield. The compound was 
characterised and its structure confirmed as 28 using NMR spectroscopy. The crystals were 
sent to Dr. Anthony Willis at the Australian National University (ANU) for X-ray analysis. The 
crystal structure of (R)-nosyl-northioridazine 28 was obtained and its Ortep diagram is shown 
in Figure 29. X-ray diffraction data are provided in Appendix 6.2.1. 
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The high-quality structure unambiguously confirmed the expected stereochemistry at C-17 
as (R). To our knowledge, this is the first X-ray crystal structure to be reported for any 
thioridazine derivative. This finding supports northioridazine 27 as a suitable substrate for 
creating N-substituted thioridazine analogues in enantiomerically pure form 
 
Figure 29. X-ray crystal structure of (R)-nosyl-northioridazine 28.  Anisotropic displacement 
ellipsoids show 30% probability levels.  Hydrogen atoms are drawn as circles with small radii. 
Crystallographic data are provided in Appendix 6.2.1.   
 
2.3.6 Synthesis of N-Propargyl Northioridazine Enantiomers (R)-19 and (S)-19 
Generation of (R)-nosyl-northioridazine 28 showed that N-substituted derivatives can be 
obtained from northioridazine 27. Synthesis of the target hybrid molecules required practical 
quantities (10-100’s mg) of N-propargyl northioridazine enantiomers (R)-19 and (S)-19. These 
were pursued via N-alkylation of the requisite northioridazine enantiomers (R)-27 and (S)-27 
with propargyl bromide. A summary of conditions and isolated yields is shown in Table 9.  
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Table 9. Conditions and isolated yields the N-alkylation of northioridazine enantiomers with 
propargyl bromide. 
 
Entry Scale (mg) Northioridazine Solvent Base (eq) Temperature Yield (%) 
1 100 (S) CH2Cl2 DIPEA (1.5) rt - 
2 97 (S) Acetone Cs2CO3 (1.5) rt 31 
3 61 (R) Acetone Cs2CO3 (1.5) reflux 17 
4 40 (S) Acetone K2CO3  (3.0) reflux 29 
5 50 (R) THF Cs2CO3 (1.5) rt 10 
6 50 (R) CH3CN Cs2CO3 (1.5) rt trace 
7 50 (R) DMF K2CO3 (1.5) 80 °C 20 
8 140 (R) DMF NaH (1.1) rt 58 
9 156 (S) DMF NaH (1.1) rt 51 
 
 
Optimisation experiments were performed on the two northiordazine enantiomers to 
progress both materials forward. Anhydrous solvents were prepared for the reactions and 
the inorganic bases (Cs2CO3 and K2CO3) were dried in vacuo. Solutions of (R)-27 and (S)-27 in 
dry CH2Cl2 treated with DIPEA (2 eq) and propargyl bromide 80 wt.% in toluene (2 eq) at 
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room temperature failed to yield any product by TLC and LR-MS analysis (Entry 1). Use of 
Cs2CO3 in acetone formed (S)-19 in 31% yield (Entry 2) and heating the reaction reduced the 
yield to 17% (Entry 3). Use of anhydrous K2CO3 (1.5 eq) yielded no product at room 
temperature but when heated at reflux with more K2CO3 (3 eq) the yield was returned to 
29% (Entry 4). THF and acetonitrile proved to be poor solvent systems, producing (R)-19 in 
only 10% yield or trace amounts (Entries 5 and 6). DMF was investigated with Cs2CO3 and 
K2CO3 at various temperatures but low yields were again obtained. For example, (R)-19 was 
produced in 20% yield with K2CO3 at 80 °C (Entry 7).  
Use of sodium hydride was investigated next. When sodium hydride (1.1 eq) was added to a 
solution of northioridazine 27 in DMF a sudden colour change from yellow to orange was 
observed. Propargyl bromide was slowly added to the vessel and the reaction monitored by 
TLC analysis. After one hour, substantially more product had clearly formed using this 
method. Purification by silica gel column chromatography afforded (R)-19 and (S)-19 in 58% 
and 51% yields, respectively (Entries 8 and 9). The compounds were pure by analytical 
RP-HPLC (Figure 30) and their structures confirmed by spectroscopic analysis. 
 
Figure 30. RP-HPLC chromatogram of (S)-propargyl northioridazine (S)-19 after purification 
by preparative HPLC. Solvent A: H2O, 0.1% TFA, Solvent B: CH3CN, 0.1% TFA. Gradient: 0% B 
to 100% B over 40 minutes, 254 nm, tR = 14.5 min. 
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To understand the modest yields, the products from the NaH reaction (Entry 8) were isolated 
by silica gel column chromatography. The compounds isolated included the starting material 
(23%) and the quaternary amine (R)-bis-N,N-propargyl northioridazine salt 29 in 13% yield 
(Figure 31).  
 
Figure 31. Putative structure of (R)-bis-N,N-propargyl northioridazine 29. 
 
The structure of 29 was consistent with a peak observed at m/z 433 by LR-MS. Upon isolation, 
compound 29 was observed by TLC analysis to decompose over 24 hours to 
(R)-northioridazine (R)-27 and (R)-N-propargyl northioridazine (R)-19 and characterisation 
data for 29 could not be obtained. Use of potassium hydride resulted in more of the 
quaternary salt 29 and was not used any further. In the process of completing these 
experiments, sufficient material was prepared for the synthesis of the hybrid molecules 
(R)-17 and (S)-17.  
 
2.4 Synthesis of the Epimeric Hybrids (R)-17 and (S)-17  
At this point the convergent synthesis had successfully yielded the key northioridazine 19 
and VLA-4 antagonist 20 fragments for the CuAAC ‘click’ reaction. Enantiomers (R)-19 and 
(S)-19 were to be independently reacted with 20 to generate the respective hybrid epimers 
(R)-17 and (S)-17 after subsequent methyl ester hydrolysis (Figure 32). 
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Figure 32. Structure of the hybrid molecules (R)-17 and (S)-17. 
 
2.4.1 CuAAC ‘Click’ Reaction to form Methyl Ester 30 
The ‘click’ reaction was initially investigated using (R)-19. Standardised CuAAC ‘click’ 
conditions were trialled to gauge reaction behaviour. (R)-N-Propargyl northioridazine 19 and 
azido VLA-4 antagonist derivative 20 (1.1 eq) were dissolved in a mixture of tert-butanol and 
water (1:1) and catalytic copper acetate (20 mol%) and sodium ascorbate (40 mol%) were 
added. The reaction was allowed to stir at room temperature and monitored by TLC analysis 
(Scheme 15).  
 
 
Scheme 15. Synthesis of methyl ester precursor (R)-30 via a CuACC ‘click’ reaction of 
(R)-N-propargyl northioridazine 19 with azido VLA-4 antagonist derivative 20. Reagents and 
conditions: (a) Cu(OAc)2.H2O (40 mol%), sodium ascorbate (80 mol%), tBuOH:H2O (1:1), 33 °C, 
18 h, 64%. 
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After two hours TLC and LR-MS showed that the hybrid (R)-30 was being formed. Progress of 
the reaction appeared to cease after 6 hours and no further progress was seen after 
overnight stirring. Adding more catalyst gave only slight improvements leading to alternative 
conditions being explored.  
A key observation from the trial reaction was its cloudy appearance, suggesting poor 
solubility of the reactants in the tert-butanol/water mixture. With freshly prepared materials 
the reaction was attempted again with gentle heating at 33 °C. The increased solubility of 
the reactants was evident from the homogenous solution. After 2 hours, a yellow precipitate 
had formed and TLC analysis indicated complete consumption of (R)-N-propargyl 
northioridazine (R)-19. The reaction mixture was submitted to an aqueous work-up and the 
crude residue was purified by silica gel column chromatography (100% EtOAc). The desired 
ester (R)-30 was obtained in 64% yield. Detailed analyses of the NMR spectra for (R)-30 are 
provided below.  
 
2.4.2 Analysis of 1H NMR Spectrum of (R)-30 
A sample of (R)-30 prepared in deuterated chloroform (CDCl3) provided a high quality 
1H NMR spectrum (Figure 33). The spectrum showed signals for contaminating grease at 0.87 
and 1.25 ppm and efforts to remove or reduce this by trituration failed. Two-dimensional 
NMR experiments indicated that no peaks from (R)-30 were obscured beneath the grease 
peaks.  
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Figure 33. 1H NMR spectrum of hybrid precursor (R)-30.  
 
The similar character of the proline and piperidine portions of (R)-30 meant signal 
assignment would be ambiguous without 2D-NMR spectra. In Total Correlation Spectroscopy 
(TOCSY), cross peaks are observed between directly coupled nuclei and spin systems linked 
by a chain of 3J vicinal couplings. The 2D-TOCSY spectrum clearly showed the three alkyl spin 
systems in (R)-30 (Figure 34). Diastereotopic CH2 signals were also identified and assigned 
from the data. The spin system corresponding to the p-NH2 phenylalanine (orange) region 
showed cross-peaks for the amide-NH (7.17 ppm), Tyr-α-CH (4.90 ppm) and two 
diastereotopic Tyr-β-CH2 protons (3.09 and 3.28 ppm). This was the only system containing 
an amide-NH. The second spin system identified the proline ring (green), which included 
cross-peaks for the Pro-α-CH (3.85-4.05 ppm), Pro-β-CH2 (2.27 ppm), Pro-γ-CH2 (2.00 ppm) 
and Pro-δ-CH2 (2.62 ppm). The third spin system corresponded to the ethyl-piperidine region 
of thioridazine (blue). The TOCSY spectrum identified each of the 7 peaks (4.20, 3.36, 3.20, 
2.85, 2.12 1.66, 1.65 ppm) and unambiguous assignments were provided from additional 
gHSQC and gCOSY experiments.  
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Figure 34. TOCSY spectrum of (R)-30 showing the p-NH2 phenylalanine (orange), proline 
(green) and ethyl-piperidine (blue) spin systems.  
 
Interpretation of the aromatic region of (R)-30 was straight forward and an expansion of the 
region is shown in Figure 35. Spectral integration showed the correct number of protons 
(H = 18) and unambiguous assignments were possible from the gHSQC spectrum. From the 
TOCSY spectrum, it was evident that the phenylalanine amide (NH) sat beneath the peak at 
7.16 ppm. The only proton not shown is the isonicotoyl amide (NH), which had undergone 
exchange in CDCl3. 
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Figure 35. Aromatic region of the 1H NMR spectrum of (R)-30 (CDCl3, 7.26 ppm).  
 
2.4.3 Hydrolysis of Methyl Ester (R)-30 
Hydrolysis of the methyl ester (R)-30 to the target carboxylic acid (R)-17 was the final step in 
the synthesis (Scheme 16). The hydrolysis was attempted by dissolving (R)-30 in THF:H2O 
(3:1) and adding 1 M LiOH (3 eq). The reaction was allowed to stir at room temperature and 
monitored by TLC analysis and LR-MS. After one hour, TLC analysis indicated substantial 
decomposition of the molecule, with the plate showing multiple product spots. A sample 
tested by LR-MS indicated the presence of 17, along with many unidentified peaks. Another 
attempt at 0 °C with less LiOH (1.5 eq) produced the same disappointing result. 
 
Scheme 16. Attempted hydrolysis of methyl ester (R)-30 to give the target hybrid (R)-17. 
Reagents and conditions: (a) 1 M LiOH, THF:H2O (3:1), rt, 1 h. 
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Rather than experiment further with precious advanced material, hydrolysis reactions were 
instead explored with VLA-4 antagonist fragment 20. Fortunately, the same conditions 
resulted in quantitative cleavage of the methyl ester to the carboxylic acid 31 (Figure 36a), 
and the compound did not require further purification, showing excellent purity by analytical 
RP-HPLC (Figure 36b). This finding indicated that the thioridazine and/or triazole portions 
were sensitive to base hydrolysis with LiOH. 
 
 
 
Figure 36. (a) Structure of VLA-4 antagonist 31 produced by hydrolysis of 20. (b) Analytical 
RP-HPLC chromatogram of 31. Solvent A: H2O, 0.1% TFA, Solvent B: CH3CN, 0.1% TFA. 
Gradient: 0% B to 100% B over 40 minutes, 254 nm, tR = 13.0 min. 
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2.4.4 ‘Click’ Reactions Using Carboxylic Acid 31 to Generate (R)-17 
Performing the ‘click’ reaction on the carboxylic acid 31 was subsequently investigated. 
Increased polarity of the acid relative to the methyl ester was predicted to improve solubility 
under the ‘click’ reaction conditions (tBuOH/H2O). The ‘click’ reaction using either (R)-19 or 
(S)-19 N-propargyl-northioridazine enantiomers with carboxylic acid 31 successfully 
delivered the epimeric hybrids (R)-17 and (S)-17 (Scheme 17).   
 
 
Scheme 17. Synthesis of hybrid epimers (R)-17 and (S)-17 via ‘click’ reaction of (R)-19 and 
(S)-19 enantiomers with carboxylic acid 31. Reagents and conditions: (a) Cu(OAc)2.H2O 
(40 mol%), sodium ascorbate (80 mol%), tBuOH:H2O (1:1), 33 °C; (b) Preparative RP-HPLC; 
(R)-17 20%, (S)-17 24%. 
 
Compound 31 (1.1 eq) and (R)-19 or (S)-19 (1.0 eq) were dissolved in tBuOH/water (1:1). 
Catalytic copper acetate (20 mol%) and sodium ascorbate (40 mol%) were added and the 
reaction warmed to 33 °C with stirring. Analytical RP-HPLC chromatograms of aliquots taken 
from the reaction that gave (S)-17 are shown in Figure 37. Retention times for the ‘click’ 
partners 19 and 31 were previously established (Figures 30 and 36b) and are labelled with 
blue squares and red circles, respectively. After two hours the chromatogram indicated 
formation of a new major peak, which was assumed to be the desired ‘click’ product (S)-17 
(tR = 16.1, blue square joined to a red circle).  
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Figure 37. Analytical RP-HPLC monitoring of ‘click’ reaction mixture at various time points. 
Peaks for (S)-propargyl northioridazine (S)-19 (      , tR = 15.0), VLA-4 antagonist fragment 31 
(       ,  tR = 13.9) and the product (S)-17 (             , tR = 16.1) are indicated.* Additional catalyst 
was added at 50 hours and a sample was analysed after 1 hour. 
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A fraction collected from the HPLC corresponding to the new peak (tR =16.1) was analysed by 
ESI-MS, which confirmed formation of (S)-17 (m/z = 1028, M+H+). An unknown side product 
(tR = 14.1) was observed in the reaction but did not appear to interfere with reaction 
progress. A second reaction aliquot drawn at 4 hours indicated little progress. After 8 hours, 
again no significant change was observed and the reaction was allowed to proceed 
overnight. After 24 hours, the chromatogram indicated significant progress with the peak for 
(S)-17 being the dominant species. The reaction was left for another 24 hours and at the 50 
hour mark (*) additional catalyst was added (same quantities). HPLC analysis indicated a 
slight increase in product formation after 1 hour. The reaction was stopped at 58 hours and 
the crude material lyophilised.  The product was purified by preparative RP-HPLC affording 
(S)-17 in 20% yield (Figure 38). The yield represents the combined pure fractions collected 
from the HPLC but does not include impure fractions. The product was characterised and its 
structure confirmed by spectroscopic analysis. An NMR sample made up in d6-DMSO showed 
poor spectral resolution (Appendix 6.1.1) and the presence of a large water peak made 
characterisation difficult. Nevertheless, a suite of 2D NMR experiments allowed assignment 
of peaks.  
 
Figure 38. Analytical RP-HPLC chromatogram of (S)-17 after purification by preparative 
RP-HPLC. Solvent A: H2O, 0.1% TFA, Solvent B: CH3CN, 0.1% TFA. Gradient: 0% B to 100% B 
over 40 minutes, 254 nm, tR = 15.7 min. 
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The same conditions were used to synthesise the epimeric hybrid (R)-17. After 24 hours, 
additional catalyst was added and the reaction was observed to go to completion. The 
analytical RP-HPLC trace of the crude reaction mixture after lyophilisation was virtually 
identical to that obtained for (S)-17. The crude material was purified by preparative RP-HPLC 
affording (R)-17 in 24% yield. This yield represents only the pure material isolated from a 
single purification. The compound was characterised and its structure confirmed by 
spectroscopic analysis. The quality of the 1H NMR spectrum was low in d6-DMSO and peaks 
were unable to be assigned. The quality of the 13C NMR spectrum was better and is provided 
in Appendix 6.1.1. Use of 2D-NMR experiments allowed assignment of the 13C signals and, as 
expected, the hybrid epimers (R)- and (S)-17 differed slightly in their chemical shifts. 
Purification by preparative RP-HPLC using eluents containing 0.1% TFA, produced both 
hybrids as bis-TFA salts, causing them to appear as blue-white solids after lyophilisation. 
Protonation occurring at the phenothiazine and piperidine nitrogens produced two 
additional peaks in the 1H NMR spectrum. The downfield region of (S)-17 presented in Figure 
39 shows the presence of these two peaks at 10.59 and 10.89 ppm, respectively.  
 
Figure 39. Downfield region of the 1H NMR spectrum of (S)-17 showing peaks at 10.59 and 
10.89 ppm corresponding to the bis-TFA salts of the phenothiazine and piperidine nitrogens.  
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These peaks were assigned from a 2D-TOCSY spectrum, where a spin system was associated 
with the broad peak at 10.59 ppm. This proton is part of the 9-carbon spin system within the 
thioridazine portion of the hybrid. This chain also included the CH2 adjacent to the triazole 
that previously showed no coupling. From these data, the broad singlet at 10.59 ppm was 
assigned as the proton attached to the piperidine nitrogen. The singlet at 10.89 ppm was not 
part of any spin system and was thereby assigned as the proton of the phenothiazine 
nitrogen. A partial TOCSY spectrum of (S)-17 displaying the spin system with the 
corresponding structure is shown in Figure 40. The bis-TFA salts were exchanged to bis-HCl 
salts for biological testing. This was done by dissolving the material into CH3CN:0.5 M HCl 
(2:1) and lyophilising the solution. This process was repeated twice to ensure complete 
exchange of the counter ion to chloride.  
 
Figure 40. Region of the TOCSY spectrum of (S)-17 showing the 9-carbon spin system 
associated with the protonated piperidine nitrogen. 
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2.5 Preliminary Biological Results 
The hybrid epimers (R)-17 and (S)-17 were sent to Dr. Alexandre Chigaev at the University of 
New Mexico (USA) for biological evaluation. At the time of writing this thesis, only 
preliminary experiments had been completed. The first experiment investigated the effect 
of the hybrids on cell viability using a classical propidium iodide (PI) assay. Human U937 cells 
(model for AML) were treated with increasing concentrations of the hybrid molecules or 
thioridazine (control) for 24 and 48 hours. The cells were stained with PI according to the 
manufacturer’s instructions and the percentage of PI negative cells (viable) and PI positive 
cells (non-viable) was determined. Propidium iodide is membrane impermeable and is 
excluded from viable cells. The data are shown in Figure 41.  
 
 
Figure 41. Effect of hybrid epimers (R)-17 and (S)-17 and thioridazine (control) on viability of 
U937 AML cells over 24 and 48 hours.  
 
The data suggest that (R)-17 and (S)-17 did not retain thioridazine’s cytotoxic effects on U937 
cells, which showed EC50 values of 1.7 and 5.3 µM after 24 and 48 hours, respectively. The 
finding that (R)-17 had a more significant effect than the (S)-17 epimer on viability after 48 
hours hinted that (R)-thioridazine may be the more active enantiomer responsible for the 
thioridazine-induced apoptosis observed in previous studies (Chapter 1.7).77,76,75    
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In vivo experiments established that thioridazine 16 can induce comparable mobilisation of 
HSPCs to AMD3100, a well-established HSPC mobilising agent (Chapter 1.6).61 A recent 
experiment by Chigaev (personal communication) compared their effects on cell viability and 
mobilisation in a Colony Forming Unit (CFU) assay. This experiment found that the number 
of non-proliferating cells was significantly lower for thioridazine than AMD3100. This was 
determined by comparing the pictures shown in Figure 42 (Chigaev, personal 
communication). The reduced number of CFUs is presumably caused by rapid leukocyte 
apoptosis induced by thioridazine. This result suggests that thioridazine 16 is an unsuitable 
HSPC mobilising agent. This effect has also been postulated to cause significant toxicities and 
therefore is an important factor to note.89 A CFU assay will determine each response for 
hybrids (R)-17 and (S)-17 to indicate their suitability as HSPC mobilising agents.    
Upcoming in vitro experiments will evaluate the effectiveness and affinity of each hybrid as 
competitive and allosteric VLA-4 antagonists. These experiments will use the assay 
previously developed by Chigaev (Figure 16, Chapter 1.7). Depending on the outcome these 
experiments, the compounds will be evaluated further on their ability to induce apoptosis 
and selective differentiation to confirm their multi-action abilities. 
 
 
Figure 42. The effect of mobilising agents AMD3100 and thioridazine on cell background in a 
Colony-Forming Unit (CFU) assay. 
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2.6 Activity of Northioridazine against Multi-Drug Resistant Mycobacterium tuberculosis 
As discussed in Chapter 1.7, thioridazine 16 reportedly shows activity against multi-drug 
resistant Mycobacterium tuberculosis (MDR-MTB). Unfortunately its clinical implementation 
as an anti-tuberculosis drug is hampered by its cardiac and CNS side effects.75 The literature 
has started to unravel the mechanisms responsible for its activity against MDR-MTB.74 The 
thioridazine (R)-16 and (S)-16 and northioridazine (R)-27 and (S)-27 enantiomers prepared in 
this work were sent to Dr. Gregory Cook at the University of Otago, New Zealand, for MIC 
testing against MDR-TB. A summary of the results compared to reported findings90 is shown 
in Table 10. 
 
Table 10. Summary of MIC values against M. tuberculosis for (±)-thioridazine and 
(±)-northioridazine and their enantiomers against M. tuberculosis. Literature values are 
included for comparison. 
 
Compound M. tuberculosis 
MIC50 (mg/L) 
Reported M. tuberculosis 
MIC50 (mg/L)90 
(±)-TDZ 16 4  4  
(-)-(S)-TDZ 16 4 4 
(+)-(R)-TDZ 16 8 8 
(±)-NDZ 27 11.4 - 
(+)-(S)-NDZ 27 22.8 - 
(-)-(R)-NDZ 27 22.8 - 
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The data report the first MICs for northioridazine and its enantiomers against M. 
tuberculosis. The results indicate that thioridazine 16 is more potent than northioridazine 27, 
suggesting that further exploration of N-substitution is a reasonable direction to pursue. 
Both racemic thioridazine 16 and northioridazine 27 were more active than either 
enantiomer, suggesting there may be some synergy between the enantiomers.  
2.7 Conclusions and Future Directions 
The aim of synthesising two epimeric thioridazine-VLA-4 antagonist hybrids was successfully 
accomplished. The convergent synthetic strategy delivered ‘click’ substrates N-propargyl 
northioridazine (R)-19 and (S)-19 and azido-VLA-4 antagonist derivative 20. The key ‘click’ 
reaction led to production of the targets (R)-17 and (S)-17. The hybrid molecules were 
purified by preparative RP-HPLC, structurally characterised and sent for biological evaluation 
to Dr. Alexandre Chigaev at the University of New Mexico, USA. Further biological results are 
pending.  
During this project, several new reactions were developed and multiple novel compounds 
were isolated and characterised. Synthesis of the azido-VLA-4 antagonist derivative 20 was 
successfully achieved, installing the aryl-azide on the benzene sulfonamide. Using a copper 
mediated reaction, the aryl bromide 23 was converted to aryl amine 25. From the aryl amine 
25, the formation and displacement of the aryl diazonium intermediate with sodium azide 
generated 24. Azide substitution on VLA-4 antagonists from this class is novel, and the 
compound represents a useful ‘click’ partner to study VLA-4. For example, the azide could be 
attached via a ‘click’ reaction to an affinity matrix and used for affinity purification of VLA-4. 
Isolation of other proteins that bind to the affinity probe would allow identification of off-
targets for this class of VLA-4 antagonists. A practical synthesis of northioridazine 
enantiomers (R)-27 and (S)-27 from racemic thioridazine was also developed. Racemic 
thioridazine 16 was converted into two menthyl carbamate diastereomers ((R)-D1-26 and 
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(S)-D2-26), which were readily separated. Absolute stereochemistry was established by 
reducing each menthyl carbamate diastereomer to the parent thioridazine enantiomer 
(R)-16 and (S)-16 and comparing their optical rotations to reported values. Hydrolysis of each 
menthyl carbamate to the respective northioridazine enantiomer (R)-27 and (S)-27 with neat 
TFA in a sealed tube was low yielding. N-Demethylation of each thioridazine enantiomer was 
instead used to generate the respective northioridazine enantiomers in good yields. The 
absolute stereochemistry of the northioridazine enantiomers was established by X-ray 
crystallographic analysis of the (R)-nosyl-northioridazine derivative 28. Using each 
northioridazine enantiomer, optimisation reactions identified conditions that delivered 
N-propargyl northioridazine (R)-19 and (S)-19. The possibility of repurposing thioridazine 16 
has sparked interest in the development of analogues that lack cardiac and CNS side effects. 
The chemistry developed here could be used to generate a series of novel, optically pure 
N-substituted thioridazine analogues. Additionally, reports on the activity of northioridazine 
27 are sparse and its biological properties are largely unexplored. N-Propargyl 
northioridazine 19 may also serve as a versatile reactant to explore bioconjugation ‘click’ 
reactions. The first MIC data for northioridazine and its enantiomers against M. tuberculosis 
were reported here. The data shows that N-substituted analogues are of interest and that 
racemic northioridazine 27 and its enantiomers warrant further investigation. A small series 
of N-substituted analogues could be used to identify key structure-activity relationships 
against multi-drug resistant M. tuberculosis.  
In conclusion, both epimeric hybrids were synthesised and their biological evaluation is 
ongoing. Their high molecular weight probably makes them unlikely candidates as drugs for 
the treatment of haematological malignancies. Nevertheless, the molecules have the 
potential to serve as pharmacological tools to probe the allosteric and competitive binding 
pockets of VLA-4.  
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Chapter 3 – Introduction  
3.1 G-Quadruplex DNA  
In 1953, Watson and Crick proposed the model for the DNA B-form double helix; the 
structure most commonly associated with DNA.91 The antiparallel strands of a double helix 
are held together by hydrogen bonding between complimentary base pairs; adenine (A) to 
thymine (T) and guanine (G) to cytosine (C). Duplex DNA base-pairing is most common, 
however atypical base-pairings can result in less common DNA secondary structures. In 1962, 
a secondary DNA structure known as the G-quadruplex was reported by Davies and 
co-workers.92 When four guanine base pairs arrange themselves in a square planar array, 
they form a secondary structure known as a G-tetrad (Figure 43). 
 
  
Figure 43. Structure of a G-tetrad stabilised by a monovalent cation (i.e Na+ or K+). Stacking 
of G-tetrads leads to formation of a G-quadruplex.  
 
The four guanine base pairs are held together by ‘Hoogsteen’ hydrogen bonding, named 
after Karst Hoogsteen.93 The planar orientation of four guanine residues causes G-tetrads to 
have a large π-surface area. Through π-π interactions, multiple G-tetrads stack to form a 
G-quadruplex, which is supported by four linking strands called loops. The G-quadruplex is 
further stabilised by monovalent cations, such as Na+ or K+, which are located between 
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alternating stacks of G-tetrads. The cations are coordinated by eight guanine carbonyl 
oxygens and are essential for G-quadruplex stability. Additional stabilisation from 
hydrophobic and dispersion effects give G-quadruplex DNA a thermodynamic stability that 
is comparable to duplex DNA.94  
 
3.1.1 G-Quadruplex Structure and Topology 
G-Quadruplexes show greater structural diversity than duplex DNA, and can be formed from 
one, two or four DNA (or RNA) stands.95 Combinations of strand polarities, loop size and the 
number of stacked G-tetrads create the diverse structural topologies.95 Folding of the 
G-quadruplex is dependent upon nucleotide sequence length and the surrounding 
environment, which effect the type of G-quadruplex structure formed. G-quadruplexes are 
classified into three main structures; unimolecular (intramolecular), bimolecular (dimeric) 
and tetramolecular (tetrameric).95 Tetramolecular G-quadruplex requires four individual 
strands, dimeric G-quadruplex two, and unimolecular one (Figure 44). 
 
Figure 44. Classifications of G-quadruplexes is based on the number of DNA strands. 
  
G-quadruplexes are also classified according to strand polarity and the loop configurations 
that link the guanine strands.96 The three major orientations that G-quadruplexes adopt are 
parallel, antiparallel and hybrid (Figure 45). ‘Parallel’ topology exists when the four backbone 
strands are orientated in the same direction, and ‘antiparallel’ topology exists when two 
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strands are aligned in opposing directions. The ‘hybrid’ (3+1) arrangement exists when one 
of the four strands is aligned in the opposite direction to the other three.  
 
 
Figure 45. Parallel, antiparallel and hybrid topology of intramolecular G-quadruplex.  
 
Three types of loops that are typically found in G-quadruplexes (Figure 46): (a) diagonal loop, 
where antiparallel strands are joined across the diagonal face, (b) edgewise loops (lateral 
loops), where adjacent antiparallel strands are joined and (c) propeller loops (double-chain 
reversal loops), which joins the head of one parallel strand with the tail of another. 
 
Figure 46. Three loop types in G-quadruplex DNA:(a) diagonal loop, (b) edgewise (lateral) 
loop and (c) propeller (double-chain reversal) loop. 
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In G-tetrads the glycosidic conformation of adjacent guanosines is restricted depending on 
strand orientation. This means that G-quadruplexes contain four structural grooves that 
define the cavities between the guanine base pairs and the phosphodiester backbone. These 
grooves are labelled wide, medium or narrow depending on the G-quadruplex structure and 
the guanine glycosidic angles. In duplex DNA, all glycosidic guanosine conformations are 
found in the anti-configuration. In G-quadruplex DNA, the guanosine glycosidic angles are 
also anti for parallel topology but are a mix of anti and syn for antiparallel G-quadruplexes 
(Figure 47).96  
 
 
Figure 47. Structures of syn and anti-guanosine conformations that can exist in G-quadruplex 
DNA. 
 
The four grooves of a tetramolecular parallel G-quadruplex form a ‘medium’ cavity whose 
size is dictated by four syn glycosidic torsion angles. The antiparallel orientation produces all 
three groove sizes depending on strand direction. An antiparallel bimolecular G-quadruplex 
generates a medium groove from syn-guanosines and a wide and narrow groove from the 
anti-guanosines (Figure 48).  
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Figure 48. Examples of a parallel and antiparallel G-quadruplexes showing how groove size 
depends on strand orientation and guanosine glycosidic angles. 
 
3.1.2 G-Quadruplexes in the Human Genome 
Within the human genome there are an estimated 376,000 sequences that are predicted to 
have G-quadruplex forming potential.97 G-quadruplex forming motifs are most prevalent in 
telomeric regions, RNA and transcriptional regulatory sites.97,98,99 Although the exact 
biological relevance of G-quadruplexes is disputed, the structures are thought to be involved 
in maintaining chromosome stability,100 gene expression101 and regulation of telomere 
length.102 There is much current research focusing on the important biological roles and 
diseases associated with G-rich motifs. Repetitive G-rich nucleotide sequences are 
associated with an increased risk of developing, for example, Friedreich’s ataxia, myotonic 
dystrophy and Fragile X syndrome.103,104 
Biffi and co-workers reported the first quantitative method for visualising G-quadruplexes in 
human cells using G-quadruplex specific antibodies.100 Prior to this discovery there was little 
evidence of their existence in vivo. Small molecules are being developed that target 
G-quadruplexes to inhibit cancer growth via two distinct mechanisms; (i) inhibition of 
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telomerase and (ii) deactivation of overexpressed oncogene promotors.105,106 These 
therapeutic strategies are discussed in more detail later in the chapter.  
 
3.1.3 Telomeres  
Telomeres are DNA-protein complexes found at the ends of linear chromosomes that serve 
to protect the genome from degradation and recombination.107 The human telomeric region 
is composed of the sequence 5’-TTAGGG-3’ repeated over 1000 times. The sequence ends in 
a single stranded guanine rich (G-rich) overhang of 100-200 nucleotides where 
G-quadruplexes are able to form.108 Telomeric G-quadruplexes adopt antiparallel topology 
in the presence of Na+ and the 3+1 hybrid arrangement with K+.109,110  
Telomere regulation is central to the ‘end replication problem’. With each cell division, the 
length of the telomere shortens by 50-200 base pairs until it loses its capping function, 
leading to chromosome fusion, cell senescence and apoptosis.111 The lifespan of a cell is 
therefore limited by the ability to maintain telomere length and replicative capacity.  
Protection of telomere length is controlled by the shelterin (or telosome) protein complex, 
which consists of six telomere specific subunits: TRF1, TRF2, POT1, RAP1, TIN2, and TPP1.106 
Each of these proteins plays a role in aiding the telomere from being identified as a DNA 
break by DNA repair mechanisms. POT1 shelters the telomeric G-overhang from degradation 
by nucleases. When POT1 is bound to the telomeric G-overhang, G-quadruplex structures 
are unable to form.112 However when stabilised by a ligand, G-quadruplexes can promote 
rapid dissociation of POT1 from the telomere motif.113 This suggests that the telomeric 
G-overhang can exist either with POT1 bound as part of the shelterin complex, or as a 
G-quadruplex. This duality is thought to act like a dynamic switch, allowing maintenance of 
and access to the telomere during cell division.  
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Telomere maintenance is mandatory in stem cells and other immortal tissues for retention 
and restoration of replicative capacity. One maintenance pathway relies on the enzyme 
telomerase. In humans, telomerase acts as a reverse transcriptase that adds 5’-TTAGGG-3’ 
repeats to the telomere (Figure 49).114 In embryonic stem cells, telomerase is thought to 
maintain telomere length and immortality, although it is often absent or found at low 
levels.115 Human telomerase levels reduce significantly after birth and activity diminishes 
with age. 
 
Figure 49. Telomerase extends the telomere by adding 5’-TTAGGG-3’ repeats. 
 
Telomerase is overexpressed in 80-90% of cancers and is considered a potential anticancer 
drug target.116 A number of strategies for inhibition of telomerase have been investigated, 
including the use of reverse transcriptase inhibitors and targeting the RNA component hTR. 
G-Quadruplex stabilising ligands are a class of compounds that are able to indirectly inhibit 
telomerase activity as telomeric G-quadruplexes prevent telomerase from recognising its 
binding motif (Figure 50).117 Without stabilising ligands, the G-quadruplex can unfold and 
telomerase will continue to extend telomeres without impediment. Novel stabilising ligands 
are highly sought after as potential cancer drugs. 
  Chapter 3 – Introduction 
90 
 
 
Figure 50. Telomerase activity is impeded by G-quadruplex as it prevents telomerase from 
recognising its binding motif. G-Quadruplex stabilising ligands reduce telomerase activity by 
impeding its passage along telomeres.  
 
Bound G-quadruplex ligands have been shown to induce several cellular responses.  For 
example, ligand-induced inhibition of telomerase causes telomere uncapping that triggers 
cellular senescence and apoptosis. Ligands also tend to induce DNA damage response 
mechanisms leading to similar cellular fates. Similarly, bound ligands can impair functioning 
of the replication fork leading to genome instability and disruption of the cell cycle.118  
 
3.1.4 Oncogene Promotors 
Many oncogenes, such as c-MYC, VEGF, HIF-1a, bcl-2, k-RAS, h-RAS and HSP90, carry an 
abundance of potential G-quadruplex forming motifs. Computational calculations estimate 
that 43% of human promotors contain G-rich sequences capable of forming G-quadruplex 
structures.97 The most widely studied is the c-MYC oncogene, which codes for a 
transcriptional factor involved in cell proliferation and apoptosis. c-MYC is overexpressed in 
80% of cancer cells and has been linked to tumorigenesis119 and numerous malignancies, 
including breast, colon, and cervical cancers. c-MYC activity is controlled by regulatory 
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proteins such as the nuclease hypersensitivity element III1 (NHE III1), which is responsible for 
80-90% of its transcriptional activity.120 The region coding NHE III1 is capable of forming 
potassium dependent G-quadruplexes under physiological conditions.121 These have been 
shown to act as transcriptional repressors that modulate c-MYC expression (Figure 51). 
Stabilising NHE III1 G-quadruplex with the ligand TMPyP4 was shown to deactivate c-MYC 
oncogene expression and down-regulate cell proliferation.122 Furthermore, c-MYC 
transcriptionally regulates the hTERT gene that encodes telomerase. TMPyP4 was able to 
decrease telomerase production, suggesting ligand-mediated inhibition of telomerase 
activity is achievable.122  
 
 
Figure 51. G-Quadruplexes forming in NHE III1 act as transcriptional repressors that modulate 
c-MYC oncogene expression. Stabilising ligands (e.g. TMPyP4) can deactivate c-MYC 
expression reducing cell proliferation.  
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3.2 G-Quadruplex Stabilising Ligands  
The rationale for using G-quadruplex stabilising ligands to modulate cancer cell activity 
originated with the discovery that potassium cations are able to stabilise G-quadruplex 
structures and trigger (partial) inhibition of telomerase activity.123 A plethora of stabilising 
ligands have since been studied for their indirect inhibition of telomerase activity or 
deactivation of oncogene expression (e.g. c-MYC). Structural data from X-ray crystallography 
and NMR spectroscopy of human G-quadruplexes has facilitated the rational design of 
G-quadruplex ligands.124,125  
G-quadruplex stabilising ligands are generally hydrophobic, flat, aromatic molecules that 
complement the flat, π-electron rich topology of the G-tetrad. Rational design of 
G-quadruplex ligands is typically guided by three considerations: (1) a large aromatic surface 
to make π-stacking interactions, (2) selectivity for G-quadruplex DNA over duplex DNA and 
(3) an overall net positive charge to provide electrostatic interactions with the phosphate 
backbone.126 The complexity introduced by polymorphisms and the varying electrostatic 
potential of different G-quadruplexes has meant that empirical approaches are also needed. 
Many notable ligands have been reported and a representative selection is discussed in 
3.2.2. 
 
3.2.1 Ligand Binding Affinities and Specificity 
The effectiveness of ligands is measured by their binding affinity and specificity for 
G-quadruplex DNA over duplex DNA. Dissociation constants (KD) are typically determined 
using spectroscopic techniques, namely fluorescence and UV-vis assays.127 As duplex DNA is 
much more abundant, poorly selective ligands that bind to duplex (or single-stranded) DNA 
would be expected to show low G-quadruplex binding in vivo. Ligand selectivity is thus often 
reported as a ratio of the dissociation constants (Kd) for duplex and G-quadruplex DNA.127  
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Ligands are also assessed for their potential to thermodynamically stabilise G-quadruplexes 
by measuring the differences in melting temperature for G-quadruplexes with and without 
bound ligand (ΔTm). Ligands that increase the melting temperature thus stabilise the 
G-quadruplex. Measurements of ΔTm can be obtained by UV spectroscopy, fluorescence and 
circular dichroism (CD) techniques.  
Telomerase inhibition (IC50) by ligands can be measured using the telomere repeat 
amplification protocol (TRAP) assay.128 This assay is performed over two steps where a 
telomere primer is first elongated by telomerase and then the elongated products are 
amplified by polymerase chain reaction (PCR). The TRAP assay was originally designed for 
measuring telomerase inhibition by molecules that bind directly to the enzyme. Molecules 
that bind to duplex DNA were found to interfere with the PCR step, causing overestimation 
of the measured IC50 values. This problem was solved by adding a step that removed the 
ligand prior to PCR.129 Prior to this amendment (2008), all reported telomerase inhibition 
data for G-quadruplex ligands was deemed inaccurate and required revision. 
 
3.2.2 Classes of G-Quadruplex Stabilising Ligands 
Over a few decades, several notable G-quadruplex ligands have been developed (Figure 52). 
Bisamido-anthraquinones were among the first G-quadruplex stabilising ligands reported. In 
1997 Neidle and co-workers reported a compound BSU-1051 that showed moderate 
telomerase inhibitory activity (IC50 = 23 µM), while at higher concentrations (100 µM) near 
complete inhibition was observed. BSU-1051 was able to bind to and stabilise 
G-quadruplexes  (ΔTm= +20 °C).130 Structure-activity studies that varied the core and amide 
groups were undertaken in an attempt to improve telomerase inhibition and reduce 
anthraquinone-associated cytotoxicity.131,132 A series of fluorenone analogues showed 
reduced cytotoxicity and comparable telomerase inhibition to BSU-1051.133 The authors 
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concluded that specificity of the compounds for G-quadruplex DNA over duplex DNA was not 
high enough to warrant further investigation. 
 
Figure 52. Structures and telomerase inhibitory activity of G-quadruplex stabilising ligands. 
 
Neidle and co-workers continued their attempts to improve G-quadruplex selectivity and 
affinity by changing the aromatic core, where the aim was to enhance π-stacking interactions 
with the G-tetrad. The two basic side arms were also altered to increase electrostatic 
interactions. A series of 3,6-bisamido-acridines were created, with the acridine nitrogen’s 
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partial positive charge (pKa= 5.6) served to provide additional electrostatic interactions with 
the G-tetrad.  
BSU-6039 proved to be very useful in G-quadruplex ligand design as an X-ray crystal structure 
of the compound bound to a G-quadruplex was obtained.134 The structure revealed that the 
acridine core π-stacks with the G-tetrad and the two side chains reinforced binding through 
electrostatic contacts in the G-quadruplex grooves. BRACO-19 was subsequently designed to 
interact with three G-quadruplex grooves and boost affinity.135 In 2008, an X-ray co-crystal 
structure of BRACO-19 bound to G-quadruplex showed that a third groove had been 
occupied.136  Unlike BSU-1051, BRACO-19 displayed relatively low cytotoxicity and showed 
potent inhibition of telomerase (IC50= 0.15 µM). The compound was also 31-fold more 
selective for G-quadruplex over duplex DNA and afforded greater thermodynamic stability 
to G-quadruplexes (FRET: ΔTm= +27 °C). BRACO-19 showed remarkable in vivo anticancer 
activity in tumour xenografts, producing a 96% decrease in primary tumour volume in 
UXF1138L small human uterine carcinomas.137 Unfortunately, BRACO-19 showed very low 
membrane permeability and was not stable in vivo, limiting its progression into the clinic. 
Further development of acridine ligands is ongoing, with recent derivatives showing very 
potent telomerase inhibition (IC50 = 10 nM).138  
SAR studies with BRACO-19 focussed on enhancing the electrostatic interactions of the 
side-arms. In 1998, Hurley and co-workers reported ligands with extended aromatic cores 
that aimed to improve hydrophobic interactions with the G-tetrad.139 An important 
compound is the perlyene called PIPER; a moderately potent telomerase inhibitor 
(IC50= 20 µM) that can accelerate formation of G-quadruplexes in vitro.140 NMR studies 
showed that PIPER shows varying binding stoichiometries to G-quadruplexes depending on 
topology.139 PIPER was the first ligand to demonstrate pH-mediated selectivity for DNA 
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structures.141 At pH 7.0, PIPER exhibited little selectivity for G-quadruplex DNA but at pH 8.5 
its selectivity increased 42-fold.  
A related pentacyclic acridine RHPS4 showed high selectivity for G-quadruplex DNA (qDNA 
Kd= 100 nM vs. dsDNA Kd= 1 µM)142 and excellent telomerase inhibitory activity 
(IC50= 0.33 µM).143 An RHPS4-G-quadruplex complex solved by NMR spectroscopy, indicated 
that RHPS4 binds to the face of the G-quartet, making strong π-stacking interactions.144 
Exposure of RHPS4 to vulval (A431) or breast cancer (21NT) cell lines resulted in significant 
growth reduction after 15 days.145 RHPS4 also induces POT1 uncapping from telomeres in 
melanoma cell lines causing significant DNA attrition.146  
RHPS4 has been evaluated in combination with taxol and doxorubicin, where it increased the 
sensitivity of MCF-7 breast carcinoma cells to the cancer drugs in vitro.147 RHPS4 was recently 
shown to induce telomeric dysfunction, resulting in impressive cytotoxicity against U251MG 
astrocytoma cells. In the same study, when evaluated as a radiosensitiser RHPS4 produced 
synergistic effects in combination with X-ray treatments against U251MG radioresistant 
glioblastoma cells.148 Although these studies are still early-stage, RHPS4 warrants further 
investigation due to its superior pharmacokinetics and drug-like properties compared to 
most G-quadruplex binding ligands.  
Porphyrins can be good G-quadruplex ligands due to their large aromatic core and cationic 
substituents decorating the periphery. Porphyrins containing positively charged quaternary 
nitrogens are ideal as they don’t rely on in situ protonation to promote electrostatic 
interactions, and are also more water soluble and cell permeable. In 1998, Hurley and 
co-workers reported TMPyP4 as a selective G-quadruplex ligand.149 The compound has since 
become one of the most heavily investigated G-quadruplex binding ligands. 
The ligand favours binding to G-quadruplex DNA (Kd= 73 nM) over duplex DNA 
(Kd= 370 nM),150 it thermodynamically stabilises G-quadruplexes (ΔTm= +17 °C) and shows 
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moderate inhibitory activity against telomerase (IC50= 6.5 µM).149 It also displays irregular 
binding patterns and stoichiometries (up to 5:1 TMPyP4:qDNA) depending on G-quadruplex 
topology and conditions151 and is unique in its ability to intercalate between G-tetrads and 
possibly stack on the external faces of G-quadruplexes.152 The biological effects and 
applications of TMPyP4 have not been comprehensively explored but some studies have 
reported noteworthy activity for TMPyP4 in various cancer cell lines. For  example, treating 
osteosarcoma cells with TMPyP4 induces telomere shortening and leads to apoptosis.153 The 
compound also shows growth impairment of K562 leukaemia154 and retinoblastoma cell 
lines.155  In 2016, whole genome sequencing was used to explore alterations in gene 
expression by TMPyP4. At low concentrations (<0.5 µM), TMPyP4 altered cell adhesion 
signalling and promoted tumour cell migration. At higher concentrations (>2 µM), cell 
proliferation was inhibited and apoptosis occurred.156  
Cylene Pharmaceuticals developed a fluoroquinolone-derived compound quarfloxin 
(CX-3543), the first G-quadruplex ligand to reach Phase II clinical trials (neuroendocrine and 
carcinoid tumours).157 Unlike most fluoroquinolones, quarfloxin was optimised not to inhibit 
topoisomerase II (for antibacterial activity) but to maximise selectivity for G-quadruplexes.158  
Quarfloxin selectively disrupts interactions between nucleolin-protein and G-quadruplexes, 
a critical DNA-protein interaction in aberrant cell growth. Binding prevents transcription by 
RNA polymerase I, causing redistribution of the nucleolin-protein into the nucleoplasm 
where it can bind to NHE III1 G-quadruplexes and interrupt MYC expression.159,160 A later 
study showed that MYC mRNA expression was  reduced in mice after treatment with 
quarfloxin.161   
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3.3 (R)-Telomestatin 32 
In 2001, Shin-ya and co-workers isolated and structurally characterised the natural product 
(R)-telomestatin 32, a secondary metabolite from Streptomyces anulatus 3533-SV4.162 The 
compound presented a unique macrocyclic scaffold composed of eight contiguous 
heterocycles, including five oxazoles, two methyl-oxazoles and an (R)-thiazoline (Figure 53).  
 
Figure 53. Structure of the natural product (R)-telomestatin 32. 
 
(R)-Telomestatin 32 was originally thought to be one of the most potent inhibitors of 
telomerase (IC50 = 5 nM) but it was later identified that the compound inhibits the PCR 
polymerases used in the telomerase inhibition assay.163 When the telomerase inhibition 
experiments were revised (Chapter 3.2.1) the compound showed lower potency 
(IC50= 0.6 µM).129 (R)-Telomestatin 32 stabilises G-quadruplexes (ΔTm= +24 °C) and shows 
excellent selectivity (70-fold) for G-quadruplex over duplex DNA.126,105 The compound binds 
to most G-quadruplexes with high affinity (Kd= 10-100 nM), especially intramolecular 
G-quadruplexes.105,164 Its unique macrocyclic structure and interesting properties have made 
(R)-telomestatin 32 one of most exciting G-quadruplex ligands discovered to date. With its 
high specificity and selectivity for telomeric G-quadruplex DNA, (R)-telomestatin 32 is 
considered a lead compound for telomere-directed therapies.165 
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The macrocyclic structure and aromatic character of (R)-telomestatin 32 gives rise to its 
affinity and specificity for G-quadruplexes. Monchaud et al. generated an in silico model 
showing how (R)-telomestatin 32 could bind to the top of a G-tetrad.166 An adapted 
representation is shown in Figure 54. This model shows that (R)-telomestatin 32 is 
complimentary in size to the face of a G-tetrad and likely forms multiple π-π interactions. 
The presence of the chiral, non-aromatic (R)-thiazoline prevents (R)-telomestatin 32 from 
being completely planar, and it is thought that this may be detrimental to binding potency.167   
 
 
Figure 54. In silico model of (R)-telomestatin 32 bound to the top face of a G-tetrad. Figure 
adapted from Monchaud et al.166 (PDB: 2A5R) using PyMol (version 1.8.6.2.).  
 
3.3.1 Biological Activity of (R)-Telomestatin  
In 2006, Tahara and co-workers reported several biological effects for (R)-telomestatin 32. A 
major finding was that the compound induces dissociation of TRF2 (telomere-binding 
protein), a key regulator of telomere stability, resulting in loss of telomeric 3’overhangs in 
cancer cells.113 It also inhibited cell growth in SiHa, MFC-7 and HeLa cancer cell lines but not 
in normal fibroblasts and epithelial cells. (R)-Telomestatin 32 interacts with the 3’ telomeric 
overhang in cancer cells causing cell apoptosis via DNA damage signalling pathways.168,169  
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Other studies showed that (R)-telomestatin 32 can impair glioma stem cell growth by 
disturbing transcription and inducing a DNA damage response. This finding may provide clues 
for the treatment of glioblastoma, a fatal brain cancer where self-renewing gliomal stem cells 
drive tumour growth and survivability.170,171 Treating multiple myeloma and leukaemic cells 
with (R)-telomestatin 32 causes telomere shorting and apoptosis,172,173 and it can induce 
anti-tumour effects both alone and in combination with cytotoxic agents.174,175 For example, 
it was shown to enhance the sensitivity of leukaemia K562 cells to imatinib, doxorubicin and 
vincristine.176  
Difficulties in obtaining practical quantities of (R)-telomestatin 32 have hampered studies of 
the compound. Its impressive specificity and biological activities have spurred research 
groups to pursue various analogues and derivatives (Figure 55). In 2006 Rice and co-workers 
synthesised the hexaoxazole compound HXDV, which showed selective binding to 
G-quadruplexes and significant stabilising effects on G-quadruplexes (ΔTm= +17.5 °C).177 
Variants of HXDV included a series of hexaoxazole dimers (6OTDs) that act as terminal caps 
on both faces of the same G-quadruplex, resulting in improved selectivity for telomeric DNA 
(compared to the monomeric form).178 
Seyfried and co-workers postulated that planarity in (R)-telomestatin 32 was very important 
for binding based on a high-resolution solution X-ray crystal structure of an analogue bound 
to human telomeric G-quadruplex.179 They speculated that replacing the thiazoline ring with 
a planar thiazole would increase π-stacking interactions, leading to creation of the planar 
analogue cyclo(-ox-thia)4 (Figure 55).167 This compound was synthesised using methods 
related to those of Shin-ya180 (Chapter 3.3.2) but no biological activities were reported.  
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Figure 55. Telomestatin analogues HXDV, 6OTDs and cyclo(-ox-thia)4.167,178  
 
3.3.2 Total Synthesis of (R)-Telomestatin 
A major limitation to studying the biological effects of (R)-telomestatin 32 is the difficulty in 
obtaining practical quantities of the compound by isolation from the natural source. Bacterial 
production of (R)-telomestatin 32 is very low yielding due to difficulties in fermenting 
Streptomyces anulatus 3533-SV4.162 Additionally, the unique, highly strained macrocyclic 
structure of (R)-telomestatin 32 has hampered total synthesis efforts. Multiple attempts 
have been reported in the literature but most have failed to generate the target natural 
product.181,182,183,184,185 Structural complexity of the molecule creates numerous synthetic 
challenges, namely formation of the contiguous heterocycles, closure of the macrocycle and 
the formation of the chiral thiazoline. Only one successful total synthesis of (R)-telomestatin 
32 has been reported to date.180 In this synthesis, Shin-ya et al. used a convergent strategy 
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that linked two trisoxazole fragments (Fragments 1 and 2) to construct the majority of the 
backbone.   
Fragment 1 was prepared by coupling two 2,5-disubstituted oxazole units (Scheme 18). 
Initially, the N-Boc oxazolidine was N-deprotected with 4 M HCl in dioxane and the resulting 
amine was coupled to a second 2,5-disubstituted oxazole carboxylic acid using PyBrop as the 
coupling reagent. Cyclodehydration of the resulting hydroxy amide using diethylaminosulfur 
trifluoride (DAST) formed an oxazoline intermediate that was immediately oxidised to the 
oxazole with BrCCl3 and DBU. Hydrogenation of the benzyl ester furnished Fragment 1. 
 
 
Scheme 18. Synthesis of Fragment 1.180 Reagents and Conditions: (a) 4 M HCl, 1,4-dioxane, 
rt, 1 h; (b) PyBrop, DIPEA, CH2Cl2, rt, 1.5 h, 84%; (c) DAST, CH2Cl2, -78 °C, 1 h (d): BrCCl3, DBU, 
CH2Cl2, rt, 8 h, 71%; (e) H2, Pd/C, EtOAc-MeOH, rt, 1.5 h.  
 
Preparation of Fragment 2 began with N-Boc-Cys(StBu)-Thr-OMe (Scheme 19). The 
secondary alcohol of the threonine residue was oxidised to the ketone using SO3-pyridine 
and DMSO (Parikh-Doering oxidation) and cyclodehydration of the ketone with PPh3 and 
iodine generated the trisubstituted carboxylic acid after ester hydrolysis. Numerous 
cyclodehydration conditions were explored but no reasoning for their use was provided. 
Presumably, cyclodehydrations of the threonine alcohol with DAST and other reagents were 
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not effective so alternative conditions were explored. PyBrop coupling to the amino group 
of a 2,5-disubstituted oxazole methyl ester produced a bisoxazole-containing intermediate. 
Cyclodehydration of the hydroxy amide using Burgess reagent (Et3NSO2-NCO2Me) followed 
by oxidation with BrCCl3 and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) generated the 
trisoxazole core. N-Boc deprotection with 4 M HCl in dioxane afforded Fragment 2. 
 
 
Scheme 19. Synthesis of Fragment 2.180  Reagents and Conditions: (a) SO3.Py, DMSO, DIPEA, 
CH2Cl2, rt, 2h; (b) PPh3, I2, Et3N, THF, -78 °C, 2.5 h, 73%; (c) LiOH, MeOH:THF:H2O, rt, quant; 
(d) PyBrop, DIPEA, CH2Cl2, rt, 1.5 h, 93%; (e) Burgess reagent, THF, 70 °C, 8 h; (f) BrCCl3, DBU, 
CH2Cl2, rt, 8 h, 75%; (g) 4 M HCl, 1,4-dioxane, rt, 1 h.  
 
Deprotection and a peptide coupling using PyBrop led to formation of the linear hexaoxazole 
intermediate (Scheme 20). Deprotection at the C and N-termini followed by macrocyclisation 
with diphenyl phosphorazidate (DPPA) gave the macrocyclic hexaoxazole. Formation of the 
seventh oxazole failed, under cyclodehydration conditions with DAST or Burgess reagent. 
Mesylation of the serine alcohol with methanesulfonyl chloride (MsCl) and DBU produced 
the dehydroamide which could be advanced to generate the final oxazole. 
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Scheme 20. Preparation of the macrocyclic dehydromide.180  Reagents and Conditions: (a) 
PyBrop, DIPEA, CH2Cl2, rt, 1.5 h, 85%; (b) 4 M HCl, 1,4-dioxane, rt, 1.5 h; (c) LiOH, 
MeOH:THF:H2O, rt; (d) DPPA, HOBt, DIPEA, DMAP, DMF-CH2Cl2, 3 mM, rt, 3 d, 48%; (e) MsCl, 
DBU, CH2Cl2, 0 °C, 1 h, 92%. 
 
To complete the total synthesis, the seventh oxazole and the thiazoline ring needed to be 
generated on the macrocycle (Scheme 21). Treatment of the dehydroamide with 
N-bromosuccinamide (NBS) in CH2Cl2/MeOH followed by intramolecular cyclisation triggered 
by K2CO3 produced a 4-methoxyoxazoline intermediate. Subsequent elimination of methanol 
with camphor sulfonic acid generated the seventh oxazole. Finally, the thiazoline ring needed 
to be obtained from the tBu-thiol. By modifying the method of Kelly et al., simultaneous 
deprotection and cyclodehydration was achieved using triphenylphosphine oxide, triflic 
anhydride and anisole, generating the (R)-thiazoline ring and completing the total 
synthesis.186 After purification by HPLC only 0.78 mg of (R)-telomestatin 32 was isolated.  
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Scheme 21. Final stages in the total synthesis of (R)-telomestatin 32.  Reagents and 
Conditions: (a) NBS, MS 4 Å, CH2Cl2-MeOH, 0 °C, 1 h, 90%; (b) K2CO3, 1,4-dioxane, 60 ° C, 6 h, 
79%; (c) camphor sulfonic acid, toluene, MS 5 Å sieves, 70 °C, 14 h; (d) Ph3P(O)-Tf2O, anisole, 
CH2Cl2, rt, 3.5 h, 20%.  
 
Shin-ya et al. modified the  route to produce the un-natural enantiomer (S)-telomestatin 32 
by using (S)-cysteine in Fragment 2.187 The synthetic steps were identical except for the 
macrocyclisation, which was low yielding (19%) and produced a mixture of diastereomers. 
Optimisation experiments determined that DPPA and HOBt with catalytic 
4-(dimethylamino)pyridine N-oxide (DMAPO) produced the macrocyclic hexaoxazole in the 
highest yield. Analogous procedures were subsequently applied to furnish (S)-telomestatin 
32. The paper also reported that the (S)-enantiomer inhibits telomerase with four-times the 
potency of (R)-telomestatin.  
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3.4 Thesis Aims 
No G-quadruplex binding ligands have advanced to clinical use despite their impressive 
pre-clinical activity against various malignancies. G-Quadruplex ligands typically need planar 
and hydrophobic structural requirements that often result in poor pharmacokinetic and 
other drug properties. (R)-Telomestatin 32 is considered an important compound for 
studying telomere biology and telomerase activity and access to practical quantities of the 
compound would facilitate further studies. The reported total synthesis of 
(R)-telomestatin 32 used multi-step chemistry that could not generate useful quantities. 
Additionally, several studies have suggested that structural features of (R)-telomestatin 32 
could be modified to enhance G-quadruplex affinity.167,187 A practical synthetic route to 
(R)-telomestatin 32 that was flexible enough to allow access to analogues for SAR studies 
would therefore be highly valuable. The aim of this project was to develop a new, more 
practical and efficient total synthesis using a mixed solid/solution-phase strategy.  
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Chapter 4 – Results and Discussion 
4.1 Proposed Total Synthesis of (R)-Telomestatin 
Although the exact biosynthesis of (R)-telomestatin 32 is unknown, we set out to design a 
biomimetic route that aligns with a possible biosynthesis. Three fundamental stages were 
considered to produce (R)-telomestatin 32: (1) formation of the linear peptide backbone 
using solid phase peptide synthesis (SPPS), (2) ‘head-to-tail’ macrocyclisation and (3) 
simultaneous universal generation of the contiguous heterocycles in one-pot (Figure 56).  
 
 
Figure 56. Simplified representation of the three key stages in the proposed synthesis of 
(R)-telomestatin 32. 
 
The route was inspired by the idea that (R)-telomestatin 32 is most likely produced from the 
amino acid precursors available to the organism. Inspection of the structure shows that the 
molecule would be formed from the sequence NH2-Ser-Ser-Ser-Cys-Thr-Thr-Ser-Ser-OH. The 
contiguous heterocycles of (R)-telomestatin 32 could then be produced from the parent 
amino acids i.e., oxazoles from serine and methyl oxazoles from threonine. The (R)-thiazoline 
ring would ultimately come from the cysteine. The macrocycle could be formed by a 
‘head-to-tail’ cyclisation and each serine and threonine amino acid would then undergo 
cyclodehydration/oxidation to their respective oxazoles, with formation of the thiazoline 
completing the biosynthesis (Figure 57). 
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Figure 57. Proposed biosynthesis of (R)-telomestatin 32. 
 
4.2 Design of Protected Linear Peptide 35 
Design of the linear peptide was integral to the likely success of the total synthesis as its 
structure would influence the outcome of later reactions. As the molecule is asymmetric, the 
point of disconnection was important as this could dramatically impact the macrocyclisation 
yield. As the macrocycle has no termini, multiple linear precursors were theoretically 
available from the eight possible macrocyclic disconnections (Figure 58).  
 
Figure 58. Eight possible disconnections for macrocyclisation of the linear peptide precursor. 
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Choosing the best disconnection point is difficult as there is no way to predict how efficiently 
the eight possible linear peptides would cyclise. The linear nature of peptides with multiple 
trans-configured amide bonds makes their macrocyclisation unfavourable. In cyclic peptide 
chemistry, several strategies have been developed to promote macrocyclisation whilst 
avoiding oligomerisation and C-terminal epimerisation. For example, terminal residues with 
opposite stereoconfigurations (L and D) can improve yields, as can placing turn inducing 
residues (e.g. proline or glycine) in the middle of the sequence. The amino acids that make-up 
(R)-telomestatin 32 contain neither of these so could not be used.  
 
4.2.1 Pseudoprolines as Traceless Turn Inducers  
Proline is the only natural amino acid that prefers the cisoid amide conformation, with all 
others forming trans-amides.188 The cisoid conformation introduces a bend into the linear 
sequence that assists with head-to-tail cyclisation, as it brings the amino and carboxy termini 
into closer proximity. Pseudoprolines (ψ) are unnatural amino acid modifications that lock 
the parent amino acid into the cisoid amide conformation, to artificially encourage 
cyclisation. 
Pseudoprolines are five membered saturated heterocycles that are obtained from the 
condensation of serine, threonine or cysteine residues with carbonyls to form a ketal (ψMe,Me) 
or acetal (ψH,H). They can be reliably installed into peptide sequences and have the advantage 
of acting as side chain protecting groups. Pseudoprolines are traceless ‘removable’ turn 
inducers since they can be hydrolysed under acidic conditions to reveal the parent amino 
acid (Figure 59). After macrocyclisation, the pseudoproline is no longer required and the 
native amino acid is restored. Pseudoprolines are often installed into peptides as pre-formed 
Fmoc-protected dipeptides because the secondary amine of the pseudoproline does not 
couple well during solid-phase peptide synthesis. 
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Figure 59. Synthesis of ψMe,Me pseudoproline dipeptides via condensation, where R can be any 
side chain, and X = O (serine) or S (cysteine). Acidic hydrolysis restores the parent amino acid. 
 
In bringing the two termini into closer proximity and making the cyclisation more favourable, 
pseudoprolines reduce formation of the undesired linear and/or cyclic oligomers that are 
commonly observed with un-assisted macrocyclisations. In our proposed synthesis of 
(R)-telomestatin 32, it was anticipated that use of pseudoprolines in a linear peptide 
precursor would promote macrocyclisation. It is known that use of multiple pseudoprolines 
can provide added benefits in the cyclisation step and improve peptide solubility.189 After 
cyclisation, acidic hydrolysis of pseudoprolines restores the native amino acid.  
With an Fmoc-protected N-terminus, SPPS is easily deployed for the synthesis of 
pseudoproline containing linear peptides and allows for the facile generation of high quality 
peptides, often in almost quantitative yields. Additionally, practical quantities (1-5 g) of 
complex peptides can easily be prepared. Based on the above, an Fmoc-SPPS strategy was 
devised for the synthesis of the linear precursor of (R)-telomestatin 32 that incorporated two 
pseudoprolines to assist in the macrocyclisation.  
The linear peptide was designed to position the pseudoproline dipeptides at the centre of 
the linear sequence to facilitate head-to-tail macrocyclisation and at the C-terminus to 
minimise epimerisation (and further assist in cyclisation).189 The C-terminal serine 
pseudoproline was used as serine-derived pseudoprolines are easier to prepare and confer 
less steric hindrance during macrocyclisation reactions compared to threonine-derived 
pseudoprolines.  
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The central pseudoproline was to come from a cysteine residue. Cysteine-derived 
pseudoprolines are less reactive and require more strongly acidic conditions for cleavage 
(e.g. triflic acid). This enhanced stability could be exploited as the (R)-thiazoline ring functions 
as a thiol protecting group throughout a synthesis and can be unmasked near its completion. 
Shin-ya et al. demonstrated that it is possible to perform a simultaneous thiol-deprotection 
and cyclodehydration of the cysteine residue to complete the thiazoline ring and total 
synthesis of (R)-telomestatin 32.180 Although Shin-ya’s penultimate intermediate contained 
a Cys(StBu) protecting group, we postulated that a similar result might occur with the 
cysteine pseudoproline (Figure 60) 
 
 
Figure 60. Completion of Shin-ya’s total synthesis involved simultaneous deprotection and 
cyclodehydration of a Cys(StBu) group.180 Reagents and conditions: (a) Ph3P(O)-Tf2O, anisole, 
CH2Cl2, rt, 3.5 h, 22%. In the proposed total synthesis, the cysteine pseudoproline would be 
subjected to similar conditions.  
 
The amino acids N-terminal to the pseudoproline-containing residues in the linear sequence 
were included as a dipeptide. The residues were N-Fmoc protected and included tert-butyl 
side chain protecting groups on the serine hydroxyl groups. The two dipeptides required for 
production of the linear peptide 35 were Fmoc-Ser(OtBu)-Ser(ψMe,MePro)-OH 33 and 
Fmoc-Ser(OtBu)-Cys(ψMe,MePro)-OH 34 (Figure 61). 
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Figure 61. Structures of pseudoproline dipeptides 33 and 34 required for the SPPS of a linear 
peptide precursor. 
 
A general summary of the proposed total synthesis of (R)-telomestatin 32 is shown in 
Figure 62. Using the appropriate Fmoc/t-butyl-protected amino acids and the two 
pseudoproline dipeptides 33 and 34, the linear precursor 35 would be obtained by SPPS. 
After macrocyclisation to give 41, all protecting groups except the cysteine pseudoproline 
would be globally deprotected, affording the polyol precursor 42.  
The presence of t-butyl protecting groups was expected to provide good solubility during the 
macrocyclisation step, which is usually carried out in DMF. A one-pot poly-cyclodehydration 
of all hydroxy amides would generate the polyoxazoline 43 and subsequent oxidation would 
produce 44. The total synthesis would be completed by simultaneous deprotection and 
cyclodehydration of the thiazolidine.  
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Figure 62. Proposed total synthesis of (R)-telomestatin 32 using a mixed solid-phase/solution 
phase strategy. 
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 4.2.2 Synthesis of Pseudoproline Dipeptides 33 and 34 
Various pseudoproline containing dipeptides are commercially available but they are 
expensive and sold in small quantities (~$US400/1g).  A synthesis was therefore undertaken 
to produce the larger quantities (5 g) of the dipeptides required for the SPPS. Preparation of 
pseudoproline containing dipeptides differs depending on the residue to be cyclised (i.e. 
serine, threonine or cysteine).189 Syntheses of the requisite dipeptides 33 and 34 have not 
been published despite their commercial availability. A synthesis of the dipeptide 33 was 
undertaken using the route shown in Scheme 22. 
 
 
Scheme 22. Synthesis of Fmoc-Ser(OtBu)-Ser(ψMe,MePro)-OH 33. Reagents and conditions: 
(a) HATU, DIPEA, DMF, rt, 18 h, 93%; (b) 2,2-dimethoxypropane, PPTS, THF, reflux, 4 Å sieves, 
16 h, 82%; (c) Me3SnOH, 1,2-DCE, 80 °C, 16 h, 45%.   
 
Commercially available Fmoc-Ser(OtBu)-OH was coupled with L-Ser-OMe.HCl to produce 
dipeptide methyl ester 36. This was achieved by dissolving Fmoc-Ser(OtBu)-OH, 
L-Ser-OMe.HCl (1.5 eq) and HATU (1.3 eq) in dry DMF and slowly adding DIPEA (3 eq). After 
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18 hours, the crude residue was purified by silica gel column chromatography and the target 
dipeptide 36 isolated in excellent yield (93%). Its structure was confirmed by spectroscopic 
analysis. The reaction was performed several times up to 5.8 gram scales in consistent yield. 
The methyl ester protected pseudoproline 37 was obtained by reacting 36 with 
2,2-dimethoxypropane in the presence of catalytic pyridinium p-toluenesulfonate (PPTS, 
20 mol%) in anhydrous THF. The reaction was heated to reflux and the condensate passed 
through a soxhlet extractor containing activated 4 Å sieves to remove water formed during 
the reaction. TLC analysis (EtOAc:Pet. Spirit, 40:60) indicated that pseudoproline dipeptide 
37 was by being formed after 6 hours. After 17 hours, the reaction was concentrated in vacuo 
and the resulting crude residue was purified by silica gel column chromatography (EtOAc:Pet. 
Spirit, 0:100 to 40:60) to give 37 in 85% yield consistently on scales up to 5 g. The literature 
reports procedures that quenched similar reactions by addition of triethylamine, however, 
it was found that this led to N-Fmoc deprotection.189 
Hydrolysis of the methyl ester with lithium hydroxide or sodium hydroxide led to removal of 
the Fmoc protecting group. In 2005, Nicolaou et al. reported a ‘mild and selective method’ 
for the hydrolysis of esters using trimethyltin hydroxide (Me3SnOH) in 1,2-dichloroethane 
(1,2-DCE).190 Preliminary experiments indicated that these conditions successfully 
hydrolysed the methyl ester so a series of optimisation experiments were undertaken 
(Table 11).  
The reaction was found to be temperature sensitive. At 70 °C no Fmoc-derived fluorenyl side 
products were observed by TLC and 33 was isolated in modest yield (61%, Entry 1). Heating 
the reaction at reflux (83 °C) resulted in Fmoc-deprotection and led to a lower yield of 33 
(17%, Entry 2).  
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Table 11. Optimisation of hydrolysis of methyl ester 37 to 33 using trimethyl tin hydroxide 
(Me3SnOH) in 1,2-dichloroethane (1,2-DCE). 
 
Entry Scale (g) Temperature (°C) Yield (%) 
1 0.05 70  61 
2 0.1 83 17 
3 0.5 75 51 
4 1.0 80 79 
5 5.2 80 45 
 
 
 
At 75 °C the reaction didn’t reach completion after overnight heating and 33 was obtained 
in 51% yield (Entry 3). The highest isolated yield was obtained when the temperature was 
kept at 80 °C. At this temperature, complete hydrolysis of the ester 37 was observed by TLC 
analysis and 33 was isolated in 79% yield (Entry 4). Despite an apparent increase in N-Fmoc 
deprotection and other side-products by TLC analysis, consumption of 37 was complete and 
better yields were obtained. On larger scales (5 g), however, purification was difficult and 
required multiple procedures to produce useable quantities for SPPS (45%, Entry 5). While 
the route provided sufficient material to proceed with SPPS, the difficulties associated with 
the reaction led to exploration of alternatives for producing 33. 
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It was postulated that the pseudoproline could be installed directly on the free acid dipeptide 
Fmoc-Ser(OtBu)-Ser-OH 38, which would avoid the need for ester hydrolysis. Synthesis of 
dipeptide 38 was attempted by coupling L-Ser-OH to Fmoc-Ser(OtBu)-OH. Under standard 
coupling conditions (e.g. HBTU or HATU with DIPEA) no reaction was observed by TLC 
analysis, possibly because L-Ser-OH appeared to be poorly soluble in DMF. Heating the 
reaction and use of different solvents (CH3CN, CH2Cl2 and DMSO) did not improve solubility 
and resulted in significant N-Fmoc deprotection.  
Several other C-terminal activating groups, such as acid chlorides, acid fluorides and 
activated esters, are typically used for amide couplings. A common activating group in 
peptide synthesis is the pentafluorophenol ester (OPfp), which is substituted by most amines 
to form amides.191 The Pfp ester is produced by reacting a carboxylic acid with 
pentafluorophenol under Steglich esterification conditions (DCC). The resulting 
pentafluorophenol esters are generally stable and can be purified by column 
chromatography. This strategy was explored with Fmoc-Ser(OtBu)-OPfp 39, which was to 
undergo amide coupling with L-Ser-OH to generate dipeptide acid 38. 
Fmoc-Ser(OtBu)-OH, pentafluorophenol (1.2 eq) and DCC (1.2 eq) were dissolved into EtOAc 
at 0 °C and allowed to warm to room temperature (Scheme 23). After 6 hours, TLC analysis 
indicated that most of the starting material had been consumed. Depending on the reaction 
scale and ambient temperature, the reaction time extended out to 12 hours. Upon 
completion, the insoluble dicyclohexylurea by-product was filtered through a fritted funnel 
and the resulting eluent placed into a separating funnel. After aqueous work-up, the organic 
layer was concentrated in vacuo to produce a dense oil, which under high-vacuum formed a 
hygroscopic amorphous foam.  
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Scheme 23. Synthesis of Fmoc-Ser(OtBu)-OPfp 39. Reagents and conditions: (a) 
pentafluorophenol, DCC, EtOAC, 0 °C - rt, 6 h, 97%. 
 
The quality of the material obtained after aqueous work-up varied between reactions and 
although relatively clean, purification by column chromatography (EtOAc:Pet. Spirit, 40:60) 
was employed to increase purity if needed. On larger scales (> 5 g) it was easier to remove 
contaminating pentafluorophenol via trituration with n-hexane and diethyl ether. When the 
quality of the product was lower, the crude pentafluorophenol ester 39 was adsorbed onto 
a plug of silica and thoroughly washed with EtOAc:Pet. Spirit (20:80). The ester 39 was 
characterised and its structure confirmed by spectroscopic analysis. This intermediate was 
prepared multiple times on scales up to 10 g in consistently high yields.  
To prepare dipeptide 38, pentafluorophenol ester 39 and L-Ser-OH (1.5 eq) were dissolved 
into DMF and DIPEA (2 eq) was slowly added. After 6 hours, TLC analysis indicated product 
formation with signs of N-Fmoc deprotection. After 18 hours, the reaction was stopped and 
purification by silica gel column chromatography produced 38 in 21% yield. The poor 
solubility of L-Ser-OH in organic solvents was again thought to contribute to the low yield.  
An aqueous solution of L-Ser-OH was then trailed to improve solubility (Scheme 24). L-Ser-OH 
(3 eq) was dissolved into a minimum volume of aqueous sodium carbonate (10% w/v) at 
pH 9. The aqueous L-Ser-OH solution was added dropwise to a stirring solution of 39 in 
acetone and the reaction was stirred vigorously at room temperature while monitoring by 
TLC analysis and LR-MS. 
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Scheme 24. Synthesis of Fmoc-Ser(OtBu)-Ser-OH 38. Reagents and conditions: (a) L-Ser-OH, 
Na2CO3 (10% w/v), pH 9, rt, 18 h, 81%.  
 
After 18 hours, a substantial amount of product had cleanly formed by TLC analysis but 
starting material remained. The reaction mixture was acidified to pH 1 with 1 M HCl, 
concentrated in vacuo to half volume and placed into a separating funnel. The aqueous 
solution was extracted with ethyl acetate to give a dense oil after removal of the solvent. 
Purification by silica gel column chromatography was difficult due to the high polarity of 38. 
The crude product was instead precipitated using a hot solution of 30% EtOAc/n-hexane, 
which was then chilled to 0 °C. The white solid collected by Buchner filtration was compound 
38 (81% yield). The compound was characterised and its structure confirmed by 
spectroscopic analysis. When performed on larger scales (6.2 g) a slightly lower yield (69%) 
was obtained. 
Installation of the pseudoproline onto 38 was explored next using the same conditions as 
used previously (Scheme 25). The pseudoproline dipeptide 33 was observed by TLC analysis 
after 6 hours. After 16 hours the reaction was concentrated in vacuo the crude material 
purified by silica gel column chromatography (CH2Cl2:MeOH, 100:0 to 95:5). The procedure 
gave the target pseudoproline dipeptide 33 in 63% yield. The isolated yield of 33 was lower 
than it was for methyl ester 37 (82%) due to uncharacterised side products, possibly resulting 
from the naked C-terminus. Nevertheless, this route produced 33 in a higher overall yield 
(80% over 3 steps vs. 73% over 3 steps) and avoided use of toxic trimethyl tin hydroxide. 
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Scheme 25.  Installation of pseudoproline to give dipeptide 33. Reagents and conditions: (a) 
2,2-dimethoxypropane, PPTS, THF, reflux, 4 Å sieves, 16 h, 63%. 
 
Synthesis of pseudoproline dipeptide 34 was different as the pseudoproline residue was to 
be installed prior to amide coupling. The literature reports that cysteine can be directly 
converted into a dimethyl thiazolidine when heated at reflux in acetone (Scheme 26).192 
When a solution of L-Cys-OH.HCl in acetone was heated at reflux a white precipitate 
immediately formed within the flask. After 18 hours, the reaction was cooled to 0 °C and the 
white suspension collected by Buchner filtration. The product was confirmed as the cysteine 
pseudoproline 40 (hydrochloride salt) and its yield (98%) and purity was excellent. The 
compound was prepared several times on scales of up to 20 g with near quantitative yields 
consistently obtained. The chirality of the cysteine residue, which ultimately becomes the 
thiazoline ring of (R)-telomestatin 32, was set at this point and would remain throughout the 
synthesis. 
 
 
Scheme 26. Synthesis of Cys(ψMe,MePro)-OH.HCl 40. Reagents and conditions: (a) acetone, 
reflux, 18 h, 98%. 
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To obtain dipeptide 34, cysteine pseudoproline 40 was needed to be coupled to 
Fmoc-Ser(OtBu)-OH. Under standard coupling conditions (HBTU or HATU, DIPEA, DMF), 
however, no product was observed by TLC analysis or LR-MS, possibly due to the steric 
hindrance around the thiazolidine nitrogen and/or low solubility in organic solvents. The 
related problem with 38 was solved by displacing a pentafluorophenol ester 38 with L-Ser-OH 
in an aqueous solution of sodium carbonate (10% w/v). The analogous method was thus 
investigated here. A solution of cysteine pseudoproline 40 (3 eq) in sodium carbonate 
(10% w/v) was added to Fmoc-Ser(OtBu)-OPfp 38 in DMF. After 3 hours, TLC analysis 
indicated the presence of 34, along with Fmoc-deprotected by-products. After aqueous 
workup and purification by silica gel column chromatography, 34 was isolated in only 12% 
yield. 
An alternative method was thus sought that avoided use of the sodium carbonate solution 
(Scheme 27). It was found that neutralising the hydrochloride salt of 40 (2 eq) with DIPEA 
(4 eq) significantly improved its solubility in DMF. After 30 minutes, the pentafluorophenol 
ester 39 in DMF was added dropwise to the now homogenous solution and the reaction was 
stirred at room temperature. Under these conditions a substantial amount of 34 was 
apparent with very little Fmoc-deprotection by-products visible by TLC analysis. After 18 
hours, the mixture was concentrated in vacuo and the crude residue purified by silica gel 
column chromatography (EtOAc:Pet. Spirit, 0:100 to 70:30) to afford 34 in 73% yield.  
Although the yield was good, unreacted pentafluorophenol ester 39 was still present and 
isolated in 12% yield. Gently heating the reaction or altering the quantity of DIPEA resulted 
in lower yields. The product 34 was characterised and its structure confirmed by 
spectroscopic analysis. The reaction was performed several times on scales up to 7.3 g and 
produced 34 in similar yield (67%). 
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Scheme 27. Synthesis of the pseudoproline dipeptide 34. Reagents and conditions: (a) 
Cys(ΨMe,Me,Pro)-OH.HCl 40, DIPEA, DMF, rt, 18 h, 73%. 
 
In summary, an efficient synthesis of the requisite pseudoproline dipeptides 33 and 34 was 
successfully accomplished (Scheme 28). Several strategies for introducing the serine and 
cysteine pseudoprolines into dipeptides were investigated that ultimately led to the final 
divergent synthesis from a common pentafluorophenol intermediate 39. The method made 
the synthesis very practical, where multigram batches of the pentafluorophenol ester 39 
could be produced and used for parallel production of both dipeptides 33 and 34. More than 
10 g of each dipeptide were produced in preparation for the solid phase peptide synthesis. 
The synthetic strategy could potentially be applied for production of any C-terminal 
pseudoproline dipeptide that contains a N-terminal common amino acid.  
 
  Chapter 4 – Results and Discussion 
123 
 
 
Scheme 28.  Optimised synthesis of pseudoproline dipeptides 33 and 34 from a common 
pentafluorophenol intermediate 39. Reagents and conditions: (a) pentafluorophenol, DCC, 
EtOAC, 0 °C - rt, 6 h, 97%; (b) L-Ser-OH, Na2CO3 (10% w/v), pH 9, rt, 18 h, 81%; (c) 
2,2-dimethoxypropane, PPTS, THF, reflux, 4 Å sieves, 16 h, 63%; (d) acetone, reflux, 18 h, 98%; 
(e) Cys(ΨMe,Me,Pro)-OH.HCl 40, DIPEA, DMF, rt, 18 h, 67%.  
 
4.2.3 Solid Phase Synthesis of Linear Peptide 35 
With both pseudoproline dipeptides 33 and 34 in hand, SPPS of the linear precursor 35 was 
attempted using an Fmoc/OtBu protecting group strategy. Preparation of peptides by SPPS 
is performed by repeating cycles of deprotection and amide coupling steps. Various resins 
are available to suit the protecting group strategy and functionality required at the 
C-terminus. The resin 2-chlorotrityl chloride is suitable for an Fmoc/OtBu protecting group 
strategy and produces a free carboxylic acid at the C-terminus upon resin cleavage. SPPS on 
2-chlorotrityl chloride resin involves four key steps; loading, deprotection, iterative peptide 
coupling/deprotection and cleavage (Scheme 29).  
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Scheme 29. Overview of SPPS of linear peptides on 2-chlorotrityl chloride resin. Reagents and 
conditions: (a) Fmoc-AAx-OH, DIPEA, CH2Cl2, rt, 3 h; (b) 20% (v/v%) piperidine in DMF, rt, 3 x 
3 min; (c) Fmoc-AAx-OH, HBTU, DIPEA, DMF, rt, 2 h; (d) TFA:TIPS:H2O (95:2.5:2.5), rt, 2 x 1 h 
or HFIP:TFE:CH2Cl2 (1:2:7), rt, 2 x 1 h.  
 
Fmoc-protected C-terminal amino acids can be loaded onto the resin by agitating in a 
solution of DIPEA in CH2Cl2. The N-Fmoc protecting group of the loaded amino acid residue 
is then removed by treatment with piperidine in DMF (20% v/v). A by-product of this reaction 
is the highly coloured dibenzofulvene, which can be used to spectroscopically determine the 
percentage of compound loaded on the resin. The next Fmoc-amino acid is then coupled to 
the free amine of the resin-attached amino acid using HBTU and DIPEA in DMF. The process 
of deprotection and coupling is repeated as required to form the desired peptide sequence.  
Upon completion of the linear sequence a final Fmoc deprotection generates the N-terminal 
free amine. When the peptide is cleaved from the resin using a mixture of TFA, TIPS and 
water all acid labile groups (OtBu, OTrt, N-Boc) are removed to yield the parent peptide. To 
retain the protecting groups on the amino acid side-chains less acidic cleavage conditions are 
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required, such as 1,1,1,3,3,3-hexafluoroisopropanol (HFIP), 2,2,2-trifluoroethanol (TFE) in 
CH2Cl2. The latter method was required for the synthesis of 35 as serine pseudoprolines are 
vulnerable to TFA.189 Deprotection of the serine pseudoproline prior to macrocyclisation 
would render its inclusion useless. The proposed SPPS of linear peptide 35 is shown in 
Scheme 30.  
 
Scheme 30. Proposed solid phase synthesis of side-chain protected linear peptide 
intermediate 35. Reagents and conditions: (a) 2-chlorotrityl chloride resin, DIPEA, CH2Cl2, rt, 
18 h; (b) 20% piperidine (v/v%) in DMF, rt, 3 x 3 min; (c) Fmoc-Thr(OtBu)-OH, HBTU, DIPEA, 
DMF, rt, 2 h; (d) Fmoc-Ser(OtBu)-Cys(ψMe,MePro)-OH 34, HBTU, DIPEA, DMF, rt, 2 h; (e) Fmoc-
Ser(OtBu)-OH, HBTU, DIPEA, DMF, rt, 2 h; (f) HFIP:TFE:CH2Cl2 (1:2:7), rt, 2 x 1 h. 
 
The synthesis begins with loading of pseudoproline dipeptide 33 onto the resin. The resin is 
thoroughly washed and capped using methanol to remove any unreacted chloromethyl 
groups. The Fmoc group is then removed with piperidine and the liberated amine 
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immediately reacted with Fmoc-Thr(OtBu)-OH using HBTU as the coupling reagent. This 
process is repeated to generate the tetrapeptide. After Fmoc deprotection the second 
pseudoproline dipeptide 34 is coupled using HBTU to produce the hexapeptide. After 
another two rounds of Fmoc deprotection and coupling of Fmoc-Ser(OtBu)-OH with HBTU, 
the linear backbone of (R)-telomestatin 35 is complete. A final Fmoc deprotection and 
cleavage from the resin with HFIP/TFE affords 35 with all side-chain protecting groups intact. 
Preliminary experiments were conducted on small scale (100 mg resin) using disposable PPE 
syringes fitted with a Teflon sinter as the reaction vessel. The pseudoproline dipeptide 33 
was loaded onto the resin using a solution of DIPEA in DMF over 3 hours. After 
Fmoc-deprotection an aliquot of the mixture containing the coloured dibenzofulvene was 
analysed by UV-vis spectroscopy, which showed that only 11% of the expected amount of 33 
had been loaded. Steric hindrance about the C-terminal pseudoproline was suspected to be 
lowering reactivity. 
Improvement was seen when the resin loading reaction was allowed to proceed overnight. 
After capping and Fmoc-deprotection, analysis of an aliquot showed a resin loading efficiency 
of just 43%. Literature suggests that use of N-methyl-2-pyrollidone (NMP) as solvent can 
improve solvation leading to better resin loading.193 Loading of the resin overnight in NMP 
was found to give  57% loading of 33. It was noted that NMP affected the resin properties 
and made draining of the SPPS vessel difficult. Subjecting the resin to a second, fresh solution 
of 33 in DIPEA-DMF for 2 hours resulted in 67% loading.  
The poor loading efficiency led us to question the quality of the resin. The batch of 
2-chlorotrityl chloride resin used had been was labelled with a loading capacity of 
1.51 mmol/g. This value was evaluated in-house by loading Fmoc-Gly-OH (a non-sterically 
hindered amino acid expected to couple very well) onto the resin, followed by immediate 
cleavage with HFIP/TFE. The procedure indicated that the loading capacity was only 
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0.97 mmol/g, or approximately 64% of the value on the label. Recalculating the loading of 33 
based on this new loading capacity indicated that the loading was 85%. The seemingly poor 
quality of the resin led to exploration of resins from other suppliers. When 2-chlorotrityl 
chloride resin obtained from Merck Millipore was used, a reaction performed under the 
same conditions resulted in 98% loading. 
The linear peptide 35 was undertaken using the Merck resin on a 0.6 mmol scale. Cleavage 
from the resin and concentration of the resulting solution produced 35 as a clear oil and 
trituration with cold diethyl ether converted 35 to a crystalline solid. The peptide was 
purified by RP-preparative HPLC and its structure confirmed by spectroscopic analysis.  
The major side product identified by mass spectrometry analysis was a deletion peptide 
missing pseudoproline dipeptide 34. Deletion occurs when an inefficient deprotection or 
coupling reaction takes place during of the SPPS. Due to higher steric hindrance around 34 
this was not unexpected. To address this issue, a double coupling of 34 was performed at 
this stage during a resynthesis of the peptide. This time 35 was produced in exceptionally 
pure form and did not require further purification.  
The 1H spectrum of 35 in d6-DMSO showed excellent resolution (Figure 63). The two sets of 
pseudoproline gem-dimethyl peaks were clearly evident at 1.50 ppm and 2.10 ppm, 
respectively. A conglomeration of tert-butyl CH3 groups and threonine methyl signals were 
present around 1.30 ppm that correctly integrated to 60 protons. However, the complexity 
of this region made unambiguous assignment of individual signals difficult and only generic 
assignments (e.g. Thr-CH3) was possible from 2D-NMR experiments (TOCSY, COSY, HSQC, 
HMBC and NOESY). 
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Figure 63. Region of the 1H NMR spectrum (500 MHz, d6-DMSO) of 35. The complete spectrum 
is provided in Appendix 6.1.1. 
 
A goal was set in this work to prepare 500 mg of 35 in each SPPS attempt. Preparing the 
peptide on this scale required more than 1 g of each 33 and 34 (3 eq) per coupling reaction. 
These quantities were easily achievable using the divergent synthesis developed here 
(Chapter 4.2.2). Additionally, extremely pure materials and solvents were important because 
purification of 35 at this scale would be laborious by preparative RP-HPLC and prohibitively 
expensive. Under the optimised conditions developed here linear peptide 35 was available 
in practical quantities (760 mg, 81%) from a single SPPS run. 
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4.3 Macrocyclisation of Linear Peptide 35 
With an abundance of the linear peptide 35 in hand, the key macrocyclisation reaction to 
generate 41 was investigated. To perform the head-to-tail cyclisation, 35 and a coupling 
reagent were dissolved in DMF and DIPEA (5 eq) was slowly added. After an acid/base 
workup the crude material was purified by silica gel column chromatography (CH2Cl2:MeOH, 
100:0 to 95:5) to give 41. A summary of the isolated yields and conditions explored for the 
reactions are summarised in Table 12.  
A coupling reagent that reportedly facilitates peptide macrocyclisation is 4-(4,6-dimethoxy-
1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride (DMTMM)194 where formation of a 
‘super-activated’ ester in situ (Scheme 31) allows rapid amide coupling and helps to limit 
C-terminal  epimerisation.195 This coupling reagent is expensive, however, so it was produced 
in-house. Synthesis of DMTMM was achieved by adding N-methyl morpholine (1.0 eq) to a 
stirring solution of the chlorodimethoxy triazine precursor in water. After 20 minutes of 
stirring at room temperature an aqueous solution of NaBF4 (1.1 eq) was slowly added. After 
1 hour, the white precipitate was collected by Buchner filtration and dried in vacuo. 
Spectroscopic and LR-MS analysis confirmed that DMTMM had been isolated in excellent 
yield (87%, Lit. 80%196) and in very high purity (Scheme 31).  
 
Scheme 31. Synthesis of coupling reagent DMTMM and structure of the ‘super-activated 
ester’. Reagents and conditions: (a) N-methyl morpholine, NaBF4, H2O, 1 h, 87% (Lit. 80%)196 
The ‘super activated’ ester intermediate formed during amide couplings with DMTMM is 
shown. 
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Table 12. Reaction conditions and isolated yields for macrocyclisation of 35 to 41. 
  
Entry Coupling reagent Mol equivalents Concentration (mM) Yield (%) 
1 DMTMM 1.5  2.5 mM 17  
2 DMTMM 2.0 2.5 mM 31  
3 DMTMM 3.0 2.5 mM 36 
4 HBTU 3.0 2.0 mM 48  
5 PyBOP 3.0 2.0 mM 53 
6 HATU 3.0 2.0 mM 67 
7 HATU 3.0 1.0 mM 79 
8 DMTMM 3.0 1.0 mM 54  
 
Preliminary reactions were explored with DMTMM (1.5 eq) in dilute solutions of DMF 
(2.5 mM). With both termini unprotected the risk in this reaction was unwanted linear 
and/or cyclic oligomerisation. Under dilute conditions the intermolecular oligomerisation 
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processes are reduced. At 2.5 mM concentrations, the cyclic peptide 41 was formed but the 
reaction failed to reach completion after 18 hours and 41 was isolated in only 17% yield 
(Entry 1). Increasing the amount of DMTMM (2-3 eq) improved the yield to 36% (Entries 2 
and 3). TLC analysis indicated that DMTMM was failing to drive the reaction to completion 
and numerous side products were forming. 
Alternative coupling reagents were explored in attempt to improve the isolated yield. Use of 
HBTU and PyBOP (3 eq) at lower concentration (2.0 mM) improved the reaction and 41 was 
isolated in 48% and 53% yields, respectively (Entries 4 and 5). Use of HATU (3 eq) was found 
to generate 41 in better yield (67%, Entry 6), but was still not driving the reaction to 
completion and multiple side-products were still present. Analysis of the crude reaction 
mixtures by LR-MS suggested that significant cyclic hexadecapeptide oligomer (m/z = 2315) 
had formed.  
A subsequent attempt with HATU (3 eq) at lower concentration (1 mM) produced a much 
cleaner reaction and an isolated yield of 79% (Entry 7). When attempted at the same 
concentration (1 mM) with DMTMM (3 eq), an improvement in the yield was seen 
(54%, Entry 8) but the reaction quality was lower, forming multiple side products. The 
superior quality of the crude 41 produced with HATU versus DMTMM is highlighted in 
Figure 64. 
Both reactions were run under identical conditions and stopped after 18 hours. Lack of a 
chromophore in 41 meant that UV detection had to be performed at 214 nm (tR = 22.7). The 
quality of the crude 41 produced following acid/base workup made it much easier to purify 
by silica gel column chromatography than the material produced with DMTMM. The side 
products observed in the DMTMM chromatogram were not identified but were likely peptide 
oligomers. In summary, cyclic peptide 41 could be obtained in good yield using HATU as the 
coupling reagent at a reaction concentration of 1 mM in DMF. 
  Chapter 4 – Results and Discussion 
132 
 
 
 
 
Figure 64. Analytical RP-HPLC chromatograms comparing the quality of crude 41 formed by 
macrocyclisation of 25 with HATU and DMTMM. Grace VisionHT C18 HL column (3 µ, 150 x 
4.6 mm). Solvent A: H2O, 0.1% TFA, Solvent B: CH3CN, 0.1% TFA. Gradient: 0% B to 100% B 
over 40 minutes, 214 nm, tR = 22.7. 
 
4.3.1 Structural Characterisation of Macrocycle 41. 
The complexity of the protected macrocycle 41 and the redundancy in its structure made 
interpretation of its NMR spectra challenging. A sample prepared in CDCl3 showed good 
signal dispersion and resolution in the 1H spectrum. The spectrum contained a complex 
upfield region with a suite of signals corresponding to the tert-butyl methyl groups at 
1.09-1.30 ppm (Figure 65). The collection of signals integrated to 57 protons corresponding 
HATU 
DMTMM 
41 
41 
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to the number of protons in the tert-butyl methyl groups plus one Thr-CH3. Lack of dispersion 
of the signals in this region made individual assignments impossible.  
The four gem-dimethyl signals from the two pseudoproline residues were easily assigned, 
with the pair of methyl groups of pseudoproline 33 corresponding to the two signals at 
1.63 ppm. The methyl signals of 34 converged into a singlet with an integration of 6 protons. 
The doublet at 1.42 ppm integrated to 3 protons, corresponding to the second Thr-CH3 signal. 
 
  
 
Figure 65. 1H spectrum (500 MHz, CDCl3) of macrocyclic peptide 41. 
 
Assigning each proton and carbon signal required extensive analysis of 2D-NMR spectra. The 
most useful experiments for assigning signals were TOCSY and g-COSY. These experiments 
are highly suited to peptides because they identify the diagnostic spin systems within each 
individual residue. For example, the spin system present in a threonine residue is shown in 
Figure 66a (red arrows). The amide nitrogen of the residue shows a correlation to the 
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adjacent α-proton. The α-proton correlates to the β-proton, which couples to the Thr-CH3. 
In TOCSY spectra, the complete spin-system from the amide proton through to the Thr-CH3 
is often observed. The amide carbonyl prevents cross over into adjacent residues thus 
allowing unambiguous assignment of signals arising from individual amino acid residues.   
 
 
Figure 66. (a) Diagnostic spin systems (red) in TOCSY/g-COSY spectra that correspond to 
threonine residues in peptides; (b) NOE’s typically observed between adjacent serine and 
threonine residues (blue).  
 
Adjacent residues can often be identified from characteristic NOE or ROE cross-peaks 
observed in NOESY or ROESY spectra, respectively. Inter-residue NOE’s typically observed in 
peptides containing neighbouring serine and threonine residues are shown in Figure 66b 
(blue). The α-proton of the serine should show an NOE to the amide NH signal of the 
threonine residue. Likewise, NOEs are expected between the Thr-CH3 and the amide NH 
signal of the preceding serine. This pattern of NOEs confirms that the two residues are 
adjacent in a sequence. In the case of 41, NOESY experiments were not informative due to 
the density of overlapping signals between 1.09-1.30 ppm. 
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TOCSY and g-COSY experiments with 41 established which signals corresponded to the two 
pseudoprolines. The TOCSY spectrum clearly indicated the correct number of spin systems, 
including 4 separate Ser-α-CH signals, which correlate to their respective Ser-β-CH2 signals 
(Figure 67). The two Thr-CH-β signals were identified from TOCSY correlations between the 
doublet at 1.42 ppm and the cluster of signals at 1.18 ppm. This revealed that both Thr-β-CH2 
protons were harboured beneath the multiplet at 3.94 ppm. TOCSY correlations from this 
multiplet allowed unambiguous assignment of the two Thr-CH-α-protons at 4.45 and 4.75 
ppm, respectively. 
 
Figure 67. TOCSY spectrum of 41 showing the amino acid spins systems corresponding to the 
Cysψ (orange), Serψ (blue), Thr (green) and Ser (purple) residues. 
 
The α-CH and β-CH2 signals of the two pseudoprolines were clearly identified upfield from 
the other α-CH signals. The Cysψ-α-CH signal at 5.35 ppm showed correlations to two β-CH2 
signals at 3.15 and 3.64 ppm, respectively. Similarly, the Serψ-α-CH signal at 5.04 ppm 
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showed correlations to β-CH2 signals at 4.05 and 4.46 ppm, respectively. Additional 
information from the gHSQC spectrum allowed unambiguous assignment of all 13C α-CH 
β-CH2 signals of 41. A partial gHSQC spectrum with positive (CH/CH3, red) and negative (CH3, 
blue) signalling is shown in Figure 68. Eight positive signals in the region between 2.50 and 
5.00 ppm corresponded to the eight α-CH signals of the octapeptide 41. The Thr-α-CH and 
β-CH signals were easily identified from the TOCSY spectrum. This spectrum confirmed which 
multiplets contained overlapping signals for α and β protons. For example, the multiplet at 
3.64 ppm contained signals from the Cysψ-β-CH2 and two Ser-β-CH2.  
  
 
Figure 68. Partial gHSQC spectrum showing CH/CH3 signals (red) and CH2 signals (blue) for 
macrocycle 41. 
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4.4 Studies Towards Formation of the Contiguous Heterocycles 
The later stages of the proposed synthesis of (R)-telomestatin 32 involved formation of seven 
contiguous oxazoles and a thiazoline ring. It was proposed that this impressive 
transformation could occur in three steps from the protected macrocycle 41. Global 
deprotection would remove all protecting groups excluding the thiazolidine to form 
poly-hydroxylated intermediate 42 (hereafter referred to as the ‘polyol’). Seven 
cyclodehydrations would then be performed on the polyol in one-pot to generate 
heptaoxazoline intermediate 43, which upon oxidation would generate the penultimate 
heptaoxazole target 43 (Figure 62). 
 
4.4.1 Global Deprotection to Generate Polyol 42 
Global deprotection was initially trialled by dissolving 41 in a mixture of TFA:TIPS:H2O at 
room temperature. After 4 hours an additional aliquot of the acidic mixture was added. The 
procedure resulted in complete consumption of the starting material after 8 hours 
(Scheme 32). 
 
Scheme 32. Global deprotection of macrocycle 41 to give cyclic polyol 42. Reagents and 
conditions: (a) TFA:TIPS:H2O (95:2.5.2.5), rt, 8 h, 56%.  
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The high polarity of polyol 42 meant that TLC analysis could not be used for reaction 
monitoring. Analytical RP-HPLC and LR-MS were used instead and confirmed complete 
consumption of starting material and that the correct product was formed (m/z 803, 
[M+Na]+). The TFA was removed under a stream of N2 and the resulting oil triturated with n-
hexane, CHCl3 and diethyl ether, leading to isolation of 42 as white crystals. The compound 
was purified by preparative RP-HPLC. As it was insoluble in organic solvents, the crude 
material was injected into the HPLC as a concentrated solution in DMSO. The purified 
product was collected and lyophilised to afford 42 in 56% yield. Significant yield was lost 
during the RP-HPLC purification and not from the reaction conditions. The compound 
showed good purity as determined by analytical RP-HPLC and LR-MS (Figure 69).  
 
 
Figure 69. LR-MS and analytical RP-HPLC of purified cyclic polyol 42. Solvent A: H2O, 0.1% 
TFA, Solvent B: CH3CN, 0.1% TFA. Gradient: 0% B to 100% B over 30 minutes, 214 nm 
tR = 14.1 min. 
M+H+ 
M+Na+ 
M+K+ 
  Chapter 4 – Results and Discussion 
139 
 
The polyol 42 was prepared several times on scales of up to 75 mg and was isolated in 
consistent yields and purity after preparative RP-HPLC.  The 1H spectrum of 42 in CD3OD was 
complex, showing many more signals than expected (Figure 70). This was unexpected given 
the apparent purity of the compound by RP-HPLC and LR-MS. It was hypothesised that the 
complexity of signals was caused by the intrinsic properties of 42, where intermolecular 
hydrogen bonding could cause oligomeric stacking leading to multiple species and sets of 
NMR signals. Additionally, conformational isomers (conformers) of the macrocycle driven by 
intramolecular hydrogen bonding could also give rise to multiple species that slowly 
interconvert on the NMR timescale. Changing the NMR solvent to d6-DMSO or D2O did not 
improve spectral quality. Thus, no NMR data for 42 could be reported in the thesis. 
Nevertheless, the quality of the sample suggested by RP-HPLC supported exploration of the 
pivotal one-pot polycyclodehydration reactions with 42.  
 
 
 
Figure 70. 1H NMR (500 MHz, CD3OD) spectrum of macrocyclic polyol 42 after purification by 
preparative RP-HPLC. 
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4.4.2 Cyclodehydration of Cyclic Polyol 42 
The key reaction in the proposed total synthesis was conversion of the cyclic polyol 42 to the 
heptaoxazoline 43 by performing seven cyclodehydrations in a one-pot process. The reaction 
was investigated first with the most common cyclodehydrating reagent, DAST. For each 
hydroxyamide (serine or threonine), one molecule of DAST is required to promote 
cyclodehydration. The mechanism of DAST-mediated cyclodehydration of hydroxyamides is 
shown in Figure 71. The reaction starts with attack of the electrophilic sulfur by the hydroxyl 
oxygen lone pair, leading to elimination of HF. Intramolecular cyclisation of the neighbouring 
amide, generates the desired oxazoline and releases diethylsulfuramidous fluoride.  
 
Figure 71. Mechanism of cyclodehydration of hydroxyamides with DAST to form oxazolines.  
 
For each hydroxy amide, an excess of DAST was trialled with reactions performed on 
15-20 mg scales (Table 13). Cyclodehydrations with DAST are typically conducted at -78 °C to 
avoid decomposition of the reagent in situ. For reactions with the cyclic polyol 42, seven 
cyclodehydrations were required, thus 1.5 equivalents of DAST for each residue was needed 
(i.e. 10.5 eq in total). Applying the conditions reported by Phillips et al.,197 DAST (10.5 eq) 
was added dropwise to a solution of 42 in CH2Cl2 at -78 °C under argon and the reaction 
monitored by TLC analysis over 16 hours (Entry 1).  
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Table 13. Reaction conditions trialled for the polycyclodehydration of 42 to 43. 
 
Entry Scale (mg) Reagent (eq) Solvent Temperature (°C) Yield (%) 
1 20 DAST (10.5) CH2Cl2 -78 - 
2 15 DAST (21) CH2Cl2 -78 - 
3 15 DAST (10.5) CHCl3 -78 - 
4 15 DAST (10.5) THF -78 - 
5 15 DAST (21) THF -78 - 
6 20 XtalFluor-E (10.5) 1,2-DCE reflux - 
7 15 XtalFluor-E (21) 1,2-DCE reflux - 
 
 
A critical observation was that cyclic polyol 42 was poorly soluble in CH2Cl2 at low reaction 
temperature. TLC and LR-MS analysis indicated that no products had been formed under 
these conditions. Doubling the amount of DAST (21 eq) and changing the solvent (CHCl3 or 
THF) had no effect (Entries 2-5). 
XtalFluor-E is a more thermal stabile reagent than DAST that enables cyclodehydrations to 
be performed at higher temperatures (Figure 74).198,199 It was proposed that formation of 
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one oxazoline may initiate partial solubilisation of polyol 42, which could drive further 
reaction progress. XtalFluor-E (10.5 and 21 eq) was added to a stirring solution of the cyclic 
polyol 42 in 1,2-DCE under argon. The reaction mixture was heated at reflux and monitored 
by TLC analysis. Cyclic polyol 42 was again found to be insoluble under these conditions and 
no new products were observed by TLC analysis (Entries 6 and 7). 
Luedtke and co-workers have published reports that aimed to improving the 
pharmacological properties of the (R)-telomestatin 32 core, along with its synthesis.199 The 
same solubility issues were highlighted when performing polycyclodehydration reactions on 
polyol substrates.167  To address this issue they made use of the in situ decomposition of 
DAST and XtalFluor-E, proposing that the more soluble polysilyl protected β-hydroxyamides 
would be deprotected in situ by released fluoride, with ensuing cyclodehydration to the 
oxazolines occurring in the same pot. A series of silyl protecting groups were explored and it 
was found that the triethylsilyl (TES) group showed the best deprotection rate relative to the 
more sterically hindered groups (e.g. TIPS). With TES, the rate of deprotection was slow 
enough to initiate cyclodehydration whilst maintaining all reaction intermediates in solution. 
A mechanism for the reaction is shown in Figure 72.167 
 
 
Figure 72. Mechanism proposed by Luedtke et al. for in situ silyl deprotection and one-pot 
cyclodehydration of β-hydroxyamides to 2-oxazolines with XtalFluor-E.167 
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Fluoride deprotection of the TES group reveals a nascent alkoxide intermediate that attacks 
the XtalFluor-E sulfur forming a stabilised intermediate. Intramolecular cyclisation of the 
neighbouring amide subsequently generates the oxazoline and diethylsulfuramidous 
fluoride. The fluoride anion released in the process initiates another cycle of TES 
deprotection and cyclodehydration. 
In endeavouring to generate five contiguous oxazolines from a penta-serine peptide, Luedtke 
et al. reported that use of XtalFluor-E produced significantly lower yields than DAST. Direct 
cyclodehydration of Fmoc-(Ser)5-OMe to the penta-oxazoline was not investigated. Poly-TES 
peptide Fmoc-Ser(OTES)5-OMe was dissolved in CH2Cl2 at -78 °C and DAST (15 eq) was slowly 
added. After 4 hours, the reaction was quenched with methanol and the product purified by 
silica gel column chromatography. The pentaoxazoline was isolated in 34% yield, consistent 
with 80+% yields for each of the 5 cyclodehydrations (Scheme 33). 
 
 
 
Scheme 33. Synthesis of a pentaoxazoline from Fmoc-Ser(OTES)5-OMe. Reagents and 
conditions: (a) DAST, CH2Cl2, -78 °C, 4 h, 34%.199  
 
Based on this precedent, it was proposed that a poly-TES protected macrocycle 45, produced 
from the polyol 42, should be investigated. The molecule would be expected to have similar 
solubility to the protected macrocycle 41, allowing cyclodehydrations to be performed more 
readily in the non-polar organic solvents used typically for these reactions. Applying the 
method of Luedtke et al., triethylsilyl chloride (21 eq) was added slowly to a stirring solution 
of polyol 42 in pyridine under argon. After 16 hours TLC analysis indicated a complex mixture 
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of products had formed. A series of peaks in the mass spectrum of the crude reaction mixture 
indicated that 1, 2 and 3 TES protecting groups had been introduced. In a second attempt, a 
solution of the polyol 42 and triethylsilyl chloride (21 eq) in DMF was treated with DIPEA 
(21 eq). The reaction was allowed to stir at room temperature and monitored by TLC analysis 
overnight (Scheme 34). Under these conditions, four major products were visible by TLC 
analysis. Analysis of the reaction mixture by LR-MS indicated that 45 was formed alongside 
other partially deprotected compounds. After concentration in vacuo, the crude material 
was purified by preparative TLC and 45 was isolated in 26% yield as a colourless oil.  
 
 
Scheme 34. Synthesis of poly-TES protected macrocycle 45 from the polyol 42. Reagents and 
conditions: (a) TESCl, DIPEA, DMF, rt, 18 h, 26%.  
 
Unfortunately, not enough material was isolated to allow characterisation or continuation of 
the total synthesis. Nevertheless, promising conditions for producing 45 were identified and 
could be optimised in future. Isolation of 45 in larger quantities would allow further 
investigations towards completion of the synthesis (Scheme 35). Cyclodehydration of 
poly-TES protected macrocycle 45 could be trialled using the procedure of Luedkte et al. 
Assuming it is possible to obtain 43 in useful quantities, oxidation of the seven oxazolines to 
produce the penultimate compound 44 would be investigated next. Oxidation of oxazolines 
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has been extensively reported and is often performed with BrCCl3 and DBU.197  The 
heptaoxazole 44 is very similar in structure to the penultimate precursor 16 reported by 
Shin-ya.180 Using Kelly’s method, a simultaneous deprotection and cyclodehydration of the 
thiazolidine to the thiazoline would be investigated for completing the total synthesis of 
(R)-telomestatin 32.186  
 
 
Scheme 35. Proposal for completing the total synthesis from poly-TES protected 
macrocycle 45. Reagents and conditions: (a) DAST, CH2Cl2, -78 °C; (b) BrCCl3, DBU, CH2Cl2, 
0 °C; (c) Ph3P(O)-Tf2O, anisole, CH2Cl2, rt. 
 
 
  Chapter 4 – Results and Discussion 
146 
 
4.5 Conclusions and Future Directions 
A mixed solid/solution-phase strategy was successfully identified that provided efficient 
access to practical quantities of advanced precursors in the new synthetic route towards 
(R)-telomestatin 32. A divergent strategy for the synthesis of two pseudoproline containing 
dipeptides 33 and 34 was developed that allowed multi-gram quantities of each to be easily 
obtained. The fragments were successfully used in the SPPS, which was optimised to afford 
near gram quantities of the linear peptidic backbone 35. A head-to-tail macrocyclisation of 
35 was optimised to give the protected macrocycle 41 in excellent yield (79%). A total of 
approximately 700 mg of 41 was produced over 10 reactions. Global deprotection of the 
side-chain protected macrocycle 41 generated cyclic polyol 42 with the thiazolidine 
protecting group intact. Synthetic investigations of the one-pot conversion of polyol 42 to 
the heptaoxazoline 43 were disappointing. A recent strategy reported by Luedtke et al.199 
was then considered, where a simultaneous deprotection and cyclodehydration of TES 
protected β-hydroxyamides had been used to generate multiple contiguous oxazolines on a 
linear peptide. To trial this approach, poly-TES protected macrocycle 45 was produced once 
and only on small scale. Due to time constraints further work on the total synthesis with 45 
was not possible. Optimisation of this reaction in the future would produce an interesting 
intermediate for further study.  
Other natural products containing contiguous oxazolines and/or oxazoles could potentially 
be synthesised using the methods developed here. For example, westiellamide and 
bistratamide G (Figure 73) have previously been synthesised using solution-phase methods 
similar to those reported by Shin-ya.199,200 Using SPPS, a peptidic linear backbone could be 
prepared containing the appropriate amino acids and pseudoproline dipeptides. After resin 
cleavage and head-to-tail macrocyclisation of the linear peptides, the protecting groups and 
pseudoprolines would be removed (via acid hydrolysis) to give the macrocyclic polyols. Each 
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free alcohol could then be re-protected with triethylsilyl protecting groups. Global 
deprotection and one-pot cyclodehydration of each β-hydroxyamide using DAST, along with 
subsequent oxidation (for oxazoles) would complete these total syntheses. Cysteine 
containing heterocycles could similarly be prepared. 
 
 
Figure 73. Structures of natural products westiellamide and bistratamide G amenable to total 
synthesis by the methods developed in this thesis. 
 
The aim of this project was to design and pursue a biomimetic synthesis that aligns with the 
likely biosynthesis of (R)-telomestatin 32. Although the proposed synthesis is currently 
incomplete, the ability to adapt the route exists. The proposed synthesis had little 
biomimetic guidance because of the few reports in the literature. In 2017, Amagai (along 
with Shin-ya) identified the gene cluster responsible for the biosynthesis of (R)-telomestatin 
32 and proposed a biosynthetic pathway (Figure 74).201  
The proposed biosynthesis is broken down into four key stages: (1) polycyclodehydration of 
the β-hydroxyamides to oxazolines with TIsQ (dehydratase), (2) polyoxidation to oxazoles 
with TIsP (oxidoreductase), (3) macrocyclisation with TIsS (peptidase) and (4) thiol 
cyclodehydration to the thiazoline with an unknown enzyme speculated to be encoded by 
TIsO.  
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Figure 74. Proposed biosynthesis of telomestatin 32.201 Figure adapted from Amagai et al. 
 
The proposed biosynthesis highlighted some key features which complement our total 
synthesis. An obvious similarity between syntheses is a global formation of the contiguous 
oxazolines followed by complete oxidisation to oxazoles while excluding the cysteine 
residue. A main difference, however, is formation of the contiguous heterocycles prior to 
macrocyclisation. Synthetic macrocyclisation of either linear intermediate is quite difficult 
due to their rigid backbone and lack of turn-inducers. This suggests that formation of the 
contiguous heterocycles might be best on the macrocyclic precursor as we proposed. Finally, 
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formation of the thiazoline as the final stage is in agreement with the proposed total 
synthesis.  
An alternative approach in the synthesis could make use of TES-protected amino acids and 
pseudoproline dipeptides directly in the SPPS to deliver a linear peptide with the 
TES-protecting groups already installed. A poly-TES protected macrocycle could then be 
obtained after head-to-tail cyclisation (Scheme 36). Deprotection of the serine 
pseudoproline and subsequent polycyclodehydration of the macrocycle using Luedtke’s 
method may generate the heptaoxazoline 43.199 This strategy is perhaps more attractive as 
it avoids re-protection of the advanced macrocyclic intermediate. If successful, this strategy 
could be adapted to prepare (S)-telomestatin and analogues for study as G-quadruplex 
stabilising ligands.   
 
 
Scheme 36. Alternative synthesis of a poly-TES protected macrocycle for conversion to 
(R)-telomestatin 32. 
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Chapter 5 – Experimental 
5.1 General 
Reagents and solvents were used without further purification unless otherwise stated. 
Dichloromethane (CH2Cl2), dimethylformamide (DMF), toluene and diethyl ether (Et2O) were 
used directly from a PureSolv Solvent purification system. Tetrahydrofuran was purified by 
drying over KOH before distillation from sodium benzophenone ketyl. Compounds were weighed 
using a Sartorius Extend 220g or OHaus Adventurer balance. Solvents were removed under 
reduced pressure (in vacuo) at 40 °C using a Heidolph or Büchi rotary evaporator with 
Vacuubrand pumps. Solvent residues were removed in vacuo using a Javac Vector RD-90 double 
stage high vacuum pump. Analytical thin layer chromatography (TLC) analysis was performed 
using Merck 0.2 mm silica gel 60 F254 coated aluminium plates. Compounds were visualised on 
TLC plates under UV light (254 nm) or by p-anisaldehyde staining. Column chromatography was 
performed on Merck silica gel 60 (230-400 mesh). Low resolution electrospray ionisation (ESI) 
mass spectra were obtained using a Shimadzu LCMS-2010EV spectrometer. ESI High Resolution 
Mass Spectra (HRMS) were obtained on a Xevo QToF mass spectrometer with perfluorokerosene 
as internal standard. Fourier-Transform Infrared (FTIR) spectra were obtained using a Shimadzu 
IRAffinity-1 spectrometer with a MIRacle 10 accessory. 1H, 13C and two-dimensional (2D) NMR 
experiments were performed using a Varian Inova 500 MHz or Varian Premium Shielded 500 
MHz spectrometer at 25 °C. Chemical shifts are reported as δ (ppm) relative to internal TMS or 
other solvent where stated. The abbreviations s = singlet, d = doublet, t = triplet, q = quartet, dd 
= doublet of doublets, m = multiplet and br s = broad singlet are used throughout. Analytical 
reverse phase HPLC (RP-HPLC) was performed using a Waters 600 Multi-solvent Delivery System 
with a Waters 2996 Photodiode Array Detector and Grace VisionHT C18 HL column (3 µ, 150 x 4.6 
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mm) at 1 mL.min-1. Preparative RP-HPLC was performed with a Waters PrepLC System and 
Waters 2489 UV/Visible Detector operating at 214 and 254 nm. Separation was achieved with a 
SunFire Prep C18 OBD column (5 µ, 100 x 30 mm) at a flow rate of 15 mL.min-1. Compounds were 
eluted with linear gradients as specified. For analytical and preparative RP-HPLC solvent A 
consisted of 100% H2O with 0.1% TFA and solvent B consisted of 100% CH3CN with 0.1% TFA. All 
RP-HPLC was conducted with Waters Empower software. 
 
5.2 General Procedure for Solid Phase Peptide Synthesis (SPPS) 
Solid phase peptide synthesis experiments were conducted manually in disposable Torviq PPE 
syringes fitted with a Teflon sinter. The SPPS vessels were agitated on a Peptides International 
variable rate shaker SVR-22701-PI. Solvents and reagents were all peptide synthesis grade. 
Amino acids and coupling reagents were purchased from ChemPep Inc (USA) and solvents were 
purchased from Chem-Supply Pty Ltd (Australia). 
Loading of amino acids onto 2-Chlorotrityl Chloride Resin  
2-Chlorotrityl chloride resin (100-200 mesh) was agitated in a sinter-fitted syringe with dry CH2Cl2 
(3 x 10 mL) for 15 minutes. For single residue attachment, the Fmoc-protected amino acid (3 eq 
relative to resin capacity) was dissolved in a solution containing 0.4 M DIPEA in CH2Cl2 (10 mL.g-1 
peptide) and the mixture was added to the resin and agitated for 3 hours. For pseudoproline 
containing dipeptides, the Fmoc-protected dipeptide (3 eq relative to resin capacity) was 
dissolved in a solution of 0.4 M DIPEA in CH2Cl2 (10 mL.g-1 peptide), added to the resin and 
agitated overnight. The vessel was drained and the resin was agitated with a fresh solution of 
the Fmoc-protected dipeptide (1 eq relative to resin capacity) for 2 hours. The resin was washed 
sequentially with anhydrous CH2Cl2/MeOH/DIPEA (17:2:1, v/v/v, 3 x 10 mL), CH2Cl2 (3 x 10 mL), 
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DMF (3 x 10 mL), CH2Cl2 (3 x 10 mL) and DMF (3 x 10 mL). The Fmoc group was removed (see 
below) and the resin was used immediately in peptide synthesis. 
Fmoc Deprotection 
The resin was washed with DMF (3 x 10 mL) and agitated in a 20% v/v piperidine DMF solution 
(3 x 5 mL, 3 minutes each). The vessel was drained and sequentially washed with DMF (3 x 10 
mL), CH2Cl2 (3 x 10 mL) and DMF (3 x 10 mL). 
Determination of Resin Loading 
After Fmoc deprotection, the drained solution containing dibenzofulvene was collected and 
diluted with piperidine in DMF (10% v/v) until the concentration of dibenzofulvene was between 
2.5-7.5 x 10-5 M (~1/100 dilution). A 1 mL aliquot of the solution was transferred to a 1 cm quartz 
cuvette. A solution of 10% v/v piperidine in DMF was used as a reference. Absorbance at 301 nm 
was measured using a UV-vis spectrometer and resin loading was quantified using 
ɛ = 7800 M-1.cm-1.202 
Peptide Coupling 
The resin was washed with DMF (3 x 10 mL). For single amino acids, the Fmoc-protected amino 
acid (3 eq relative to resin capacity) and HBTU (1 eq relative to amino acid) were dissolved into 
a solution of 0.4 M DIPEA in DMF (10 mL.g-1 peptide), added to the resin and agitated for 2 hours. 
For pseudoproline containing dipeptides, the Fmoc-protected dipeptide (3 eq relative to resin 
capacity) and HBTU (1 eq relative to dipeptide) were dissolved in a solution of 0.4 M DIPEA in 
DMF (10 mL.g-1 peptide), added to the resin and agitated for 2 hours. The vessel was drained and 
the resin agitated with a fresh solution of the Fmoc-protected dipeptide (3 eq relative to resin 
capacity) and HBTU (1 eq relative to dipeptide) in a solution of 0.4 M DIPEA in DMF (10 mL.g-1 
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peptide) for 1 hour. Upon completion, the resin was washed sequentially with DMF (3 x 10 mL), 
CH2Cl2 (3 x 10 mL) and DMF (3 x 10 mL). 
Peptide Cleavage from Resin 
Following the final Fmoc deprotection, the resin was washed sequentially with DMF (3 x 10 mL) 
and CH2Cl2 (3 x 10 mL) and then agitated in a solution of 1,1,1,3,3,3-hexafluoroisopropanol, 2,2,2-
trifluoroethanol and CH2Cl2 (1:2:7, 2 x 10 mL for 1 h each). Upon completion, the vessel was 
drained and the solution concentrated in vacuo to give the linear peptide.  
 
5.3 Compound Characterisation for Part I - Thioridazine VLA-4 Antagonist Hybrids 
 (S)-Methyl ((4-bromophenyl)sulfonyl)-L-prolinate 23 
4-bromobenzene sulfonyl chloride (2.31 g, 9.06 mmol) was dissolved in pyridine 
(25 mL) and stirred for 10 minutes. This solution was added to a round bottom 
flask containing L-proline methyl ester hydrochloride (1.00 g, 6.04 mmol) under 
argon and the mixture was stirred at 0 ˚C for 1 h followed by 16 h at room 
temperature. Upon completion, the mixture was concentrated in vacuo and the 
crude residue was redissolved into EtOAc (100 mL). The organic layer was placed into a 
separating funnel and washed with 1 M HCl (3 x 100 mL) and 10% w/v CuSO4 solution until no 
colour change occurred (5 x 100 mL). The organic layer was washed with brine (1 x 100 mL), dried 
over MgSO4 and concentrated in vacuo. The crude residue was purified using silica gel column 
chromatography (EtOAc:Pet. Spirit, 0:100 to 40:60) affording 23 (1.75 g, 83%) as a white solid. 
M.P. 90-94 ˚C. [α]25D = - 29.5 (c = 1, CH2Cl2). Rf = 0.76 (EtOAc:Pet. Spirit, 40:60). 1H NMR (CDCl3, 
500 MHz): δ 1.78-1.87 (m, 1H, H-3), 1.93-2.13 (m, 3H, H-2), 3.31-3.38 (m, 1H, H-4a), 3.42-3.49 
(m, 1H, H-4b), 3.71 (s, 3H, H-5), 4.31-4.38 (m, 1H, H-1), 7.67 (d, J = 10.0 Hz, 2H, H-6, H-7), 
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7.72-7.77 (d, 2H, H-8, H-9). 13C NMR (CDCl3, 126 MHz): δ 24.8 (C-3), 31.0 (C-2), 48.5 (C-4), 52.2 
(C-5), 60.5 (C-1), 127.9 (C-12), 129.1 (C-6, C-7), 132.4 (C-8, C-9), 137.8 (C-11), 172.5 (C-10). FTIR: 
neat (cm-1) 1754.3 (ester C=O), 1338.6 (C-O), 1155.4 (SO2), 622.1 (C-Br). HR-MS (ESI) 
m/z = 368.9775 [M+Na]+, 368.9772 calcd for C12H14BrNO4S-Na+. 
(S)-methyl ((4-aminophenyl)sulfonyl)-L-prolinate 25 
Compound 23 (800 mg, 2.29 mmol), copper(I) iodide (437 mg, 2.29 mmol) and 
sodium azide (299 mg, 4.59 mmol) were dissolved in DMSO (10 mL) and to this 
solution was added N,N′-dimethylethylenediamine (370 µL, 3.45 mmol). The 
reaction was heated to 100 °C for 3 h and then cooled to room temperature. 
Excess saturated NH4Cl solution (25 mL) was added and the resulting mixture was 
filtered through a plug of Celite. The plug was washed with excess EtOAc (3 x 25 mL) and the 
filtrate was placed in a separating funnel and washed with water (4 x 30 mL). The organic layer 
was then extracted with 1 M HCl (3 x 50 mL). The acidic aqueous extract was then made alkaline 
(pH 12) with 1 M NaOH and extracted with EtOAc (3 x 50 mL). The combined organic extracts 
were washed with brine (1 x 50 mL), dried over MgSO4 and concentrated in vacuo to afford 25 
(529 mg, 81%) as a brown oil. [α]25D = + 2.8 (c = 1, MeOH). Rf = 0.32 (EtOAc:Pet. Spirit, 40:60). 
1H NMR (CDCl3, 500 MHz): δ 1.65-1.75 (m, 1H, H-3a), 1.90-2.05 (m, 3H, H-2a, H-2b, H-3b), 
3.22-3.30 (m, 1H, H-4a) 3.41-3.52 (m, 1H, H-4b), 3.72 (s, 3H, H-5), 4.11-4.32 (m, 1H, H-1), 6.67 
(d, J = 8.5 Hz, 2H, H-8, H-9), 7.61 (d, J = 8.5 Hz, 2H, H-6, H-7). 13C NMR (CDCl3, 126 MHz): δ 24.7 
(C-3), 31.0 (C-2), 48.6 (C-4), 52.5 (C-5), 60.4 (C-1), 113.8 (C-8, C-9), 125.9 (C-11), 129.1 (C-6, C-7), 
151.1 (C-12), 173.0 (C-10). FTIR: neat (cm-1) 3470.7 (N-H), 3361.1 (N-H), 1737.9 (ester C=O), 
1592.3 (N-H bend), 1317.4 (C-O), 1143.8 (SO2), 675.1 (C-Br). HR-MS (ESI) m/z = 307.0728 
[M+Na]+, 307.0716 calcd for C12H16N2O4S-Na+. 
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(S)-methyl ((4-azidophenyl)sulfonyl)-L-prolinate 24 
The aryl amine 25 (135 mg, 0.475 mmol) was dissolved into EtOAc (2 mL) and 
cooled to 0 °C. Once cooled, 32% conc. HCl (218 µL, 2.18 mmol) was added and 
the solution was stirred for 5 minutes. A solution of NaNO2 (39 mg, 0.565 mmol) 
in water (1 mL) was added dropwise over 5 minutes and the reaction was stirred 
for 1 h and allowed to warm to room temperature. A solution of NaN3 (40 mg, 
0.615 mmol) in water (1 mL) was then added dropwise over 5 minutes and the biphasic mixture 
was stirred vigorously for 3 h. The mixture was neutralised with excess sat. NaHCO3 (20 mL), 
diluted with EtOAc (10 mL) and placed into a separating funnel. The organic layer was washed 
with water (3 x 20 mL), brine (1 x 20 mL), dried over MgSO4, and concentrated in vacuo. The 
crude residue was purified using silica gel column chromatography (EtOAc:Pet. Spirit, 0:100 to 
40:60) to give 24 (110 mg, 75%) as a yellow oil. [α]25D = - 17.9 (c = 1, CHCl3). Rf = 0.74 (EtOAc:Pet. 
Spirit, 40:60). 1H NMR (CDCl3, 500 MHz): δ 1.77-1.86 (m, 1H, H-3a), 1.92-2.13 (m, 3H, H-2, H-3b), 
3.30-3.38 (m, 1H, H-4a), 3.40-3.50 (m, 1H, H-4b), 3.72 (s, 3H, H-5), 4.33-4.37 (m, 1H, H-1), 7.14 
(d, J = 10.0 Hz, 2H, H-8, H-9), 7.87 (d, J = 10.0 Hz, 2H, H-6, H-7). 13C NMR (CDCl3, 126 MHz): δ 24.8 
(C-3), 31.1 (C-2), 48.4 (C-4), 52.3 (C-1), 60.7 (C-5), 118.6 (C-6. C-7), 129.6 (C-8, C-9), 134.9 (C-11), 
144.9 (C-12), 172.6 (C-10). FTIR: neat (cm-1) 2923 (C-H), 2130.4 (N=N=N), 1746.6 (C=O), 1160.2 
(SO2); HR-MS (ESI) m/z = 311.0829 [M+H]+, 311.0814 calcd for C12H15N4O4. 
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(S)-((4-azidophenyl)sulfonyl)-L-proline 22 
Methyl ester 24 (96 mg, 0.309 mmol) was dissolved into THF:water (2 mL, 3:1) 
and 1 M LiOH (9.25 µL, 0.925 mmol) was slowly added. The reaction was allowed 
to proceed at room temperature for 2 h before the THF was evaporated and the 
remaining mixture was placed into a separating funnel. The aqueous layer was 
washed with EtOAc (1 x, 20 mL) and acidified to pH 1 using 1 M HCl before being 
extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (1 x 
20 mL), dried over MgSO4, and concentrated in vacuo to afford pure 22 (91.2 mg, 99%) as a pale 
yellow oil. [α]25D = -15.3 (c = 1, MeOH). Rf = 0.24 (MeOH:CH2Cl2, 5:95). 1H NMR (CDCl3, 500 MHz): 
δ 1.73-1.87 (m, 1H, H-3a), 1.95-2.04 (m, 1H, H-3b), 2.04-2.16 (m, 2H, H-2), 3.19-3.37 (m, 1H, 
H-4a), 3.44-3.54 (m, 1H, H-4b), 4.31-4.36 (m, 1H, H-1), 7.16 (d, J = 10.0 Hz, 2H, H-8, H-9), 7.88 (d, 
J = 10.0 Hz, 2H, H-6, H-7), 8.74 (br. s, 1H, H-5). 13C NMR (CDCl3, 126 MHz): δ 24.9 (C-3), 31.0 (C-2), 
48.8 (C-4), 60.1 (C-1), 119.7 (C-6, C-7), 129.7 (C-8, C-9), 134.2 (C-11), 145.4 (C-12), 176.7 (C-10). 
FTIR: neat (cm-1) 2945.4 (COOH), 2129.5 (N=N=N), 1718.6 (C=O), 1111.1 (SO2). HR-MS (ESI) 
m/z = 297.0662 [M+H]+, 297.0658 calcd for C11H13N4O4S. 
 
Methyl-(S)-2-((S)-1-((4-azidophenyl)sulfonyl)pyrrolidine-2-carboxamido)-3-(4-(3,5-
dichloroisonicotinamido)phenyl)propanoate 20 
 Boc-Phe(p-3,5-dichloroisonicotinamide)-OMe 21 
(250 mg, 0.534 mmol) was dissolved in TFA:TIPS:H2O 
(95:2.5:2.5, 6 mL) and stirred  for 30 minutes at room 
temperature. The solution was concentrated in vacuo, 
redissolved in CH2Cl2 (5 mL) and concentrated to dryness with a stream of nitrogen. This was 
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repeated and the resulting oil was placed under high vacuum for 1 h. The TFA salt of 21 was used 
without further purification. The acid 22 (190 mg, 0.641 mmol) was dissolved into anhydrous 
DMF (3 mL) and pre-activated with HATU (304 mg, 0.799 mmol) and slow addition of DIPEA 
(371.3 µL, 2.56 mmol). After 10 minutes, the solution was transferred via cannula to a stirring 
solution of 21.TFA in anhydrous DMF (2 mL) under argon and the reaction allowed to proceed 
overnight (16 h) at room temperature. The mixture was concentrated in vacuo, redissolved in 
EtOAc (20 mL) and placed into a separating funnel. The organic layer was washed with water (3 
x 20 mL), sat. NaHCO3 (3 x 20 mL), brine (1 x 20 mL), dried over MgSO4 and concentrated in vacuo. 
The crude product was purified using silica gel column chromatography (EtOAc:Pet. Spirit, 0:100 
to 30:70) to provide 20 (237 mg, 69%) as a white solid. M.P. 128-132 °C. [α]25D = -10.0 (c = 1.1, 
MeOH). Rf = 0.45 (EtOAc:Pet. Spirit, 40:60). 1H NMR (500 MHz, CDCl3): δ 1.48-1.61 (m, 3H, H2, 
H-3a), 1.96-2.02 (m, 1H, H-3b), 3.00-3.15 (m, 2H, H-4a, H-16a), 3.24 (m, 1H, H-16b), 3.35-3.43 
(m, 1H, 4b), 3.78 (s, 3H, H-15), 3.98-4.06 (m, 1H, H-1), 4.72-4.87 (m, 1H, H-13), 7.16 (d, J = 8.0 Hz, 
4H, H-5, H-6, H-18, H-19), 7.29 (d, J = 5.0 Hz, 1H, H-12), 7.54 (d, J = 10.0 Hz, 2H, H-20, H-21), 7.80 
(d, J = 10.0 Hz, 2H, H-7, H-8), 8.37 (s, 1H, H-23), 8.51 (s, 2H, H-28, H-29). 13C NMR (CDCl3, 
126 MHz): δ 24.5 (C-2), 30.0 (C-3), 37.5 (C-16), 49.8 (C-4), 52.6 (C-15), 53.5 (C-13), 62.3 (C-1), 
119.8 (C-18, C-19), 120.7 (C-20, C-21), 129.2 (C-26, C-27), 129.8 (C-7, C-8), 130.3 (C-5, C-6), 132.2 
(C-17), 133.4 (C-22), 136.0 (C-10), 142.2 (C-25), 145.7 (C-11), 147.8 (C-28, C-29), 160.2 (C-24), 
170.8 (C-14), 171.3 (C-9). FTIR: neat (cm-1) 2925.2 (C-H), 2130.5 (N=N=N), 1667.5 (amide C=O), 
1114.9 (SO2), 821.7 (C-Cl); HR-MS (ESI) m/z = 668.0878 [M+Na]+, 668.0862 calcd for 
C27H25Cl2N7O6S-Na+. 
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2-Isopropyl-5-methylcyclohexyl-2-(2-(2-(methylthio)-10H-phenothiazin-10-yl)ethyl)piperidine-1-
carboxylate (R)-26 
To a solution of (±)-thioridazine.HCl (5.00 g, 12.2 mmol) and 
(1R)-(-)-menthyl chloroformate (3.95 mL, 18.4 mmol) under 
argon was added DIPEA (4.30 mL, 24.6 mmol) and the reaction 
was stirred at room temperature overnight. The reaction 
mixture was concentrated in vacuo, redissolved in EtOAc 
(100 mL) and placed into a separating funnel. The organic layer was washed with water (4 x 
50 mL), brine (1 x 50 mL), dried over MgSO4 and concentrated in vacuo to yield a mix of 
diastereomers D1-(R)-26 and D2-(S)-26. The diastereomers were purified by silica gel column 
chromatography (EtOAc:Pet. Spirit, 0:100 to 10:90). D1-(R)-26: (2.51 g, 38% yield). M.P. 41-43 ̊ C. 
[α]25D = - 5.1 (c = 2, MeOH). Rf = 0.54 (EtOAc:Pet. Spirit, 20:80). 1H NMR (400 MHz, CDCl3): δ 0.82 
(d, J = 4.0 Hz, 3H, H-25), 0.88-0.94 (m, 6H, H-30, H-31), 1.24-1.30 (m, 1H, H-17a), 1.33-1.43 (m, 
2H, H-15a, H-28), 1.45-1.53 (m, 1H, H-24), 1.53-1.62 (m, 4H, H-15b, H-17b, H-27), 1.63-1.73 (m, 
4H, H-18, H-19), 1.86-1.98 (m, 2H, H-26a, H-29), 2.00-2.07 (m, 2H, H-23), 2.13-2.23 (m, 1H, 
H-26b), 2.45 (s, 3H, H-4), 2.83 (t, J = 8.0 Hz, 1H, H-14a), 3.73-3.93 (m, 2H, H-20), 4.01-4.12 (m, 
1H, H-14b), 4.47 (br. s., 1H, H-16), 4.54-4.63 (m, 1H, H-22), 6.76 (s, 1H, H-2), 6.83 (t, J = 8.0 Hz, 
2H, H-5, H-12), 6.91 (t, J = 8.0 Hz, 1H, H-10), 7.05 (d, J = 8.0 Hz, 1H, H-6), 7.14 (t, J = 8.0 Hz, 2H, 
H-9. H-11). 13C NMR (101 MHz, CDCl3): δ 16.4 (C-4), 16.6 (C-25), 19.1 (C-27), 20.9 (C-30), 22.1 
(C-31), 23.7 (C-18), 25.6 (C-15), 26.6 (C-29), 27.8 (C-26), 29.1 (C-17), 31.4 (C-24), 34.3 (C-19), 39.4 
(C-14), 41.6 (C-23), 44.8 (C-20), 47.4 (C-28), 49.3 (C-16), 75.1 (C-22), 114.4 (C-2), 115.5 (C-12), 
120.9 (C-5), 122.3 (C-7), 122.6 (C-10), 125.4 (C-8), 127.3 (C-9), 127.5 (C-11), 127.6 (C-6), 137.6 
(C-3), 144.9 (C-13), 145.7 (C-1), 155.6 (C-21). FTIR: neat (cm-1) 2924.2 (C-H), 1683.9 (C=O, 
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carbamate), 1456.3 (C-H), 1255.7 (C-O ester), 748.4 (aromatic C-H). HR-MS (ESI) m/z = 539.2756 
[M+H]+, 539.2766 calcd for C31H43N2O2S2. 
2-Isopropyl-5-methylcyclohexyl-2-(2-(2-(methylthio)-10H-phenothiazin-10-yl)ethyl)piperidine-1-
carboxylate (S)-26 
Method of preparation as for (R)-26. (2.85 g, 43%). M.P. 41-43 ˚C. 
[α]25D = - 22.5 (c = 1.2, MeOH). Rf = 0.77 (EtOAc: Pet. Spirit, 20:80). 
1H NMR (CDCl3, 400 MHz): δ 0.76-0.81 (m, 3H, H-25), 0.86-0.93 
(m, 6H, H-30, H-31), 1.41-1.68 (m, 10H, H-15, H-17, H-18, H-24, 
H-26a, H-27), 1.82-1.95 (m, 3H, H-29, H-23), 2.15-2.27 (m, 1H, 
H-26a), 2.45 (s, 3H, H-4), 2.77-2.87 (m, 2H, H-19), 3.74-3.83 (m, 1H, H-20a), 3.84-3.94 (m, 1H, 
H-20b), 4.02-4.17 (m, 3H, H-16, H-14), 4.39-4.45 (m, 2H, H-22, H-28), 6.77 (s, 1H, H-2), 6.84 
(t, J = 8.0 Hz, 2H, H-5, H-12), 6.92 (t, J = 8.0 Hz, 1H, H-10), 7.07 (d, J = 8.0 Hz, 1H, H-6), 7.14 (t, 
J = 8.0 Hz, 2H, H-9, H-11). 13C NMR (101 MHz, CDCl3): δ 16.4 (C-4), 16.7 (C-25), 19.1 (C-27), 20.8 
(C-30), 22.1 (C-31), 23.5 (C-18), 25.6 (C-15), 26.7 (C-29), 29.1 (C-26), 31.4 (C-24), 34.3 (C-17), 39.1 
(C-19), 39.2 (C-14), 41.3 (C-23), 44.3 (C-20), 48.8 (C-28), 61.1 (C-16), 75.1 (C-22), 114.5 (C-2), 
115.6 (C-12), 120.9 (C-5), 122.4 (C-7), 122.7 (C-10), 125.7 (C-8), 127.3 (C-9), 127.6 (C-11), 127.7 
(C-6), 137.6 (C-3), 145.1 (C-13), 145.8 (C-1), 155.5 (C-21). FTIR: neat (cm-1) 2924.2 (C-H), 1681.0 
(C=O, carbamate), 1457.3 (C-H), 1254.8 (C-O ester), 749.4 (aromatic C-H). HR-MS (ESI) 
m/z = 539.2758 [M+H]+, 539.2766 calcd for C31H43N2O2S2. 
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(R)-10-[2-(1-Methyl-piperidin-2-yl)-ethyl]-2-methylsulfanyl-10H-phenothiazine (R)-16 
A round-bottom flask containing (R)-D1-26 (742 mg, 1.38 mmol) was 
placed under high-vacuum for 2 h. The flask was purged with argon 
and anhydrous THF (20 mL) was added. To the stirring solution was 
slowly added crushed portions of pelleted LiAlH4 (418 mg, 11.0 mmol) 
at room temperature and the reaction was heated at reflux for 8 h. 
Upon completion, the reaction was cooled to 0 °C, diluted with THF (20 mL) and water (5 mL) 
was slowly added over 30 minutes. The solution was concentrated in vacuo, redissolved into 
EtOAc (30 mL) and placed into a separating funnel. The organic layer was washed with sat. 
Rochelle salt (potassium sodium tartrate) solution (3 x 20 mL), water (1 x 30 mL), brine (1 x 
30 mL), dried over MgSO4 and concentrated in vacuo. The crude residue was purified by silica gel 
column chromatography (MeOH:CH2Cl2, 0:100 to 5:95) to give (R)-16 (374 mg, 73%) as a yellow 
oil. [α]25D = +9.4 (c = 1, MeOH). Rf = 0.31 (MeOH:CHCl3, 5:95). FTIR: neat (cm-1) 2930.9 (C-H), 
1455.4 (C-H), 748.4 (aromatic C-H). HR-MS (ESI) m/z = 371.1605 [M+H]+, 371.1616 calcd for 
C21H27N2S2. 1H and 13C NMR data were as for (S)-D2-16 below. 
Method of preparation as for (R)-16. From (S)-D2-26 (550 mg, 1.02 mmol) (S)-16 (257 mg, 68%) 
was obtained. [α]25D = -10.5 (C = 1, MeOH). 1H NMR (500 MHz, CDCl3): δ 1.20-1.32 (m, 1H, H-18a), 
1.38-1.48 (m, 1H, H-19a), 1.51-1.61 (m, 2H, H-17a, H-18b), 1.66-1.75 (m, 2H, H-17b, H-19b), 
1.80-1.91 (m, 1H, H-15a), 2.03-2.14 (m, 3H, H-15b, H-20), 2.20 (s, 3H, H-21), 2.44 (s, 3H, H-4), 
2.77-2.85 (m, 1H, H-16), 3.75-3.86 (m, 1H, H-14a), 3.88-3.98 (m, 1H, H-14b), 6.79 (s, 1H, H-2), 
6.81 (d, J = 10.0 Hz, 1H, H-5), 6.86 (d, J = 10.0 Hz, 1H, H-12), 6.89-6.92 (m, 1H, H-10), 7.03 (d, 
J = 5.0 Hz, 1H, H-6), 7.09-7.15 (m, 2H, H-9, H-11). 13C NMR (126 MHz, CDCl3): δ 16.2 (C-4), 22.5 
(C-18), 23.0 (C-19), 27.6 (C-15), 28.5 (C-17), 41.3 (C-21), 43.3 (C-14), 57.0 (C-20), 63.7 (C-16), 
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114.8 (C-2), 116.5 (C-12), 121.3 (C-5), 123.0 (C-7), 123.5 (C-10), 126.6 (C-8), 127.7 (C-9), 127.9 
(C-11), 127.9 (C-6), 138.6 (C-3), 144.2 (C-1), 145.5 (C-13). FTIR: neat (cm-1) 2926.1 (C-H), 1442.8 
(C-H), 748.4 (aromatic C-H). HR-MS (ESI) m/z = 371.1599 [M+H]+, 371.1616 calcd for C21H27N2S2. 
 
2-Methylsulfanyl-10-(2-piperidin-2-yl-ethyl)-10H phenothiazine (R)-27 
Route A88 
(R)-D1-26 (500 mg, 0.927 mmol) was added to a sealed tube and 
dissolved in TFA:TIPS:H2O (95:2.5:2.5, 10 mL). The vessel was sealed 
and heated at 110 °C with stirring for three days. The tube was then 
transferred to a beaker and cooled to 0 °C. To this solution was slowly 
added 10 M NaOH until there was a colour change to yellow. The 
mixture was placed into a separating funnel and extracted with EtOAc (3 x 30 mL). The combined 
organic layers were washed with water (2 x 30 mL) and brine (1 x 30 mL), dried over MgSO4 and 
concentrated in vacuo. The crude residue was purified by silica gel column chromatography 
(MeOH:CH2Cl2, 0:100 to 5:95) to provide (R)-27 (119 mg, 36%) as a yellow oil. The same method 
was used to prepare (S)-12 (102 mg, 31%) from (S)-D2-26. 
Route B 
To a stirring solution of (R)-16 (273 mg, 0.736 mmol) in CH2Cl2 (5 mL) under argon was added 
DIPEA (385 µL, 2.21 mmol). 1-Chloroethyl chloroformate (159 µL, 1.47 mmol) was slowly added 
and the solution was stirred at room temperature overnight. The mixture was concentrated in 
vacuo, redissolved in EtOAc (10 mL) and absorbed onto a minimum amount of silica gel that was 
then added to the top of a silica gel plug connected to a Buchner filter funnel. The plug was 
washed with excess CHCl3 (150 mL) and the filtrate was concentrated in vacuo to produce the 
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1-chloroethyl carbamate derivative of (R)-27. The colourless oil was dissolved into methanol 
(20 mL) and heated at reflux under argon for 4 h. Upon completion by TLC analysis, the solution 
was concentrated in vacuo to produce (R)-27 (171 mg, 65%) as a yellow oil. [α]25D = +6.9 (c = 1, 
MeOH), Rf = 0.27 (MeOH:CHCl3, 5:95). FTIR: neat (cm-1) 3389.2 (N-H), 2941.6 (C-H), 1456.3 (C-H), 
751.3 (aromatic C-H). HR-MS (ESI) m/z = 357.1456 [M+H]+, 357.1459 calcd for C20H25N2S2 
 Method of preparation as for (R)-27. From (S)-16 (220 mg, 0.594 mmol) (S)-27 was obtained 
(150 mg, 71%). [α]25D = -7.5 (c = 1.3, MeOH). 1H NMR (500 MHz, CDCl3): δ 1.39 (m, 1H, H-18a), 
1.59-1.75 (m, 2H, H-17a, 19a), 1.77-1.91 (m, 3H, H-17b, 18b, 19b), 2.09-2.16 (m, 1H, H-15a), 
2.38-2.47 (m, 1H, H-15b), 2.49 (s, 3H, H-4), 2.69 (t, J = 15.0 Hz, 1H, H-20a), 3.00-3.08 (m, 1H, 
H-16), 3.31 (d, J = 10.0 Hz, 1H, H-20b), 3.96-4.14 (m, 2H, H-14), 6.83-6.87 (d, J = 5.0 Hz, 2H, H-2, 
H-12), 6.90-6.98 (m, 2H, H-5, H-10), 7.07 (d, J = 10.0 Hz, 1H, H-6), 7.13 - 7.22 (m, 2H, H-9, 
H-11).13C NMR (126 MHz, CDCl3): δ 16.3 (C-4), 21.9 (C-19), 22.4 (C-18), 28.2 (C-17), 30.4 (C-15), 
43.2 (C-14), 44.8 (C-20), 55.5 (C-16), 114.5 (C-2), 116.3 (C-12), 121.3 (C-5), 122.5 (C-7), 123.3 
(C-10), 126.0 (C-8), 127.6 (C-9), 127.7 (C-11), 127.8 (C-6), 138.4 (C-3), 144.3 (C-1), 145.6 (C-13). 
FTIR: neat (cm-1) 3389.2 (N-H), 2947.4 (C-H), 1456.3 (C-H), 751.3 (aromatic C-H). HR-MS (ESI) 
m/z = 357.1461 [M+H]+, 357.1459 calcd for C20H25N2S2. 
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(R)-2-(methylthio)-10-(2-(1-((4-nitrophenyl)sulfonyl)piperidin-2-yl)ethyl)-10H-phenothiazine 28 
To a stirring solution of (R)-northioridazine 27 (21 mg, 0.059 mmol) and 
DIPEA (41 µL, 0.236 mmol) in dry CH2Cl2 (3 mL) under argon was added 
4-nitrobenzene sulfonyl chloride (26 mg, 0.112 mmol). The solution 
was allowed to stir at room temperature overnight before the reaction 
mixture was concentrated in vacuo, redissolved in EtOAc (20 mL) and 
placed into a separating funnel. The organic layer was washed with water (1 x 20 mL) and brine 
(1 x 20 mL), dried over MgSO4 and concentrated in vacuo. The crude residue was purified by silica 
gel column chromatography (EtOAc:Pet. Spirit, 0:100 to 20:80) to afford 28 (18 mg, 56%) as a 
yellow needles. M.P. 182-186 ˚C. [α]25D = +44.5 (c = 0.4, CH2Cl2). Rf = 0.54 (EtOAc:Pet. Spirit, 
20:80). 1H NMR (500 MHz, CDCl3): δ 1.18-1.29 (m, 1H, H-17a), 1.37-1.56 (m, 5H, H-17b, H-18, 
H-19), 1.90-1.99 (m, 1H, H-15a), 2.01-2.11 (m, 1H, H-15b), 2.47 (s, 3H, H-4), 2.98-3.11 (m, 1H, 
H-20a), 3.82-3.94 (m, 3H, H-14, H-20b), 4.21-4.27 (m, 1H, H-16), 6.74 (s, 1H, H-2), 6.81-6.86 (m, 
2H, H-5, H-12), 6.95 (t, J = 10.0 Hz, 1H, H-10),  7.08 (d, 1H, J = 5.0 Hz, H-6), 7.13-7.19 (m, 2H, H-9, 
H-11), 7.90 (d, J = 10.0 Hz, 2H, H-23, H-25), 8.24 (d, J = 10.0 Hz, 2H, H-22, H-26). 13C NMR 
(126 MHz, CDCl3): δ 16.3 (C-4), 18.4 (C-18), 24.7 (C-17), 27.1 (C-15), 27.9 (C-19), 41.3 (C-20), 44.2 
(C-14), 51.5 (C-16), 114.4 (C-2), 115.7 (C-12), 120.9 (C-5), 122.7 (C-7), 122.9 (C-10), 124.4 (C-23, 
C-25), 125.9 (C-8), 127.4 (C-9), 127.8 (C-11), 127.9 (C-6), 128.0 (C-22, C-26), 137.9 (C-3), 144.9 
(C-13), 145.6 (C-1), 147.3 (C-21), 149.7 (C-24). FTIR: neat (cm-1) 2922.3 (C-H), 1522.9 (N-O), 
1338.7 (SO2), 1156.4 (C=C). HR-MS (ESI) m/z = 564.1086 [M+Na]+, 564.1061 calcd for 
C26H27N3O4S3-Na+. One of the needles was collected after column chromatography and used for 
X-ray crystallographic analysis. 
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2-(methylthio)-10-(2-(1-(prop-2-yn-1-yl)piperidin-2-yl)ethyl)-10H-phenothiazine 19 
To a stirring solution of (R)-northioridazine 27 (156 mg, 392 mmol) 
in dry DMF (4 mL) under argon was slowly added 60% NaH in mineral 
oil (17.2 mg, 432 mmol) and the solution was stirred for 2 h at room 
temperature. A solution containing 80% propargyl bromine in 
toluene (97 µL, 785 mmol) was added and the mixture was left to stir overnight. After 
concentrated in vacuo the residue was redissolved in EtOAc (20 mL) and placed into a separating 
funnel. The organic layer was washed with water (3 x 20 mL) and brine (1 x 20 mL), dried over 
MgSO4 and concentrated in vacuo. The crude residue was purified by silica gel column 
chromatography (EtOAc:Pet. Spirit, 0:100 to 40:60) to give 19 (89 mg, 58%) as a yellow oil. 
[α]25D = +11.6 (c = 1.3, MeOH). Rf = 0.60 (EtOAc:Pet. Spirit, 40:60). FTIR: neat (cm-1) 3292.6 (C≡H), 
2923.3 (C-H), 1456.3 (C-H), 748.4 (aromatic C-H). HR-MS (ESI) m/z = 395.1593 [M+H]+, 395.1616 
calcd for C23H27N2S2. 1H and 13C NMR data were as for (S)-19 below. 
Method of preparation as for (R)-19. From (S)-27 (156 mg, 0.438 mmol) (S)-19 (88 mg, 51%) was 
obtained. [α]25D = -11.0 (c = 0.5, MeOH). 1H NMR (500 MHz, CDCl3): δ 1.56-1.68 (m, 2H, H-18), 
1.75 (m, 4H, H-17, H-19), 1.81-1.89 (m, 1H, H-15a),  2.17-2.27 (m, 1H, H-15b), 2.46 (s, 3H, H-4), 
2.52-2.66 (m, 2H, H-16, H-20a), 2.79-2.81 (m, 1H, H-20b), 3.27 (d, J = 5.0, 1H, H-21a), 3.69 (d, 
J = 5.0 Hz, 1H, H-21b), 3.82-3.91 (m, 1H, H-14a), 3.92-4.01 (m, 1H, H-14b), 6.79 - 6.81 (S, 1H, H-2), 
6.82 (d, J = 10 Hz, 1H, H-5), 6.88 (d, J = 10 Hz, 1H, H-12), 6.91 (d, J = 10 Hz, 1H, H-10), 7.04 (d, 
J = 10 Hz, 1H, H-6), 7.10-7.16 (t, J = 15 Hz, 2H, H-9, H-11). N.B. The alkyne signal (H-23) was not 
observed due to deuterium exchange. 13C NMR (126 MHz, CDCl3): δ 16.5 (C-4), 24.1 (C-18), 25.5 
(C-19), 29.3 (C-15), 30.4 (C-17), 43.0 (C-21), 44.1 (C-14), 53.3 (C-20), 57.4 (C-16), 74.0 (C-22), 76.5 
(C-23), 114.6 (C-2), 115.8 (C-12), 120.9 (C-5), 122.3 (C-7), 122.7 (C-10), 125.4 (C-8), 127.3 (C-9), 
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127.5 (C-11), 127.6 (C-6), 137.7 (C-3), 144.8 (C-13), 146.0 (C-1). FTIR: neat (cm-1) 3292.4 (C≡H), 
2924.3 (C-H), 1456.4 (C-H), 748.4 (aromatic C-H). HR-MS (ESI) m/z = 395.1613 [M+H]+, 395.1616 
calcd for C23H27N2S2. 
(R)-Thioridazine-VLA-4 Antagonist Hybrid Methyl Ester 30 
(R)-N-Propargyl northioridazine 19 
(18.8 mg, 0.047 mmol) and azido 
VLA-4 antagonist derivative 20 
(33.9 mg, 0.052 mmol) were 
dissolved in t-BuOH:H2O (1:1, 
3 mL) and stirred at room 
temperature. Copper acetate (1.9 mg, 0.009 mmol) and sodium ascorbate (3.8 mg, 0.019 mmol) 
were added and the mixture was heated to 33 °C for 4 h. Upon completion, the reaction mixture 
was diluted with EtOAc (20 mL) and placed into a separating funnel. The organic layer was 
washed with H2O (3 x 20 mL), sat. NH4Cl (3 x 20 mL), brine (1 x 20 mL), dried over MgSO4 and 
concentrated in vacuo. The crude residue was purified by column chromatography (EtOAc:Pet. 
Spirit, 0:100 to 100:0) to give (R)-30 (32 mg, 64%) as a pale yellow solid. M.P. 280 ˚C, decomp. 
[α]25D = +7.4 (c = 1.8, CHCl3). Rf = 0.12 (100% EtOAc). 1H NMR (500 MHz, CDCl3): δ 1.18-1.21 (m, 
2H, H-19), 1.24-1.34 (m, 2H, H-17), 1.54-1.64 (m, 1H, H-31a), 1.62-1.73 (m, 3H, H-31b, H-32), 
1.91-2.06 (m, 1H, H-18a), 2.15 (br. s., 2H, H-15), 2.24-2.40 (m, 1H, H-18b), 2.33-2.42 (m, 1H, 
H-20a), 2.44 (s, 3H, H-4), 2.61-2.70 (m, 1H, H-16), 2.83-2.92 (m, 1H, H-20b), 3.04-3.14 (m, 1H, 
H-39a), 3.18-3.29 (m, 2H, H-39b, H-30a), 3.34-3.42 (m, 1H, H-30b), 3.77 (s, 1H, H-21a), 3.80 (s, 
3H, H-38), 3.88-4.06 (m, 3H, H-14, H-21b), 4.19-4.25 (m, 1H, H-33), 4.85-4.92 (m, 1H, H-36), 6.80 
(d, J = 10.0 Hz, 1H, H-5), 6.84 (s, 1H, H-2), 6.90-6.41 (m, 2H, H-10, H-12), 7.02 (d, J = 10.0 Hz, 1H, 
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H-6), 7.11 (d, J = 10.0 Hz, 1H, H-9), 7.14-7.12 (m, 3H, H-11, H-41, H-45), 7.56 (d, J = 10.0 Hz, 2H, 
H-42, H-44), 7.84 (d, J = 10.0 Hz, 3H, H-23, H-26, H-28), 7.95 (d, J = 10.0 Hz, 2H, H-25, H-29), 8.53 
(s, 2H, H-50, H-51). 13C NMR (126 MHz, CDCl3): δ 16.6 (C-4), 24.8 (C-31), 28.8 (C-18), 30.2 (C-32), 
30.3 (C-15), 32.1 (C-17), 33.9 (C-19), 37.6 (C-39), 43.9 (C-14), 48.4 (C-21), 49.9 (C-30), 51.1 (C-20), 
52.8 (C-38), 53.4 (C-36), 57.5 (C-16), 62.3 (C-33), 114.8 (C-2), 116.1 (C-12), 120.8 (C-23), 120.9 
(C-26, C-28), 121.0 (C-42, C-44), 121.1 (C-5), 122.6 (C-7), 123.0 (C-10), 123.2 (C-8), 127.5 (C-9), 
127.8 (C-6), 128.0 (C-41, C-45), 129.3 (C-49, C-52), 129.8 (C-25, C-29), 130.3 (C-11), 133.5 (C-40), 
133.5 (C-22), 136.0 (C-43), 137.9 (C-3), 139.3 (C-27), 140.5 (C-24), 142.2 (C-48), 145.4 (C-13), 
146.1 (C-1), 148.0 (C-50, C-51), 160.3 (C-47), 170.7 (C-34), 171.5 (C-37). FTIR: neat (cm-1) 2931.9 
(C-H), 1730.22 (C=O ester), 1656.0 (amide C=O), 1314.5 (SO2), 1140.9 (C-O), 843.9 (C-Cl). HR-MS 
(ESI) m/z = 1038.2402 [M-H]-, 1038.2423 calcd for C50H50Cl2N9O6S3. 
 
(R)-Thioridazine-VLA-4 Antagonist Hybrid Carboxylic Acid 17 
Azido VLA-4 antagonist derivative 
20 (56 mg, 0.086 mmol) was 
dissolved into THF:water (3:1, 
4 mL) and 1 M LiOH (259 µL, 0.259 
mmol) was slowly added. After 
2 hours, the mixture was acidified 
with concentrated formic acid (3 mL) and stirred for 5 minutes. The solution was concentrated 
in vacuo to afford the free acid 31 as a pale yellow solid (54 mg, 99%). The acid was used 
immediately in the ‘click’ reaction. N-Propargyl northioridazine (R)-19 (35 mg, 0.089 mmol) and 
compound 31 (54 mg, 0.085 mmol) were dissolved in t-BuOH:H2O (1:1, 3 mL) and stirred at room 
temperature. Copper acetate (3.5 mg, 0.018 mmol) and sodium ascorbate (7.0 mg, 0.035 mmol) 
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were added and the reaction heated to 33 °C. Additional catalyst (same quantities) was added 
after 24 h. Upon completion, the reaction mixture was concentrated in vacuo and the crude 
residue purified by preparative RP-HPLC (gradient 0% B to 100% B over 40 minutes, tR = 15.1 
min). Concentration of the pure fractions via lyophilisation produced (R)-17 (22 mg, 24%) as a 
blue-white powder. M.P. 229-236 °C. The 1H spectrum was not sufficiently resolved to allow 
characterisation. See explanation in Chapter 2.4.4. [α]25D = +29.3 (c = 0.8, DMSO). 13C NMR 
(126 MHz, (CD3)2SO): δ 15.4 (C-4), 23.1 (C-31), 24.2 (C-18), 24.8 (C-19), 28.0 (C-17), 29.6 (C-32), 
30.9 (C-15), 37.1 (C-38), 43.7 (C-14), 47.8 (C-21), 49.6 (C-30), 51.1 (C-20), 57.0 (C-33), 59.0 (C-36), 
62.3 (C-16), 113.9 (C-2), 116.5 (C-12), 119.6 (C-41, C-43), 120.4 (C-5), 120.7 (C-7), 120.8 (C-25, 
C-29), 122.2 (C-10), 123.1 (C-8), 124.3 (C-23), 127.5 (C-9), 127.8 (C-11), 128.0 (C-6), 128.7 (C-48, 
C-51), 129.9 (C-26, C-28), 130.7 (C-40, C-44), 135.5 (C-42), 136.2 (C-39), 136.4 (C-24), 138.2 
(C-22), 140.1 (C-3), 142.9 (C-27), 144.9 (C-47), 145.5 (C-13), 145.8 (C-1), 148.0 (C-49, C-50), 160.2 
(C-46), 168.2 (C-34), 170.6 (C-37). FTIR: neat (cm-1) 3306.1 (COOH), 3052.5 (C-H), 1731.2 (C=O 
acid), 1668.5 (amide C=O), 1156.4 (SO2), 1044.5 (C=C), 824.6 (C-Cl). HR-MS (ESI) m/z = 1026.2416 
[M+H]+, 1026.2423 calcd for C49H50Cl2N9O6S3. 
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(S)-Thioridazine-VLA-4 Antagonist Hybrid Carboxylic Acid 17 
Compound 20 (62 mg, 0.096 mmol) 
was dissolved into THF:water (3:1,  
4 mL) and 1 M LiOH (236 µL, 
0.236 mmol) was slowly added. 
After 2 hours, the mixture was 
acidified with concentrated formic 
acid (3 mL) and stirred for 5 
minutes. The solution was concentrated in vacuo to afford the free acid 31 as a pale yellow solid 
(60 mg, 99%). The acid was used immediately in the ‘click’ reaction. N-Propargyl northioridazine 
(S)-19 (34 mg, 0.089 mmol) and compound 31 (60 mg, 0.095 mmol) were dissolved in 
t-BuOH:H2O (1:1, 3 mL) and stirred at room temperature. Copper acetate (3.1 mg, 0.015 mmol) 
and sodium ascorbate (6.2 mg, 0.031 mmol) were added and the reaction heated to 33 °C. 
Additional catalyst (same quantities) was added after 24 h. Upon completion, the reaction 
mixture was concentrated in vacuo and the crude residue purified by preparative RP-HPLC 
(gradient 0% B to 100% B over 40 minutes, tR = 15.7 min). Concentration of the pure fractions 
via lyophilisation produced (S)-17 (17.8 mg, 20%) as a blue-white powder. M.P. 234-240 ˚C. 
[α]25D = +4.4 (c = 0.92, DMSO). 1H NMR (500 MHz, (CD3)2SO): δ 1.15-1.41 (m, 1H, H-19a), 1.46-1.78 
(m, 9H, H-15, H-17, H-18 H-19b, H-31), 1.91-2.21 (m, 2H, H-32), 2.47 (s, 3H, H-4), 2.92-3.48 (m, 
6H, H-20, H-30, H-38), 3.64 (beneath H2O, 1H, H-33), 3.93-4.12 (m, 2H, H-14), 4.22-4.31 (m, 1H, 
H-16), 4.42-4.66 (m, 3H, H-36, H-21), 6.79-6.87 (m, 1H, H-5), 6.89-6.98 (m, 2H, H-2, H-10), 
7.03-7.17 (m, 3H, H-9, H-11, H-12), 7.18-7.24 (m, 1H, H-6), 7.28 (d, J = 10.0 Hz, 2H, H-40, H-44), 
7.58 (d, J = 10.0 Hz, 2H, H-41, H-43), 8.02 (d, J = 10.0 Hz, 2H, H-26, H-28), 8.06 (d, J = 10.0 Hz, 2H, 
H-25, H-29), 8.75 (s, 2H, H-49, H-50), 9.01 (s. 1H, H-23). 13C NMR (126 MHz, (CD3)2SO): δ 15.7 
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(C-4), 21.4 (C-31), 22.7 (C-18), 24.6 (C-19), 27.7 (C-17), 28.0 (C-32), 31.2 (C-15), 36.8 (C-38), 43.4 
(C-14), 46.7 (C-21), 49.5 (C-30), 52.4 (C-20), 52.7 (C-33), 54.0 (C-36), 62.0 (C-16), 114.4 (C-2), 
117.0 (C-12), 120.1 (C-41, C-43), 121.0 (C-5), 121.2 (C-7), 121.4 (C-25, C-29), 123.6 (C-10), 125.0 
(C-8), 126.2 (C-23), 128.0 (C-9), 128.2 (C-11), 128.4 (C-6), 128.8 (C-48, C-51), 130.0 (C-26, C-28), 
130.6 (C-40, C-44), 134.4 (C-42), 136.4 (C-39), 137.1 (C-24), 137.9 (C-22), 138.7 (C-3), 139.8 
(C-27), 143.1 (C-47), 144.9 (C-13), 145.9 (C-1), 148.4 (C-49, C-50), 160.4 (C-46), 171.4 (C-34), 
173.1 (C-37). FTIR: neat (cm-1) 3393.9 (COOH), 3048.6 (C-H), 1731.2 (C=O acid), 1656.0 (amide 
C=O), 1433.2 (OH acid bend), 1215.2 (SO2), 1009.8 (C=C), 839.1 (C-Cl). HR-MS (ESI) 
m/z = 1024.2301 [M-H]-, 1024.2267. calcd for C49H48Cl2N9O6S. 
 
5.4 Compound Characterisation for Part II - Synthetic Intermediates Towards (R)-Telomestatin 
Fmoc-Ser(OtBu)Ser-OMe 36 
Fmoc-Ser(OtBu)-OH (5 g, 13.0 mmol), L-Serine methyl 
ester.HCl (3.04 g, 19.5 mmol) and  HATU (6.45 g, 16.9 
mmol) were dissolved in dry DMF (25 mL) under argon 
and stirred for 5 minutes at room temperature. DIPEA 
(6.81 mL, 39.1 mmol) was added dropwise and the 
solution was left to stir at room temperature overnight. The reaction was concentrated in vacuo 
and the crude residue was redissolved in EtOAc (30 mL) and placed into a separating funnel. The 
organic layer was washed with 1 M HCl (4 x 25 mL), saturated NaHCO3 (3 x 25 mL), brine (1 x 
25 mL), dried over MgSO4 and concentrated in vacuo to afford Fmoc-Ser(OtBu)Ser-OMe 36 (5.87 
g, 93%) as a white foam. M.P. 65-70 °C. [α]25D = +13.2 (c = 1.1, MeOH). 1H NMR (CDCl3, 500 MHz): 
δ 1.23 (s, 9H, H-19), 3.45 (t, J = 5.0 Hz, 1H, H-17a), 3.74 (br.s, 4H, H-24, H-17b), 3.92-3.99 (m, 2H, 
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H-22), 4.22 (t, J = 5.0 Hz, 1H, H-21), 4.28-4.34 (m, 1H, H-7), 4.37-4.43 (m, 2H, H-14), 4.64-4.68 (m, 
1H, H-16), 7.31 (t, J = 10.0 Hz, 2H, H-4, H-10), 7.40 (t, J = 10.0 Hz, 2H, H-3, H-11), 7.61 (d, J = 10.0 
Hz, 2H, H-5, H-9), 7.76 (d, J = 10.0 Hz, 2H, H-2, H-12). 13C NMR (126 MHz, CDCl3): δ 27.6 (C-19), 
47.4 (C-7), 52.8 (C-24), 55.1 (C-21), 55.3 (C-16), 62.1 (C-17), 63.2 (C-22), 67.5 (C-14), 74.6 (C-18), 
120.2 (C-5, C-9), 125.4 (C-4, C-10), 127.3 (C-2, C-12), 127.8 (C-3, C-11), 141.5 (C-1, C-13), 143.9 
(C-6, C-8), 156.3 (C-15), 170.7 (C-20), 170.9 (C-23). FTIR: neat (cm-1) 3406 (O-H), 3070.8 (C-H), 
1733.1 (C=O, ester), 1653.1 (N-H), 1433.2 (C-H), 1208.6 (C-O), 740.7 (aromatic C-H). HR-MS (ESI) 
m/z = 507.2094 [M+Na]+, 507.2107 calcd for C26H32N2O7-Na+. 
 
Fmoc-Ser(OtBu)Ser(ΨMe,Me,Pro)-OMe 37 
A solution containing Fmoc-Ser(OtBu)-Ser-OMe 36 
(5.87 g, 12.1 mmol), pyridinium p-toluenesulfonate (0.609 
g, 20 mol%, 2.42 mmol) and 2,2-dimethoxypropane 
(8.26 mL, 66.6 mmol) in dry THF (200 mL) was heated at 
reflux under N2. The condensate was passed through a 
soxhlet apparatus containing activated 4 Å sieves to remove water. After 17 hours, the solution 
was concentrated in vacuo, redissolved into EtOAc (100 mL) and placed into a separating funnel. 
The organic layer was washed with water (3 x 100 mL), brine (1 x 100 mL), dried over MgSO4 and 
concentrated in vacuo. The crude residue was purified by silica gel column chromatography 
(EtOAc:Pet. Spirit, 0:100 to 40:60) to produce 37 (5.20 g, 82%) as a white foam. M.P 75-76 °C. 
[α]25D = - 30.4 (c = 1, MeOH). Rf = 0.76 (EtOAc:Pet. Spirit, 40:60). 1H NMR (CDCl3, 500 MHz): δ 1.16 
(s, 9H, H-19), 1.57 (s, 3H, H-23), 1.70 (s, 3H, H-24), 3.34 (t, J = 10.0 Hz, 1H, H-17a), 3.57-3.66 (m, 
1H, H-17b), 3.76 (s, 3H, H-27), 4.04-4.14 (m, 1H, H-22a), 4.17-4.28 (m, 1H, H-7), 4.31-4.39 (m, 2H, 
H-21, H-22b), 4.41-4.51 (m, 1H, H-16), 5.14 (d, J = 10.0 Hz 1H, H-14a), 5.65 (d, J = 10.0 Hz 1H, 
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H-14b), 7.31 (t, J = 15.0 Hz 2H, H-4, H-10), 7.40 (t, J = 12.0 Hz 2H, H-3, H-11), 7.60 (d, J = 12.0 Hz, 
2H, H-5, H-9), 7.76 (d, J = 12.0, Hz 2H, H-2, H-12). 13C NMR (126 MHz, CDCl3): δ 23.1 (C-23), 25.5 
(C-24), 27.5 (C-19), 47.4 (C-7), 53.1 (C-27), 53.3 (C-16), 59.4 (C-21), 64.4 (C-17), 67.0 (C-22), 67.2 
(C-14), 73.8 (C-18), 96.8 (C-25), 120.2 (C-5, C-9), 125.5 (C-4, C-10), 127.2 (C-2, C-12), 127.9 (C-3, 
C-11), 141.5 (C-1, C-13), 144.2 (C-6, C-8), 155.5 (C-15), 168.9 (C-20), 171.1 (C-26). FTIR: neat (cm-1) 
2984.0 (C-H), 1733.1 (C=O ester), 1653.1 (C=O amide), 1207.5 (C-O ester), 757.8 (aromatic C-H). 
HR-MS (ESI) m/z = 525.2584 [M+H]+, 525.2601 calcd for C29H37N2O7. 
 
Fmoc-Ser(OtBu)-OPfp 39 
Fmoc-Ser(OtBu)-OH (10 g, 26.1 mmol), DCC (6.46 g, 
31.3 mmol) and pentafluorophenol (5.76 g, 31.3 mmol) 
were dissolved in EtOAc (100 mL) at 0 ˚C under argon. The 
solution was allowed to warm to room temperature and 
after 6 h, the reaction mixture was filtered and the eluent was placed into a separating funnel. 
The organic layer was washed with water (3 x 50 mL) and brine (1 x 50 mL), dried over MgSO4 
and concentrated in vacuo to afford Fmoc-Ser(OtBu)-OPfp 39 (13.9 g, 98%). [α]25D = -12.2 (c = 1, 
MeOH). 1H NMR (CDCl3, 500 MHz): δ 1.21 (s, 9H, 3 x H-19), 3.71 (d, J = 10.0, 1H, H-17a), 4.01-4.06 
(d, J = 10.0, 1H, H-17b), 4.26 (t, J = 5.0 Hz, 1H, H-16), 4.37-4.51 (m, 1H, H-7), 4.88 (d, J = 10.0 Hz, 
1H, H-H-14a), 5.77 (d, J = 10.0 Hz, 1H, H-14b), 7.30 (t, J = 10.0, 2H, H-4. H-10), 7.39 (t, J = 10.0 Hz, 
2H, H-3, H-11), 7.61 (t, J = 10.0 Hz, 2H, H-5, H-9), 7.76 (d, J = 10.0 Hz, 2H, H-2. H-12).13C NMR 
(126 MHz, CDCl3): δ 27.2 (C-19), 47.1 (C-7), 54.8 (C-16), 62.0 (C-17), 67.5 (C-14), 73.9 (C-18), 120.0 
(C-5, C-9), 125.1 (C-4, C-10), 127.0 (C-2, C-12), 127.8 (C-3, C-11), 140.1 (C-22, C-26), 140.8 (C-24), 
141.3 (C-21), 142.2 (C-23, C-25), 143.7 (C-1, C-13), 143.8 (C-6, C-8), 156.1 (C-15), 167.2 (C-20). 
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FTIR: neat (cm-1) 2977.3 (C-H), 1727.3 (C=O ester), 1517.1 (C=O amide), 990.5 (C-F), 739.7 
(aromatic C-H). HR-MS (ESI) m/z = 572.1536 [M+Na]+, 572.1472 calcd for C28H24F5NO5-Na+. 
Fmoc-Ser(OtBu)Ser-OH 38 
L-Ser-OH (3.55 g, 33.8 mmol) was dissolved in a minimum 
volume of aqueous Na2CO3 (10% w/v) at pH 9 and the 
solution was added to a second solution containing 
Fmoc-Ser(OtBu)-OPfp 39 (6.2 g, 11.3 mmol) in acetone 
(75 mL). The resulting suspension was stirred vigorously for 22 h at room temperature. The flask 
was placed on ice and acidified to pH 1 using 1 M HCl. The solution was concentrated to half 
volume and placed into a separating funnel, where the aqueous mixture was extracted with 
EtOAc (3 x 30 mL). The combined organic fractions were washed with water (3 x 50 mL) and brine 
(1 x 50 mL), dried over MgSO4 and concentrated in vacuo. The crude residue was purified by 
recrystallisation from EtOAc/Pet. Spirit to give Fmoc-Ser(OtBu)-Ser-OH 38 (3.64 g, 69%) as a 
white powder. M.P 148-150 °C. [α]25D = +29.2 (c = 1.5, DMSO). 1H NMR (400 MHz, (CD3)2SO): 
δ 1.13 (s, 9H, H-19), 3.36-3.49 (m, 2H, H-17a, H-22a), 3.50-3.57 (m, 1H, H-17b), 3.63-3.70 (m, 1H, 
H-22b), 3.90-3.99 (m, 1H, H-21), 4.04-4.13 (m, 1H, H-16), 4.20-4.33 (m, 3H, H-7, H-14), 7.30-7.37 
(m, 2H, H-4, H-10), 7.42 (t, J = 8.0 Hz, 2H, H-3, H-11), 7.52 (d, J = 8.0 Hz, 1H, H-24), 7.69 (d, 
J = 8.0 Hz, 1H, H-25), 7.71-7.77 (m, 2H, H-5, H-9), 7.89 (d, J = 8.0 Hz, 2H, H-2, H-12). 13C NMR 
(101 MHz, (CD3)2SO): δ 27.7 (C-19), 47.1 (C-7), 55.1 (C-16), 56.1 (C-21), 62.4 (C-17), 62.5 (C-22), 
66.3 (C-14), 73.4 (C-18), 120.6 (C-5, C-9), 125.8 (C-4, C-10), 127.6 (C-2, C-12), 128.1 (C-3, C-11), 
141.0 (C-1, C-13), 144.2 (C-6, C-8), 144.4 (C-15), 156.5 (C-20), 169.6 (C-23). FTIR: neat (cm-1) 
3313.8 (O-H), 2974.4 (C-H), 1696.5 (C=O amide), 1539.3 (C-H), 737.8 (aromatic C-H). HR-MS (ESI) 
m/z = 493.1967 [M+Na]+, 493.1951 calcd for C25H30N2O7-Na+. 
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Fmoc-Ser(OtBu)Ser(ΨMe,Me,Pro)-OH 33 
Route A 
To a solution of Fmoc-Ser(OtBu)Ser(ΨMe,Me,Pro)-OMe 37 
(5.20 g, 9.91 mmol) in 1,2-DCE (50 mL) under argon was 
added Me3SnOH (5.37 g, 29.7 mmol) in small portions. The 
reaction was heated at 80 ˚C with stirring overnight. The 
mixture was concentrated in vacuo and the residue 
redissolved in EtOAc (75 mL) and placed into a separating funnel. The organic layer was washed 
with 1 M HCl (3 x 50 mL), water (3 x 50 mL) and brine (1 x 50 mL), dried over MgSO4 and 
concentrated in vacuo. The crude residue was purified by silica gel column chromatography 
(CH2Cl2:MeOH 100:0 to 95:5) to afford 33 (2.27 g, 45%) as a white foam. 
Route B 
A solution containing Fmoc-Ser(OtBu)-Ser-OH 38 (3.64 g, 7.74 mmol), pyridinium 
p-toluenesulfonate (0.389 g, 20 mol%, 1.55 mmol) and 2,2-dimethoxypropane (5.28 mL, 
42.5 mmol) in dry THF (200 mL) under N2 was heated at reflux with the condensate being passed 
through a soxhlet apparatus containing activated 4 Å sieves. After 18 hours, the solution was 
concentrated in vacuo and the residue was redissolved into EtOAc (100 mL) and placed into a 
separating funnel. The organic layer was washed with water (3 x 100 mL) and brine (1 x 100 mL), 
dried over MgSO4 and concentrated in vacuo. The crude residue was purified by silica gel column 
chromatography (CH2Cl2:MeOH 100:0 to 95:5) to afford 33 (3.95 g, 63%) as a white foam. 
M.P 87-89 °C. [α]25D = -24.9 (c = 1, MeOH). Rf = 0.46 (MeOH:CHCl3, 5:95). 1H NMR (500 MHz, 
CDCl3): δ 1.15 (s, 9H, H-19), 1.56 (s, 3H, H-23), 1.69 (s, 3H, H-24), 3.32-3.38 (m, 1H, H-17a), 
3.57-3.63 (m, 1H, H-17b), 4.04-4.10 (m, 1H, H-22a), 4.11-4.15 (m, 1H, H-22b), 4.23-4.30 (m, 1H, 
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H-7), 4.39 (d, J = 10.0 Hz, 1H, H-21), 4.63 (d, J = 5.0 Hz, 1H, H-16), 5.11 (d, J = 5.0 Hz, 1H, H-14a), 
5.93 (d, J = 5.0 Hz, 1H, H-14b), 7.24-7.29 (m, 2H, H-4, H-10), 7.33-7.38 (m, 2H, H-3, H-11), 7.51 
(d, J = 5.0 Hz, 1H, H-5, H-9), 7.55 (d, J = 5.0 Hz, 1H, H-5, H-9), 7.71 (d, J = 5.0 Hz, 2H, H-2, H-12). 
13C NMR (126 MHz, CDCl3): δ 23.0 (C-23), 25.6 (C-24), 27.5 (C-19), 47.2 (C-7), 53.1 (C-16), 59.3 
(C-21), 64.1 (C-17), 67.1 (C-22), 67.7 (C-14), 73.8 (C-18), 96.9 (C-25), 120.1 (C-5, C-9), 125.5 (C-4, 
C-10), 127.3 (C-2, C-12), 127.9 (C-3, C-11), 143.7 (C-1, C-13), 144.1 (C-6, C-8), 156.1 (C-15), 168.9 
(C-20), 173.7 (C-26). FTIR: neat (cm-1) 3326.4 (O-H carboxylic acid), 2974.4 (C-H), 1714.8 (C=O 
acid), 1517.1 (C-H), 1192.1 (C-O), 738.8 (aromatic C-H). HR-MS (ESI) m/z = 533.2243 [M+Na]+, 
533.2264 calcd for C28H34N2O7-Na+. 
 
Fmoc-Ser(OtBu)Cys(ΨMe,Me,Pro)-OH 34 
To a solution of Cys(ΨMe,Me,Pro)-OH.HCl 40 (5.29 g, 
26.8 mmol) in DMF (25 mL) under argon was added DIPEA 
(9.33 mL, 53.6 mmol). The solution was allowed to stir for 30 
minutes at room temperature before slowly adding 39 
(7.36 g, 13.4 mmol) as a solution in DMF (20 mL). The mixture was stirred at room temperature 
overnight and then concentrated in vacuo, redissolved into EtOAc (100 mL) and placed into a 
separating funnel. The organic layer was washed with water (3 x 100 mL) and brine (1 x 100 mL), 
dried over MgSO4 and concentrated in vacuo. The residue was purified by silica gel column 
chromatography (EtOAc:Pet. Spirit, 0:100 to 70:30) to produce 34 (4.71 g, 67%) as a white foam. 
M.P 99-102 °C. [α]25D = -19.6 (c = 1, MeOH). Rf = 0.49 (MeOH:CHCl3, 5:95). 1H NMR (500 MHz, 
CDCl3): δ 1.15 (s, 9H, H-19), 1.83 (s, 3H, H-23), 1.87 (s, 3H, H-24), 3.15-3.24 (m, 1H, H-22a), 
3.30-3.40 (m, 2H, H-17a H-22b), 3.57-3.64 (m, 1H, H-17b), 4.11-4.17 (m, 1H, H-7), 4.27 (d, J = 10.0 
Hz, 2H, H-14), 4.55-4.61 (m, 1H, H-21), 4.65-4.73 (m, 1H, H-16), 7.27-7.30 (m, 2H, H-4, H-10), 7.36 
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(t, J = 5.0 Hz, 2H, H-3, H-11), 7.52 (d, J = 10.0 Hz, 1H, H-5, H-9), 7.56 (d, J = 10.0 Hz, 1H, H-5, H-9), 
7.72 (d, J = 10.0 Hz, 2H, H-2, H-12). 13C NMR (126 MHz, CDCl3): δ 27.5 (C-19), 27.9 (C-23), 29.8 
(C-24), 30.3 (C-22), 47.2 (C-7), 53.5 (C-16), 64.3 (C-17), 66.5 (C-21), 67.6 (C-14), 73.4 (C-25), 73.8 
(C-18), 120.1 (C-5, C-9), 125.6 (C-4, C-10), 127.3 (C-2, C-12), 127.8 (C-3, C-11), 143.8 (C-1, C-13), 
144.1 (C-6, C-8), 164.1 (C-15), 169.6 (C-20), 172.7 (C-26). FTIR: neat (cm-1) 3217.1 (O-H acid), 
2970.5 (C-H), 1718.65 (C=O acid), 1648.2 (C=O amide), 1193.0 (C-O), 728.2 (aromatic C-H). 
HR-MS (ESI) m/z = 549.2033 [M+Na]+, 549.2035 calcd for C28H34N2O6S-Na+. 
 
Synthesis Linear Peptide 35 
The linear peptide was synthesized on 2-chlorotrityl 
chloride resin using the general SPPS procedure (0.8 
mmol scale). Concentration of the final cleavage mixture 
in vacuo afforded linear octapeptide 35 (761 mg, 81%) as 
a colourless solid. M.P. 137-140 ˚C. [α]25D = -29.0 (c = 1, 
MeOH). Rf = 0.21 (MeOH:CHCl3 5:95). 1H NMR (500 MHz, (CD3)2SO): δ 1.06-1.12 (m, 60H, 6 x 
Ser/Thr(OtBu), 2 x Thr-CH3), 1.44 (s, 3H, Ser(ψPro-CH3a), 1.53 (s, 3H, Ser(ψPro-CH3b), 1.75 (s, 3H, 
Cys(ψPro-CH3a)), 1.84 (s, 3H, Cys(ψPro-CH3b)), 3.17-3.28 (m, 3H, N-Ser-β-CH2, Cys-β-ψPro-CH2a), 
3.29-3.36 (m, 2H, Ser-β-CH2a, Cys-β-ψPro-CH2b), 3.39-3.45 (m, 1H, Ser-β-CH2b), 3.46-3.57 (m, 
4H, 2 x Ser-β-CH2), 3.61-3.68 (m, 1H, N-Ser-α-CH), 3.94-4.01 (m, 1H, Ser-β-ψPro-CH2a), 4.03-4.12 
(m, 2H, 2 x Thr-β-CH), 4.13-4.22 (m, 2H, Thr-α-CH, Ser-β-ψPro-CH2b), 4.28-4.37 (m, 2H, Ser-α-CH, 
Thr-α-CH), 4.42-4.49 (m, 1H, Ser-α-CH), 4.51-4.57 (m, 1H, Ser-α-CH), 4.71-4.75 (m, 1H, 
Ser-α-ψPro-CH), 5.38-5.43 (m, 1H, Cys-α-ψPro-CH), 7.45-7.52 (m, 1H, Ser-NH), 7.54-7.60 (m, 2H, 
2 x Ser-NH), 7.62 (br. s., 1H, Thr-NH), 8.31-8.43 (m, 3H, Ser-NH2, Thr-NH). 13C NMR (126 MHz, 
(CD3)2SO): δ 18.7 (Thr-CH3), 19.6 (Thr-CH3), 23.5 (Ser(ψPro)-CH3), 25.6 (Ser(ψPro)-CH3), 27.5 (6 x 
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OtBu-CH3), 27.8 (6 x OtBu-CH3), 28.5 (6 x OtBu-CH3), 28.8 (Cys(ψPro)-CH3), 28.9 (Cys(ψPro)-CH3), 
33.0 (Cys-β-ψPro-CH2), 52.2 (N-Ser-α-CH), 53.3 (Ser-α-CH), 54.9 (Ser-α-CH), 58.7 (Ser-α-CH), 60.6 
(Ser-α-ψPro-CH), 62.2 (Ser-β-CH2), 62.9 (Ser-β-CH2), 63.9 (Ser-β-CH2), 67.0 (Thr-α-CH), 67.2 
(Cys-α-ψPro-CH), 67.6 (Thr-α-CH), 67.8 (Ser-β-ψPro-CH2), 67.8 (Thr-β-CH), 68.1 (N-Ser-β-CH2), 
68.4 (C-Thr-β-CH), 73.5 (C-OtBu), 73.6 (C-OtBu), 73.7 (C-OtBu), 73.8 (C-OtBu), 74.0 (Cys(ψPro)-C), 
74.4 (C-OtBu), 75.0 (C-OtBu), 95.6 (Ser(ψPro)-C), 167.9 (Ser-C=O), 168.9 (N-Ser-C=O), 169.1 
(Ser-C=O), 169.4 (Ser-C=O), 169.9 (C-Thr-C=O), 169.9 (Cys(ψPro)-C=O), 170.3 (Thr-C=O), 173.0 
(Ser(ψPro)-C=O). FTIR: neat (cm-1) 3391.0 (N-H), 3048.1 (O-H acid), 2967.3 (C-H), 1734.1 (C=O 
acid), 1653.1 (C=O amide), 1207.5 (C-O). HR-MS (ESI) m/z = 1175.7266 [M+H]+, 1175.7213 calcd 
for C56H103N8O16S..  
 
Synthesis of Macrocycle 41 
 The linear peptide 35 (150 mg, 0.128 mmol) and HATU 
(146 mg, 0.383 mmol) were dissolved in anhydrous 
DMF (128 mL, 1 mM) under argon and DIPEA (111 µL, 
0.638 mmol) was slowly added. The mixture was stirred 
vigorously at room temperature overnight before being 
concentrated in vacuo. The residue was redissolved in 
EtOAc (20 mL) and placed into a separating funnel. The 
organic layer was washed with 1 M HCl (3 x 20 mL), 1 M NaOH (3 x 20 mL) and brine (1 x 20 mL), 
dried over MgSO4 and concentrated in vacuo. The crude residue was purified by silica gel column 
chromatography (CH2Cl2:MeOH, 100:0 to 95:5) to give 41 (116 mg, 79%) as white crystalline solid. 
M.P. 134-140 ˚C. [α]25D = - 10.3 (c = 1, MeOH), Rf = 0.43 (MeOH:CHCl3, 5:95). 1H NMR (CDCl3, 
500 MHz): δ 1.07-1.31 (m, 57H, 6 x Ser/Thr(OtBu), Thr-CH3), 1.42 (d, J = 5.0 Hz, 3H, Thr-CH3), 1.62 
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(d, J = 15.0 Hz, 6H, Ser(ψPro-CH3), 1.89 (s, 6H, Cys(ψPro-CH3), 3.10-3.21 (m, 1H, Cys-β-ψPro-CH2), 
3.29-3.36 (s, 1H, Ser-β-CH2), 3.39-3.46 (m, 2H, Ser-β-CH2, Ser-α-CH), 3.51-3.56 (m, 1H Ser-β-CH2), 
3.59-3.72 (m, 5H, Cys-β-ψPro-CH2, Ser-β-CH2, Ser-α-CH), 3.88-3.98 (m, 2H, 2 x Thr-β-CH), 4.03-
4.10 (m, 1H, Ser-β-ψPro-CH2), 4.41-4.45 (m, 3H, Ser-β-ψPro-CH2, Thr-α-CH, Ser-α-CH), 4.55-4.64 
(m 2H, 2 x Ser-α-CH), 4.71-4.81 (m, 2H, Ser-α-CH, Thr-α-CH), 5.01-5.08 (m, 1H, Ser-α-ψPro-CH), 
5.32-5.38 (m, 1H, Cys-α-ψPro-CH), 7.43-7.49 (m, 1H, Ser-NH), 7.54-7.62 (m, 1H, Ser-NH), 
7.85-7.93 (m, 2H, Thr-NH, Ser-NH), 8.31 (br. s., 1H, Thr-NH), 8.47 (b. s., 1H, Ser-NH). 13C NMR 
(126 MHz, CDCl3): δ 17.6 (Thr-CH3), 18.5 (Thr-CH3), 22.4 (Ser(ψPro)-CH3), 25.3 (Ser(ψPro)-CH3), 
27.1 (Cys(ψPro)-CH3), 27.4 (6 x OtBu-CH3), 28.0 (6 x OtBu-CH3), 28.2 (Cys(ψPro)-CH3), 28.6 (6 x 
OtBu-CH3), 32.1 (Cys-β-ψPro-CH2), 51.8 (2 x Ser-α-CH) 53.1 (Ser-α-CH), 53.8 (Ser-α-CH), 56.6 
(Thr-α-CH), 57.16 (Thr-α-CH), 60.5 (Ser-α-ψPro-CH), 61.1 (Ser-β-CH2), 61.3 (Ser-β-CH2), 62.5 
(Ser-β-CH2), 66.8 (Cys-α-ψPro-CH), 67.7 (Ser-β-CH2), 67.8 (Ser-β-ψPro-CH2), 67.9 (2 x Thr-β-CH), 
73.5 (C-OtBu), 73.6 (C-OtBu), 74.3 (C-OtBu), 74.4 (C-OtBu), 74.5 (Cys(ψPro-C), 75.2 (C-OtBu), 75.4  
(C-OtBu), 96.4 (Ser(ψPro)-C), 169.4 Cys(ψPro)-C=O), 170.0 (Thr-C=O), 170.4 (Ser(ψPro)-C=O), 
170.5 (Ser-C=O), 171.1 (Thr-C=O), 171.2 (Ser-C=O), 170.7 (Ser-C=O), 170.8 (Ser-C=O). FTIR: neat 
(cm-1) 2974.4 (C-H), 1653.1 (C=O amide), 1506.5 (C-H), 1189.2 (C-O). HR-MS (ESI) 
m/z = 1179.6956 [M+Na]+, 1179.6927 calcd for C56H100N8O15S-Na+. 
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Synthesis of the macrocyclic Polyol 42 
The macrocycle 41 (71 mg, 0.031 mmol) was dissolved in 
TFA:TIPS:H2O (95:2.5:2.5, 4 mL) and stirred at room 
temperature for 4 h. A further 1 mL aliquot of the same 
TFA:TIPS:H2O cocktail was added and the mixture was stirred 
for a further 8 h. The mixture was concentrated under a 
stream of N2 followed by vacuum drying to produce an oily 
film. Trituration with n-hexane (2 x 5 mL), CHCl3 (2 x 5 mL) and diethyl ether (2 x 5 mL) produced 
a crystalline powder that was purified by preparative RP-HPLC (gradient of 0% B to 100% B over 
30 minutes, tR = 14.1 min). Concentration of the pure fractions via lyophilisation produced 42 as 
a white crystalline solid (27 mg, 56%). 1H and 13C spectra were of low quality and unsuitable for 
characterisation. See explanation in Chapter 4.4. M.P. 182-185 ˚C decomp. [α]25D = -50.1 (c = 0.3, 
MeOH). FTIR: neat (cm-1) 3283.9 (O-H), 2942.5 (C-H), 1647.3 (C=O amide), 1517.1 (C-H), 1085.0 
(C-O). HR-MS (ESI) m/z = 803.2858 [M+Na]+, 803.2854 calcd for C29H48N8O15S-Na+. 
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Chapter 6 Appendices 
6.1 Appendix 1 
6.1.1 NMR Spectra of Final Compounds 
 1H and 13C APT NMR spectra of (R)-thioridazine-VLA-4 antagonist hybrid methyl ester 30 
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1H and 13C APT NMR spectra of (S)-thioridazine-VLA-4 antagonist hybrid 17  
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13C APT NMR spectra of (R)-thioridazine-VLA-4 antagonist hybrid 17  
 
 
1H NMR spectrum of macrocyclic polyol 42  
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1H and 13C NMR spectra linear peptide 35 
 
 
 
 
 
 
 
 
 
 
 
   References 
183 
 
1H and 13C NMR spectra protected macrocycle 41  
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6.2 Appendix 2 
6.2.1 Crystallographic Data  
(R)-nosyl-northioridazine 28  
 
C26H27N3O4S3, Mr = 541.72, T = 150 K; Triclinic, space group P1, Z = 1; a = 5.6394 (1) Å, 
b = 10.2321 (2) Å, c = 11.1716 (2) Å; α = 89.7777 (19)°; β = 83.7998 (18)°; γ = 76.4297 (19)°; 
V = 622.82 (2) Å3; Dx = 1.444 Mg.m-3; 21077 reflections measured (θ= 4-72°) merged to 4234 
unique data; Rint = 0.017 (for 4227 data with I > 2ơ(I)), WR(F2) = 0.061 (all data); S = 1.00. 
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